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Abstract
Breast cancer is one of the leading causes of cancer death in women. If not diagnosed early,
the 5-year survival rate of patients is just about 26%. Furthermore, patients with similar
phenotypes can respond differently to the same therapies, which means the therapies might
not work well for some of them. Identifying biomarkers that can help predict a cancer
class with high accuracy is at the heart of breast cancer studies because they are targets
of the treatments and drug development. Genomics data have been shown to carry useful
information for breast cancer diagnosis and prognosis, as well as uncovering the disease’s
mechanism. Machine learning methods are powerful tools to find such information. Feature
selection methods are often utilized in supervised learning and unsupervised learning tasks
to deal with data containing a large number of features in which only a small portion of
them are useful to the classification task. On the other hand, analyzing only one type
of data, without reference to the existing knowledge about the disease and the therapies,
might mislead the findings. Effective data integration approaches are necessary to uncover
this complex disease.
In this thesis, we apply and develop machine learning methods to identify meaningful biomarkers for breast cancer survivability prediction after a certain treatment.
They include applying feature selection methods on gene-expression data to derived genesignatures, where the initial genes are collected concerning the mechanism of some drugs
used breast cancer therapies. We also propose a new feature selection method, named
PAFS, and apply it to discover accurate biomarkers.
In addition, it has been increasingly supported that, sub-network biomarkers
xv

are more robust and accurate than gene biomarkers. We proposed two network-based
approaches to identify sub-network biomarkers for breast cancer survivability prediction
after a treatment. They integrate gene-expression data with protein-protein interactions
during the optimal subnet searching process and use cancer-related genes and pathways to
prioritize the extracted sub-networks. The sub-network search space is usually huge and
many proteins interact with thousands of other proteins. Thus, we apply some heuristics
to avoid generating and evaluating redundant sub-networks.
Experimental results show that our approaches are effective. We have found
potential gene signatures and sub-network biomarkers that are biologically meaningful and
can yield significantly high accuracy in predicting breast cancer outcomes after treatment.
Among the potential biomarker extracted there are well-known breast-cancer-related genes
such as TP53, MYC, PIKCA3, SPY1, ERBB4/HER4, STAT3, STAT5A, FGFR2.
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Chapter 1
Introduction

1.1

Breast Cancer

Breast cancer is among the most common cancers in Canadian women and worldwide.
One in eight women is diagnosed with breast cancer in her lifetime. According to the
Public Health Agency of Canada, in 2019, nearly 27000 Canadian women were estimated
to be diagnosed with breast cancer and about 70% of them would be at stage 1 and 2, for
which the 5-year survival rate is 99%. The exact causes of breast cancer have not been
clear but there is always changes in the activity of the cell’s DNA, which might lead to
abnormal cell growth. The malignant cells start developing in the breast, form the tumors,
and can spread to nearby tissues or metastasize to other areas of the body (metastasis).
Breast cancer treatment options depend on many factors including, tumor stage, tumor
type, tumor subtype, age of the patient, the risk of recurrence, and other factors such as
the hormone receptor’s status [1].
1

1.1.1

Treatment Options

Usually, the standard treatments for breast cancer are surgery, radiation therapy, hormone
therapy, chemotherapy, target therapy, or a combination of them.
Surgery includes lumpectomy (remove a tumor/lump and a small amount of
nearby normal tissue), and mastectomy (partially or totally remove the breast and the
tissue surrounding the breast). Some patients have to undergo additional radiation therapy,
chemotherapy, or hormone therapy after surgery to kill any remaining tumor.
Radiation therapy uses x-rays or other types of radiation to kill cancer cells or
stop their growth, depending on the type and stage of the cancer being treated.
Chemotherapy refers to the treatment that uses drugs to prevent the cells
from dividing or to kill the cells. For systemic chemotherapy, drugs are introduced into
the blood system so that they can reach the whole body. For regional chemotherapy,
drugs are injected directly into certain places of the body to handle cancer cells in those
areas. Chemotherapy is often used for patients of stages 2–4, and particularly for estrogen
receptor-negative (ER-) patients. The type of chemotherapy given is mainly based on the
type and stage of the cancer being treated.
Hormone therapy refers to the treatment that stops cancer cells from growing
by removing hormones or blocking their action. If estrogen receptors (ER) and progesterone
receptors (PR) are present on the surface of cancer cells then cancer can be treated with
drugs that block these receptors (e.g., tamoxifen), or with a surgery or radiation therapy
that can reduce/block the production of hormones. Adjuvant hormone therapy for at least
5 years can reduce the risk of recurrence for hormone receptors positive patients.
2

Targeted therapy is a newer and more effective type of treatment that uses
drugs or other substances to identify and attack specific breast cancer cells without harming
normal cells. It often has less severe side effects than standard chemotherapy. For example,
Trastuzumab, a monoclonal antibody, blocks the effects of the growth factor protein HER2,
thus stops these proteins from sending growth signals to breast cancer cells. Such therapy
can be used in combination with adjuvant therapy for patients with HER2 positive.
Immunotherapy, also called biotherapy or biologic therapy, refers to a treatment
using the substances (made by the body or made in a laboratory) to help the patient’s
immune system fight against cancer.
“Breast cancer prognosis and treatment options are generally based on tumornode-metastasis staging. Lymphovascular spread, histologic grade, hormone receptor status, ERBB2 (formerly HER2 or HER2/neu) overexpression, comorbidities, and patient
menopausal status and age are also important factors” [2]. Table 2 in [2] presents the
standard treatment options mainly based on the stage and the type of breast cancer.

1.1.2

Breast Cancer Stages

Breast cancer is classified into five stages [3] which indicates the severity of breast cancer.
Stage 0 indicates there might be a risk of cancer. In Stage 1, breast cancer
cells begin to develop, and the tumor size is about 2 centimeters or smaller. In Stage
2, a typical tumor size is between 2 and 5 centimeters. The tumours are growing within
the breast tumor or extending to the nearby lymph nodes. Stage 2 is divided into Stage
2A and Stage 2B depending on the size of the tumor and whether the breast cancer has
3

spread to lymph nodes. These three stages are considered as early stages [4]. Breast cancers
Stages 1 and 2 are usually treated with breast-conserving surgery and radiation therapy.
Depending on the type of cancer cells and additional risk factors, hormone therapy might
be recommended [2].
In Stage 3, the breast cancer is considered as locally advanced since tumors have
extended to regional lymph nodes and muscles but have not spread to distant organs. Stage
3 is further divided into sub-stages 3A, 3B, and 3C depending on the size of the tumor and
whether the breast cancer has spread to lymph nodes or nearby tissues. The treatments for
these stages may consist of mastectomy and radiation for local treatment, and hormone
therapy or chemotherapy for systemic treatment. Most of the patients diagnosed with
Stage 3 will respond well with a combination of two or more treatments [5, 6]. In [2],
they suggested that “stage 3 breast cancer typically requires induction chemotherapy to
down-size the tumor to facilitate breast-conserving surgery. Inflammatory breast cancer,
although considered stage 3, is aggressive and requires induction chemotherapy followed
by a mastectomy, rather than breast-conserving surgery, as well as auxiliary lymph node
dissection and chest wall radiation.”
Stage 4 breast cancer means that cancer has spread to other areas of the body,
such as the brain, bones, lungs, and liver. “Prognosis is poor in women with recurrent or
metastatic (stage IV) breast cancer, and treatment options must balance benefits in length
of life and reduced pain against harms from treatment” [2].

4

1.1.3

Common Types of Breast Cancer

Ductal Carcinoma In Situ (DCIS). Stage 0 is either not considered as cancer or DCIS,
a non-invasive cancer. The cancer is still contained in the milk duct and has not invaded
any other area. However, patients may be prescribed a hormone therapy to prevent cancer
cells from growing into the surrounding tissue [7].
Invasive Ductal Carcinoma (IDC). IDC is cancer that begin growing in the
duct and invading the surrounding tissue. IDC accounts for 80% of all breast cancer cases.
The treatment options for IDC vary, depending on cancer staging, medical history, along
with a physical exam, and other tests [8].
Inflammatory Breast Cancer (IBC). IBC is rare but aggressive and fastgrowing. In this case, cancer spreads to the skin of the breast, blocks the lymph vessels
in the skin making the breast looks red and swollen and feels warm. IBC can be in stages
3B and 3C. With aggressive treatment, the survival rate for IBC patients has improved
significantly in recent years.
Recurrent Breast Cancer. Recurrent breast cancer is cancer that has come
back after it has been treated.
Metastatic Breast Cancer. Metastatic breast cancer is also classified as Stage
4 breast cancer. Cancer has spread to other parts of the body such as the lungs, liver,
bones or brain.

5

1.1.4

Molecular Subtypes of Breast Cancer

The types of breast cancer are mainly classified based on a combination of procedures, including physical examination and mammography, ultrasound, breast MRI, biopsy, staging
workup, and other risk factors. Researches on how molecular subtypes can be useful in
planning treatment and developing new therapies have been conducted. From a list of 496
genes, breast cancers can be divided into the following five subtypes (also called intrinsic
subtype) which reflect the status of estrogen-receptor (ER), progesterone-receptor (PR),
and the human epidermal growth factor receptor 2 (HER2), the expressed levels of certain
genes and other characteristics [9, 10]. These subtypes were later refined by the PAM50
classification using the expression of the 50 genes [11, 12].
Luminal A breast cancer is estrogen-receptor-positive (ER+) and/or progesteronereceptor-positive (PR+), HER2-negative (HER2-), and has low levels of the protein Ki-67.
Luminal A cancers tend to grow slowly and have better prognosis and survival rate than
other subtypes. This subtype accounts for about 30%-40% of all invasive breast cancers [10, 13, 14].
Luminal B breast cancer is ER+ and/or PR+, and either HER2+ or HER2with high levels of Ki-67. This subtype accounts for about 20%-30% of all breast cancers.
In comparison to Luminal A, Luminal B cancers have larger tumor size, poor tumor grade,
generally slightly faster growth, and slightly worse prognosis. However, its survival rate is
still fairly high [10, 13, 15].
Triple-negative/Basal-like breast cancer is ER-, PR-, and HER2-. This type
of cancer accounts for about 15%-20% of all invasive breast cancers and is more common
6

in women with BRCA1 gene mutations. It is often aggressive, difficult to treat, and likely
to spread and recur. The common hormone therapy and drugs targeting the three genes
will not work. However, early-stage patients of this type respond to chemotherapy better
than other forms of breast cancer [10, 13, 16].
HER2-enriched breast cancer tends to be ER-, PR-, and HER2+. HER2enriched cancers tend to grow faster than luminal cancers and can have a worse prognosis.
This subtype accounts for 12% to 20% of all invasive breast cancers. They are often
successfully treated with HER2-targeted therapies (e.g., trastuzumab) [10, 13].
Normal-like breast cancer is similar to Luminal A disease but its prognosis is
slightly worse. It “remains enigmatic as to whether it reflects a real subtype or a technical
artifact of contaminating stromal tissue” [17].
Although not designed for prognosis purposes, the intrinsic subtypes have strong
prognostic implications. For example, Luminal A has a significantly better prognosis than
other subtypes [17]. The Oncotype DX test, based on 21 genes, provides meaningful
information in hormone receptor-positive luminal breast cancer and it is more useful for
Luminal A than for Luminal B. It can also tell how likely patient will benefit from radiation
therapy after lumpectomy [8]. The PAM50 (Prosigna) test that has recently been included
in recommendations of breast cancer treatment helps identify the risk of recurrence and
metastasis. If the risk of metastasis is fairly high, doctors can suggest both hormone
therapy and chemotherapy; otherwise, hormone therapy alone may be considered to avoid
the side effects of chemotherapy [11].
Understanding the breast cancer stages, types, subtypes, treatments, and other
7

factors would provide researchers reasonable strategies to conduct their studies.

1.2

Machine Learning Methods and Their Applications in Breast Cancer Studies

Most of the machine learning (ML) methods are designed to build a model to perform
a specific task without being explicitly or directly programmed but by learning the underlying patterns from training data. It is expected that the training data conveys the
true patterns, which might be previously unknown, and the ML methods can capture such
hidden patterns. Supervised learning methods are used to develop predictive models from
training data having class labels. They aim at learning a decision surface that can separate
samples of different classes as much as possible. Such methods include the classification
methods used to predict category outcome (e.g., Naı̈ve Bayes, Decision Tree [18], Random
Forest [19]), and the regression methods used to predict numeric outcome (e.g., Logistic Regression [20], Linear Regression [21]). Unsupervised learning methods mainly deal
with grouping/clustering on uncategorized data (e.g., K-means [22], Hierarchical clustering methods [23]), or finding a structure/pattern (e.g., Apriori [24], FP-Growth [25] ) in
such data for interpretation purpose. ML has been shown effective to solve many problems in breast cancer studies. Such problems include breast cancer diagnosis (classifying
whether breast cancer is present), subtype diagnosis (classifying patient into subtypes),
recurrence/metastasis risk prediction, survivability prediction (classifying whether patient
will be disease-free, or survive longer than a certain amount of time, or estimating the
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survive time of patient). Figure 1.1 shows some types of biomarkers that can be identified
by ML methods.

Figure 1.1: Some types of biomarkers.
Some studies have used only clinical information to construct ML models and
still be able to achieve high accuracy [26–28]. For example, the authors of [27] learned
the prediction models from a Wisconsin Diagnostic Breast Cancer dataset obtained from
the UCI machine learning repository (available at http://archive.ics.uci.edu/ml) to classify
benign vs. malignant breast cancer. The dataset contains 32 clinical information of 458
benign patients and 241 malignant patients. They could achieve more than 90% accuracy
using the algorithms K-Nearest Neighbor (KNN), Naives Bayes, Decision Tree and Support
Vector Machine (SVM).
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Others have relied on genomics data such as DNA methylation, gene expression
(GE), mutations, copy number variations (CNVs) or copy number alterations (CNAs) to
build ML models. These types of data can provide information in more detail than traditional clinical and histological factors and might be more useful to discover the underlying
mechanism of the disease. For example, in [29], a cluster analysis on an integration data
of CNVs and GE showed that breast cancers can be regrouped into a new ten-class categorization, each group has distinct copy number profiles and clinical outcome. Patricio et
al. developed models using SVM to predict the presence of breast cancer in women. The
model based on personal information (Age, Body mass index) and clinical features computed from blood analysis (Glucose, Resistin) performed better performance than other
combinations of personal and clinical features [30]. By applying an unsupervised method
on microarray data of about 5,000 differentially expressed genes of 98 patients, Laura J.
van ’t Veer et al. [31] identified a set of 70 genes that can accurately separate patients
into two groups of good prognosis (for patients who continued to be disease-free at least 5
years from the initial diagnosis) and poor prognosis (for those developed distant metastases
within 5 years).
One common challenge in using genomics data is that the number of features is
usually far more than the number of samples, and many features are redundant. The curse
of dimensionality can lead to over-fitting issues or prevents even state-of-the-art algorithms
from being able to learn good models. In this regard, the feature selection methods in ML
can be employed to extract the subsets of informative features for model construction while
maintaining the generalization ability of the model. Then, the selected features can be,
in turn, considered as potential biomarkers. The feature selection methods include filter
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methods, wrapper methods, and hybrid methods.

Figure 1.2: Typical framework for wrapper feature selection.
Filter methods evaluate one feature at a time using a particular statistic criterion
such as Information Gain [18], Chi-Squared [32], Relief [33], for which we can rank the
features and select the top ones. Some criteria can evaluate a subset of features, such
as mRMR [34], MRMD [35]. As they are not tailored to any specific type of classifiers,
the filter selection methods are often used as a pre-processing step in ML applications.
Meanwhile, wrapper approaches search for an optimal subset of features using a searching
algorithm along with a classification method [37–39]. The typical framework for wrapper
approaches is shown in Figure 1.2. For example, in a linear forward selection (or greedy
forward selection), we begin the current optimal subset of features as an empty set and
try to add new features one by one. In each forward step, the classification method (e.g.,
Decision Tree) evaluates the combination of the current optimal subset and a new feature
and the feature that gives the best improvement in performance (e.g., accuracy) is chosen
for further extension. Wrapper methods usually produce better performance than filter
11

ones as they consider the combinations of the features into account. However, they still
require a lot of computations if the number of available features is large enough, especially
when using expensive classifiers such as SVM or Neural Network. In hybrid approaches,
candidate features are first selected by one or more filter criteria to shrink the search space
before applying a wrapper method to find the final subset of features, especially when there
are too many features as compared to the number of samples.

1.3

Integrative Machine Learning Approaches

Analyzing only one type of data type might mislead the findings in studying breast cancer
because of many reasons including lack of data, noise, heterogeneity in data, and others.
The effective integration of many types of data and knowledge is necessary to compensate for such drawbacks and to better uncover the mechanism of diseases. Integrative
approaches have recently gained a lot of interest in the research community. In these approaches, multiple types of data are examined to provide different points of views of a
problem, and they may be integrated into one unique view before applying an algorithm to
solve the problem. Once integrating useful knowledge from different sources into the machine learning process, we can obtain more accurate models, more robust/stable findings,
or biomarkers with stronger support [29, 40–45]. (A robust classifier or biomarker is the
one, the testing error of which is close to the training error, where training and testing data
are just slightly different by sufficiently small perturbations of the data samples [46, 47].)
Drier and Domany argued that gene signatures derived without reference to the underlying
mechanisms of chemotherapy response do not capture meaningful biological results [48].
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Thus, in [49], Dorman et al. analyzed the correlation of gene copy number, mutation, and
expression to the growth inhibitory concentrations of paclitaxel and gemcitabine (GI50 ) in
breast cancer cell line and then in patients using Multiple factor analysis (MFA). Then,
SVM built on expressions of 15 genes can predict paclitaxel resistance with 82% accuracy and SVM built on copy number profiles of 3 genes and expression of 7 genes can
achieve 85% accuracy for gemcitabine resistance prediction. Curtis et al. also suggested
that integrating multiple genomics information may help to derive more robust patient
classifiers [29].
Network-based prediction approaches are also considered as integrative approaches,
where the existing relations among genes or molecules are taken into account for identifying relevant biomarkers. These methods often integrate primary data (e.g., GE, DNA
methylation, CNV) with one or more secondary network data expressing the functional
relationships among genes, such as gene co-expression networks, gene regulatory networks,
protein-protein interaction networks (PINs) or other “omics” data. Protein-protein interaction networks capture physical interactions determined by experiments and computationally derived interactions. There are public databases for PINs that are well-maintained
such as HPRD [50], StringDB [51], PathwaysCommons [52]. A transcriptional regulatory
network is a directed graph where nodes are transcript factors/microRNA or genes and
edges connect a regulator to its targets. Available databases for transcriptional regulatory
networks include RegNetwork [53] and TRRUST [54]. Meanwhile, a gene co-expression
network is often a weighted undirected graph and its construction depends on the problem
of interest [43]. Edge weights are usually computed based on GE data using a co-expression
measure such as Pearson’s correlation coefficient or mutual information. In [55], they con13

struct a gene co-expression network based on the expression quantitative trait loci (eQTLs),
where the gene-gene co-regulation coefficient is calculated based on the eQTLs that regulate
the two genes.
Most of the network-based approaches aim at identifying the sub-networks of
interacting molecules that can be potential signatures for certain conditions of interest.
Such signatures are so-called sub-network biomarkers. The rationale behind this is that
the molecules tend to interact with each other to perform their functions. Thus, functionally related genes tend to be located nearby each other in the molecular networks [56]. In
an extensive study on millions of gene-prognostic biomarkers and sub-network-prognostic
biomarkers across 20 different training-testing partitions of 4960 breast cancer patients,
Grzadkowski et al. [44] found that sub-network biomarkers produced higher overall performance and concordance across partitions. They also mentioned that integrating functional
information, such as pathway data, improves biomarker performance and replicability, and
that smaller biomarkers are more robust across patient cohorts. Researchers have tried
different ways to assign score/weight to the nodes, edges, and even subnets of the networks
in order to apply existing algorithms to find sub-network biomarkers that can accurately
separate the classes. The search includes greedy search, simulated annealing, genetic algorithms, random walk with re-start, and integer linear programming [41–43, 55, 57]. For
example, in [55], after constructing a weighted undirected graph, where edge weight expresses the gene-gene co-regulation coefficient they adopted random walk with re-start to
find the disease genes. A node in an interaction network can involve thousands of edges,
thus, searching for such subnet biomarkers has been a computational challenge.

14

1.4
1.4.1

Motivations and Contributions
Motivations

In brief, our studies have mainly been motivated by several observations and assumptions
from previous studies. First, many studies and the commercial uses of the Oncotype DX,
(PAM50) Prosigna and MammaPrint tests for decision making in breast cancer treatment
have supported the fact that genomics data contain the blueprints for cancer, especially
gene expression data. Second, the effectiveness of adjuvant chemotherapy agents for breast
cancer has been related to changes in the genomics profile of tumors [49]. Chemotherapy or
hormone therapy can reduce the risk of distant metastases by 1/3 [31]. But still, a study of
Lee et al., in 2014 [58], breast cancer patient response rates to paclitaxel and gemcitabine
after 6 cycles of chemotherapy were found to be only 50.0% and 78.6% respectively. There
have been pieces of evidences that patients have not received the proper treatments [31].
These facts motivate us to develop the ML models to identify accurate biomarkers for predicting survivability outcome of breast cancer patients after a therapy such as chemotherapy or hormone therapy. We focus mainly on using gene expression data for gene signature
extraction, but with reference to the underlying mechanisms of therapy responses to capture meaningful biomarkers as Drier and Domany suggested in [48]. As showed in [44, 45]
that biomarkers of small size are preferred and more robust, biomarkers should be searched
in a bottom-up manner when there are many available features. We mainly have used the
METABRIC data (available at https://www.cbioportal.org/study/summary) which contains clinical data and GE profiles of about 2500 patients for learning the classification
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models (there is no information about the gender of the patients in this data). After data
cleaning steps, patients are extracted based on the therapy of interest and used for model
construction.
In addition, as reviewed in [59] the hypothesis that cancer is a pathway-based
or network-based disease has been discussed a lot and increasingly well supported. Now,
the important matter is how to apply this principle effectively and interpretably. Thus,
we also develop network-based approaches for sub-network biomarker detection, where
protein-protein interaction networks are integrated with gene expression data, and the
candidate sub-networks generated in a bottom-up manner for classification robustness.
Pathways are not directly integrated into the sub-network generation process, however,
their functional information is somewhat captured by the protein-protein interactions. For
example, the interactions in PathwayCommons data are derived from pathway data of
many reliable sources including Reactome [60], KEGG [61], Wikipathway [62]. Pathway
data and cancer-related genes from the literature are used in a post-processing step for
sub-network prioritization and biological insight analysis.
Besides, mining the frequent itemsets (FIs), closed frequent itemsets (CFIs), and
generators are important tasks in data mining [63], and have been applied a lot in bioinformatics [64]. These patterns can be used to mine the association rules for classification [64].
Due to the simple and intuitive interpretability of the rules and the patterns, frequent
pattern mining techniques can be powerful tools to capture the complex mechanism in
biological data. However, researchers have focused more on enhancing the techniques to
mine FIs or CFIs directly from data than on how to efficiently enumerate FIs from the
CFIs or extract association rules from the FIs. The latter tasks are not as trivial as they
16

have been considered. Apriori, the first algorithm to extract association rules for each
FI, is simple but exponentially expensive in computation, even for an FI with a moderate
number of features (say 20 features) [24], because we have to deal with overlapping rules
that are induced from different FIs.
Instead of directly mining the FIs from data, it is preferred to mine only the closed
frequent itemsets (CFIs) first and then extract the FIs for each CFI. This approach can
be especially convenient when users have to repeatedly try different parameters to extract
a set of FIs that must satisfy some property. The CFIs allow to separate the FIs into
equivalence classes, thus, inspire the parallel approaches, or to process a whole subclass
via some of its representatives [65, 66].
The generators of each CFI are the key itemsets to enumerate all FIs in the equivalence subclass induced by that CFI. Some recent state-of-the-art algorithms can use the
generators of each CFI to efficiently extract the FIs, association rules, and condense/minimal association rules, without the need of checking for overlapping results [65, 67]. Yet,
mining the generators from data or from CFIs needs a significant extra cost in terms of
time and memory. These facts motivate us to develop efficient algorithms to extract the
FIs and generators for a given lattice of FCIs, and apply them for breast cancer prediction
problems.

1.4.2

Contributions

The contributions of the thesis can be summarized as the following.
In Chapter 2, we apply feature selection approaches to derive gene expression sig17

natures for survival outcome prediction at different survival times in METABRIC patients
receiving hormone (HT) and, in some cases, chemotherapy (CT) agents. The contributions
are:
• The initial genes used for feature selection are collected from [49] based either on their
known involvement in paclitaxel metabolism or evidence that their expression levels
and/or copy numbers correlate with paclitaxel GI50 values. The initial genes correlate
with other drugs such as tamoxifen (used in hormone therapy), methotrexate, 5fluorouracil, epirubicin, and doxorubicin (used in chemotherapy) are studied as well.
• Multiple factor analysis with SVM as an evaluator (MFA+SVM), or mRMR with
SVM (mRMR+SVM), or mRMR with Random Forest (mRMR+RF) is applied to
extract the final gene signatures. These combinations for wrapper feature selection
are among the best that we have tried.
• An SVM model based on paclitaxel signatures extracted by (MFA+SVM) results in
the best accuracy, 78.6%, in predicting survivability of 84 patients treated with both
HT and CT. Paclitaxel-based SVM classifiers derived by (mRMR+SVM) can achieve
at least 81.1% accuracy in 53 CT treated patients, for different survival thresholds.
• For other combinations of treatments and ML approaches, the accuracies are fairly
high, in majority cases.
In Chapter 3, we develop a feature selection algorithm, named Parallel Apriorilike Feature Selection (PAFS), inspired by the Apriori algorithm. The contributions are
the following:
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• Candidate subsets of features are generated and evaluated in batch, and in a bottomup manner, because signatures of small size are of preference. At each round, the
candidates of size k are examined and the top-N best ones are used to generate
the candidates of size (k + 1) for the next round. This saves computation time by
removing low-quality parents.
• As a result, many subsets of features with similar classification performance can be
used as the optimal outputs.
• The search behavior can be adjusted by running options to avoid being too greedy
or too exhaustive.
• PAFS can be implemented in parallel to speed up the feature selection process.
• Applied on the METABRIC datasets used in Chapter 2, for patients receiving hormone (HT), chemotherapy (CT), and a combination of them, PAFS extracted better
gene signatures for predicting survival outcome than those presented in Chapter 2.
The results showed that the classifiers are less affected by the class-imbalance in data.
• Applied on other processed METABRIC data, for predicting whether patients receiving either HT, CT, radiation therapy, or surgery-only would become disease-free,
PAFS gives as high performances as other state-of-the-art approaches.
• We also devised a Tree-based Classifier Model (TCM) algorithm that wraps PAFS
and allows us to use multiple types of classifiers in solving a multi-label classification problem. TCM outperformed a previous study in classifying five the PAM50
subtypes, using fewer genes.
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In Chapter 4, we propose an approach to construct a hierarchical classification
model to predict the 5-year survivability of breast cancer patients treated with either
hormone therapy, or radiotherapy, or surgery. The aim of the model is to suggest an optimal
treatment for new patients based on their gene expression profiles. The contributions are
the following:

• We integrate an unsupervised method and a supervised method to deal with a
multiple-label classification problem.
• A bottom-up agglomerative clustering with Ward’s linkage is applied to organize the
hierarchical clusters, in such a way that the overall within-cluster variance is as small
as possible. Thus, it might be easier for a classification method to classify different
groups of samples at each node.
• As a result, the selected set of discriminative genes at each node can separate the
samples with high accuracy. Some selected genes of the some node are functionallyrelated, or pathway/breast-cancer related.

In Chapter 5, we present a sub-network based ML method, named Sub-network
Selection Based on Predictive Ability (SSPA), to identify sub-network biomarkers for predicting breast cancer treatment outcomes, including disease-free survival, as well as overall
survival at five years and long-term. Treatments investigated are hormone therapy (HT),
chemotherapy (CT), radiation therapy (RT), or surgery-only (SO). The contributions are
the following:
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• Candidate sub-networks are generated in a bottom-up manner, based on a proteinprotein interaction network, and evaluated (using support vector machine and gene
expression data), as sub-networks biomarkers of small size are of preference.
• To reduce search space and save the computation cost, sub-network candidates are
generated starting from seed genes that are selected either due to its predictability or
its involvement in the therapy mechanism or known breast cancer mechanisms. This
aims at finding the subnet biomarkers of high classification performance containing
biologically meaningful genes.
• The seed genes include 84 genes that correlate to the GI50 of the drugs used in
chemotherapy and hormone therapy as described in Chapter 2 and 40 driver genes
collected from the literature, as cancer has been known to start from mutations in
some driver genes.
• Predictive genes, evaluated by mutual information, are also considered as seed genes
since they can induce the highly discriminatory and robust subnets [45].
• A score, named Predictive Ability (PA), is proposed to estimate the predictability
of a sub-network. Thus, we can rank the candidate sub-networks by their PA and
evaluate only the top ones for their true classification performance, using SVM; the
candidate sub-networks with low PA are skipped to save time. As the PA of a
candidate can be computed accumulatively, during the search for an optimal subnet,
with much cheaper cost than that for evaluating the candidate by a classification
method. This heuristic can save a lot of time.
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• After finding the optimal sub-networks for every seed genes, the top subnets are
ranked by their relevance to a set of pathways and previously known cancer-related
genes so that biologists can choose potentially meaningful subsets for further analysis,
among the ones having high accuracy.
• Our method significantly outperformed the approaches in previous studies. The
extracted sub-networks resulted in high accuracy, 73% to 93%, and include breastcancer related genes and genes associated with many cancer pathways.
• When applying the Recursive Feature Elimination (RFE) method with SVM linear
kernel as the evaluator for feature selection we obtained highly accurate subset of
genes, with more than 90% accuracy. This suggests that there might be better
subnets than the current ones that we obtained by SSPA.
In Chapter 6, we propose a network-based machine learning approach, named
Top-k Dense Sub-networks Based on Joint Mutual Information (KDS), used to identify
the top-k sub-networks of functionally-related genes for predicting 5-year survivability of
breast cancer patients treated with chemotherapy, hormone therapy, and a combination of
these. The contributions are the following:
• A weighted graph is constructed from gene expressions and protein-protein interactions, where the edge weight is computed via joint mutual information which
expresses the predictability (i.e., predictive ability) of the combination of the two
genes involved. This makes our weighted graph different from common gene-gene coexpression networks whose edge’s weight usually expresses the correlation between
the pair of genes, not the predictability.
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• A density function for a weighted sub-graph is proposed, which is also an estimation for its predictability, by which we can extract an (locally) optimally-dense subnetwork for each seed gene.
• The extracted dense sub-networks are evaluated by either SVM or Random Forest
for their real performance. Before training a classification model, techniques to deal
with class-imbalanced data are implemented as well.
• Based on a weighted voting scheme using multiple subnets for classification, we introduced two simple methods to select an (locally) optimal set of subnets, among the
sub-networks having the classification performance greater than a given threshold,
that can improve the classification performance of the single best subnet.
• Our approach has significantly improved the existing results in Chapter 2. SVM
based on the best subnet can predict chemotherapy-treated patients with 94.3%
accuracy (MCC = 0.883). For other treatments, the top-k subnets can yield more
than 80% accuracy. Interestingly, we found the well-known genes SP1, TP35, MYC,
PIK3CA among 14 breast-cancer-related genes that frequently appear in the sets of
top-k selected subnets.
In Chapter 7, we introduce an algorithm, called NUCLEAR, which can efficiently
extract the FIs and generators from a lattice of closed frequent itemsets (CFIs) in straightforward fashion, without the need of other information. The contributions are the following:
• We derive some theoretical results based on the notations “kernel” and “extendable
set”, which are the basis of the NUCLEAR algorithm.
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• The set of pairs (“kernel”, “extendable set”) can be used to partition the subclass
induced by a CFI into finer subclasses, where each new subclass is represented by a
pair. This will inspire the “divide-and-conquer” approaches.
• The FIs in each subclass can be quickly extracted since they are the supersets of the
kernel and subsets of the union of the kernel and extendable set.
• We derive a necessary and sufficient condition for an itemset to be a generator: the
generators are the minimal kernels. As the kernels are automatically grouped by
their CFI, the generator can be quickly identified.
• Experimental results showed that NUCLEAR is effective as compared to previous
studies.
• The time to generate the kernels and extendable sets is smaller than the time to mine
the generators.
• The time for extracting the FIs from the kernels and extendable sets is much smaller
than that for mining the CFIs from data and that for extracting the FIs from the
generators and the CFIs.
In Appendix A, we conduct preliminary research that models time-series data
using gene expressions of breast cancer patients and their survival time. The contributions
are the following:
• The time-series profile of each gene is modelized by partitioning patients into different
time-interval bins according to their survival time and then averaging their gene
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expressions.
• Time-series profiles are cubic spline interpolated and then the distance between a
pair of genes is computed based on the vertical area between them after a universal
alignment.
• We applied a clustering method to identify isolated and small clusters whose genes
can be used for survival time prediction. Some extracted genes are breast-cancerrelated.

1.5

Thesis Organization

This thesis is organized into eight chapters. Chapter 1 provides an introduction to the
area of interest and our contributions. Chapter 2 to Chapter 7 are paper-based, where the
contents are slightly edited (with respect to the main ideas, results, and discussions) or
extended with the results that we have not published (Chapter 3, Chapter 5, Chapter 6).
Chapter 2 presents a biochemically-inspired ML approach for identifying gene signatures of
breast cancer outcomes of hormone and chemotherapy base on the METABRIC. In Chapter
3, we introduce the feature selection method PAFS and apply it on the METABRIC
datasets to improve the previous results. In Chapter 4, we applied unsupervised and
supervised methods to construct a hierarchical tree model for classifying on multiple-class
problems, applied on breast cancer survivability prediction. In Chapter 5, we propose
the network-based approach SSPA for detecting sub-network bio-markers of breast cancer
survivability. It aims at extracting several equally high accurate and potentially meaningful
25

sub-networks for considering as bio-markers. In Chapter 6, we propose the network-based
approach KDS used to identify an optimal set of sub-networks that can together produce
better classification performance than that based on a single sub-network. In Chapter 7,
we present the NUCLEAR algorithm to mine the FIs and the generators from a lattice of
CFIs. Finally, Chapter 8 concludes about the contributions in our researches, points out
some limitations and the future works which can improve or extend our approaches.
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Chapter 2
Predicting Outcomes of Hormone and
Chemotherapy in the Molecular Taxonomy
of Breast Cancer International Consortium
Study by Biochemically-inspired Machine
Learning

2.1

Introduction

Current pharmacogenetic analysis of chemotherapy makes qualitative decisions about drug
efficacy in patients (determination of good, intermediate or poor metabolizer phenotypes)
based on variants present in genes involved in the transport, biotransformation, or disposition of a drug. We have applied a supervised machine learning (ML) approach to derive
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accurate gene signatures, based on the biochemically-guided response to chemotherapies
with breast cancer cell lines [1], which show variable responses to growth inhibition by paclitaxel and gemcitabine therapies [2, 3]. We analyzed stable [4] and linked unstable genes
in pathways that determine their disposition. This involved investigating the correspondence between 50% growth inhibitory concentrations (GI50) of paclitaxel and gemcitabine
and gene copy number, mutation, and expression first in breast cancer cell lines and then
in patients [1]. Genes encoding direct targets of these drugs, metabolizing enzymes, transporters, and those previously associated with chemo resistance to paclitaxel (n=31 genes)
were then pruned by multiple factor analysis (MFA), which indicated that expression levels
of genes ABCC10, BCL2, BCL2L1, BIRC5, BMF, FGF2, FN1, MAP4, MAPT, NKFB2,
SLCO1B3, TLR6, TMEM243, TWIST1, and CSAG2 could predict sensitivity in breast
cancer cell lines with 84% accuracy. The cell line-based paclitaxel-gene signature predicted
sensitivity in 84% of patients with no or minimal residual disease (n=56; data from [5]).
The present study derives related gene signatures with ML approaches that predict outcome of hormone and chemotherapies in the large METABRIC breast cancer cohort [6].

2.2
2.2.1

Methods
Support Vector Machine (SVM) Learning

Previously, paclitaxel-related response genes were identified from peer-reviewed literature,
and their expression and copy number in breast cancer cell lines were analyzed by multiple
factor analysis of GI50 values of these lines [2] (Figure 2.1). Given the expression levels
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of each gene, a SVM is evaluated on patients by classifying those with shorter survival
time as resistant and longer survival as sensitive to hormone and/or chemotherapy using
paclitaxel, tamoxifen, methotrexate, 5-fluorouracil (5-FU), epirubicin, and doxorubicin.
The SVM was trained using the function fitcsvm in MATLAB R2014a [7] and tested with
either leave-one-out or 9 fold cross-validation (indicated in Table 2.1, Table 2.2). The
Gaussian kernel was used for this study, unlike [1] which used the linear kernel. The
SVM requires selection of two different parameters, C (misclassification cost) and sigma
(which controls the flexibility and smoothness of the Gaussians) [8]; these parameters
determine how strictly the SVM learns the training set, and hence if not selected properly,
can lead to overfitting. A grid search evaluates a wide range of combinations of these
values by parallelization. A Gaussian kernel selects the C and sigma combination that
lead to the lowest cross-validation misclassification rate. A backwards feature selection
(greedy) algorithm was designed and implemented in MatLab in which one gene of the set
is left out in a reduced gene set and the classification is then assessed; genes that maintain
or lower the misclassification rate are kept in the signature. The procedure is repeated
until the subset with the lowest misclassification rate is selected as the optimal subset of
genes. These SVMs were then assessed for their ability to predict patient outcomes based
on available metadata (see Figure 2.1 and [1]). Interactive prediction using normalized
expression values as input is available at http://chemotherapy.cytognomix.com.
Initial gene sets preceding feature selection: Paclitaxel - ABCB1, ABCB11, ABCC1,
ABCC10, BAD, BBC3, BCAP29, BCL2, BCL2L1, BIRC5, BMF, CNGA3, CYP2C8,
CYP3A4, FGF2, FN1, GBP1, MAP2, MAP4, MAPT, NFKB2, NR1I2, OPRK1, SLCO1B3,
TLR6, TUBB1, TWIST1. Tamoxifen - ABCB1, ABCC2, ALB, C10ORF11, CCNA2,
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Figure 2.1: Biochemically-inspired SVM gene signature derivation workflow.
CYP3A4, E2F7, F5, FLAD1, FMO1, IGF1, IGFBP3, IRS2, NCOA2, NR1H4, NR1I2,
PIAS4, PPARA, PROC, RXRA, SMARCD3, SULT1B1, SULT1E1, SULT2A1. Methotrexate (MTX) - ABCB1, ABCC2, ABCG2, CDK18, CDK2, CDK6, CDK8, CENPA, DHFRL1.
Epirubicin - ABCB1, CDA, CYP1B1, ERBB3, ERCC1, GSTP1, MTHFR, NOS3, ODC1,
PON1, RAD50, SEMA4D, TFDP2. Doxorubicin - ABCB1, ABCC2, ABCD3, AKR1B1,
AKR1C1, CBR1, CYBA, FTH1, FTL, GPX1, MT2A, NCF4, RAC2, SLC22A16, TXNRD1.
5-Fluorouracil - ABCB1, ABCC3, CFLAR, IL6, MTHFR, TP53, UCK2.
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Table 2.1: SVM gene expression signature performance on 84 patients treated with both
chemotherapy and hormone therapy (CT and HT).
1

MCC: Matthews Correlation Coefficient. 1 AUC: Area under receiver operating curve. 3
Surviving patients; 4 Analysis included patients in the METABRIC ‘discovery’ dataset
only; 5 SVMs tested with 9 fold cross-validation, all others tested with leave-one-out
cross-validation; 6 Includes all patients treated with HT, CT, combination CT/HT,
either with or without combination radiotherapy; 7 Median time after treatment until death (> 4.4 years) was used to distinguish favorable outcome, ie. sensitivity to therapy.
Agent

Paclitaxel

ABCC1,
Final
ABCC10,
gene
BAD,
signature BIRC5,
FN1,
GBP1,
MAPT,
SLCO1B3,
TMEM243,
TUBB3,
TUBB4B

Tamoxifen

MTX

Epirubicin

Doxorubicin

ABCC2,
ALB,
CCNA2,
E2F7,
FLAD1,
FMO1,
NCOA2,
NR1I2,
PIAS4,
SULT1E1

ABCC2,
ABCG2,
CDK2,
DHFRL1

ABCB1,
CDA,
CYP1B1,
ERBB3,
ERCC1,
MTHFR,
PON1,
SEMA4D,
TFDP2

ABCC2,
ABCD3,
CBR1,
FTH1,
GPX1,
NCF4,
RAC2,
TXNRD1

5-FU
ABCB1,
ABCC3,
MTHFR,
TP53

Cost

10000

100000

10

1000

100000

10000

sigma

10

100

1

10

100

100

Accuracy

78.60%

76.20%

71.40%

72.60%

75.00%

71.40%

Precision
FMeasure

0.79
0.78

0.76
0.76

0.71
0.71

0.73
0.72

0.75
0.75

0.71
0.71

MCC1

0.56

0.51

0.41

0.43

0.49

0.42

AUC2

0.81

0.70

0.77

0.69

0.70

0.72
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Table 2.2: SVM gene expression signature performance on patients treated with other
therapies.
1

MCC: Matthews Correlation Coefficient. 1 AUC: Area under receiver operating curve. 3
Surviving patients; 4 Analysis included patients in the METABRIC ‘discovery’ dataset
only; 5 SVMs tested with 9 fold cross-validation, all others tested with leave-one-out
cross-validation; 6 Includes all patients treated with HT,CT, combination CT/HT,
either with or without combination radiotherapy; 7 Median time after treatment until death (≥ 4.4 years) was used to distinguish favorable outcome, ie. sensitivity to therapy.
Treatment

CT and/or HT3,4,5

Deceased only4,6
(CT and/or HT)

No treatment3

# Patients

735

327

304

Agent:
final gene
signature
(C
and
sigma)

Paclitaxel:
BAD,
BCAP29, BCL2, BMF,
CNGA3,
CYP2C8,
CYP3A4,
FGF2,
FN1, NFKB2, NR1I2,
OPRK1,
SLCO1B3,
TLR6,
TUBB1,
TUBB3,
TUBB4A,
TUBB4B,
TWIST1
(C=10000, g=100)

Paclitaxel:
ABCB11,
BAD,
BBC3,
BCL2,
BCL2L1,
BIRC5,
CYP2C8,
FGF2,
FN1,
GBP1,
MAPT,
NFKB2,
OPRK1, SLCO1B3,
TMEM243 (C=100,
g=10)

Paclitaxel: ABCB1,
ABCB11,
BBC3,
BCL2L1,
BMF,
CYP3A4,
FGF2,
GBP1,
MAP4,
MAPT,
NR1I2,
OPRK1, SLCO1B3,
TUBB4A,
TUBB4B, TWIST2
(C=100, g=10)

Accuracy

65.30%

75.30%

73.40%

Precision

0.65

0.75

0.73

F-Measure

0.64

0.75

0.73

MCC1

0.29

0.51

0.47

AUC2

0.66

0.76

0.77
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2.2.2

Random Forest (RF) Learning

RF was trained using the WEKA 3.7 [9] data mining tool. This classifier uses multiple
random trees for classification, which are combined via a voting scheme to make a decision
on the given input gene set. We used grid search to optimize the maximum number of
randomly selected genes for each tree in random forest. Figure 2.2 depicts the therapy
outcome prediction process of a given patient using a RF consisting of a series of decision
trees derived from different subsets of paclitaxel-related genes.

Figure 2.2: RF decision tree diagram depicts the therapy outcome prediction process of a
given patient, using a RF consisting of k decision trees.

43

Several decision trees are built using different subsets of paclitaxel-related genes.
The process starts from the root of each tree and if the expression of the gene corresponding
to that node is greater than a specific value, the process continues through the right
branch, otherwise it continues through the left branch until it reaches a leaf node; that leaf
represents the prediction of the tree for that specific input. The decisions of all trees are
considered and the one with the largest number of votes is selected as the patient outcome.

2.2.3

Augmented Gene Selection

The most relevant genes (features) for therapy outcome prediction were found using the
Minimum Redundancy and Maximum Relevance (mRMR) [10] in a wrapper feature selection approach that incrementally selects genes by maximizing the average mutual information between gene expression features and classes (i.e., the relevance (VS )), while
minimizing their redundancies (WS ):

WS =

1
|S|2

VS =

X

I(fi , fj ) ,

(2.1)

fi ,fj ∈S

1 X
I(C, f ) ,
|S| f ∈S

(2.2)

and
mRM R(S) = VS − WS ,

(2.3)

where fi corresponds to a feature in gene set S, C is the class, I(fi ,C) is the mutual
information between fi and class C, and I(fi ,fj ) is the mutual information between features
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fi and fj . The mutual information between two random discrete variables A and X is
defined as follows:
I(A, X) = H(A) − H(A|X),

(2.4)

where,
H(A) = −

X

p (a) log 2 (p (y)),

(2.5)

a∈A

H(A|X) = −

X
x∈X

p (x)

X

p(a|x)log 2 (p (ax)).

(2.6)

a∈Y

For this experiment, we used a 26-gene signature (genes ABCB1, ABCB11, ABCC1,
ABCC10, BAD, BBC3, BCL2, BCL2L1, BMF, CYP2C8, CYP3A4, MAP2, MAP4, MAPT,
NR1I2, SLCO1B3, TUBB1, TUBB4A, TUBB4B, FGF2, FN1, GBP1, NFKB2, OPRK1,
TLR6, and TWIST1) as the base feature set. These genes were selected (in [1]) based
either on their known involvement in paclitaxel metabolism, or evidence that their expression levels and/or copy numbers correlate with paclitaxel GI50 values. mRMR and SVM
were combined to obtain a subset of genes that can accurately predict patient survival
outcomes; here, we considered 3, 4 and 5 years as survival thresholds for breast cancer
patients.
Performance was evaluated with several metrics. WEKA determined accuracy
(ACC), the weighted average of precision and F-measure, the Matthews Correlation Coefficient (MCC) and the area under ROC curve (AUC).
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2.3

Results and Discussion

The performances of several ML techniques have been compared such that they distinguish
paclitaxel sensitivity and resistance in METABRIC patients using its tumour gene expression datasets. We used mRMR to generate gene signatures and determine which genes
are important for treatment response in METABRIC patients. The paclitaxel models are
more accurate for prediction of outcomes in patients receiving HT and/or CT compared
to other patient groups.
SVMs and RF were trained using expression of genes associated with paclitaxel
response, mechanism of action and stable genes in the biological pathways of these targets
(Figure 2.3). Pair-wise comparisons of these genes with those from MammaPrint and Oncotype Dx (other genomic classifiers for breast cancer) find that these signatures are nearly
independent of each other, with only a single gene overlap. The distinct differences of these
signatures are due to their methodology of derivation, based on different principles and
for different purposes (i.e. drug response for a specific reagent). SVM models for drugs
used to treat these patients were derived by backwards feature selection on patient subsets
stratified by treatment or outcome (Table 2.1 and Table 2.2). The highest SVM accuracy was found for the paclitaxel signature in patients treated with HT and/or adjuvant
chemotherapy (78.6%). Since some CT patients were also treated with tamoxifen, methotraxate, epirubicin, doxorubicin and 5-fluorouracil, we also evaluated the performance of
models developed for these drugs using the same algorithm. These gene signatures also
had acceptable performance (accuracies between 71–76%; AUCs between 0.686 – 0.766).
Leave-one-out validation (CT and HT, no treatment, and deceased patients) exhibited
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higher model performance than 9-fold crossvalidation (CT and/or HT, including patients
treated with radiation).

Figure 2.3: Schematic elements of gene expression changes associated with response to
paclitaxel. Red boxes indicate genes with a positive correlation between gene expression or
copy number, and resistance using multiple factor analysis. Blue demonstrates a negative
correlation. Genes outlined in dark grey are those in a previously published paclitaxel
SVM model (reproduced from [1] with permission).
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The RF classifier was used to predict paclitaxel therapy outcome for patients that
underwent CT and/or HT (Table 2.3). The best performance achieved with RF showed
an 85.5% overall accuracy using a 3-year survival threshold for distinguishing therapeutic
resistance vs. sensitivity for those patients that underwent HT.
Table 2.3: Results of applying RF to predict outcome of paclitaxel therapy.
1

MCC: Matthews Correlation Coefficient. 2 AUC: Area under receiver operating curve;
both Discovery and Validation patient datasets analyzed. RF predictions done using a
gene panel consisting of 19 genes (ABCB1, ABCB11, ABCC1, ABCC10, BAD, BBC3,
BCL2, BCL2L1, BMF, CYP2C8, CYP3A4, MAP2, MAP4, MAPT, NR1I2, SLCO1B3,
TUBB1, TUBB4A, TUBB4B).
Type of
treatment
Survival
years as
threshold

Chemotherapy
(CT)
3

#
Patients

4

Hormone therapy
(HT)
5

3

53

4

5

CT and/or HT
3

420

4

5

504

# genes
used
in
random
selection

7

7

19

19

9

9

9

19

7

Accuracy

56.6%

69.8%

66.0%

85.5%

78.6%

71.0%

82.7%

73.6%

65.3%

Precision

0.51

0.698

0.645

0.731

0.715

0.634

0.685

0.647

0.602

FMeasure

0.524

0.698

0.636

0.788

0.706

0.627

0.749

0.648

0.593

MCC1

-0.06

0.396

0.23

0

0.069

0.059

0

0.039

0.086

AUC2

0.441

0.7

0.653

0.606

0.559

0.632

0.506

0.527

0.588

The best overall accuracy and AUC (sensitivity and specificity) for CT/HT pa48

tients using mRMR feature selection for SVM predicting outcome of paclitaxel therapy
was obtained for CT patients with 4-year survival (Table 2.4). Genes selected for these
classification models are presented in Table 2.5. Outcomes for HT patients with 3-year survival were predicted with 85.7% accuracy; however, the specificity was lower in this group.
SVM combined with mRMR further improved accuracy of feature selection and prediction
of response to hormone and/or chemotherapy based on survival time than either SVM or
RF alone. Predicted treatment responses for individual METABRIC patients using the
described ML techniques are indicated in Dataset 1 of [11].
Table 2.4: Results of mRMR feature selection for an SVM for predicting outcome of
paclitaxel therapy.
1

For patients treated with CT with ≥ 4 Yr survival and CT+ HT for ≥ 5 Yr, the cost for
the mRMR model was set to 64. Of those treated with CT for ≥ 4 Yr, genes were selected
using a greedy, stepwise forward search, while in other cases, greedy stepwise backward
search was used. Also, gamma = 0 in all cases. 2 Predicted responses for individual
METABRIC patients are provided in Dataset 1.
CT1

Data
Survival
years
(as
threshold)

3

# Patients2

4

HT
5

3

53

CT HT
4

5

3

420

4

5

504

Accuracy (%)

81.1

81.1

84.9

85.7

79.5

72.9

83.1

74.8

67.9

Precision

0.809

0.813

0.852

0.878

0.765

0.692

0.795

0.703

0.662

F-Measure

0.809

0.811

0.845

0.794

0.726

0.663

0.772

0.672

0.666

MCC

0.582

0.625

0.675

0.119

0.17

0.173

0.161

0.137

0.238

AUC

0.783

0.812

0.82

0.508

0.533

0.548

0.53

0.531

0.61
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Table 2.5: Selected genes learned by mRMR and SVM for predicting outcome of paclitaxel
therapy, with survival years as threshold.
Data

CT

Survival
years

SVM
Par.
(gamma, cost)

3

(0, 64)

4
5

(0.5, 128)
(1, 8)

3

(1, 2)

4
5

(0.75, 64)
(1.5, 2)

3

(0.75, 16)

4

(0.5, 2)

5

(1, 2)

HT

CT HT

Selected genes
MAP4, GBP1, FN1, MAPT, BBC3, FGF2,
NFKB2, TUBB4B
TWIST, FN1, BBC3, FGF2, BCL2L1
ABCB11, BCL2, GBP1, SLCO1B3, ABCB1,
BAD, TUBB4A, MAPT, NFKB2, TUBB4B
ABCB11, BCL2, MAP4, TUBB1, GBP1,
SLCO1B3, ABCB1, BAD, TWIST1, FN1,
TUBB4A, MAPT, OPRK1, BBC3, FGF2,
NFKB2, ABCC1, NR1I2
BAD, GBP1, MAPT, BBC3
ABCB11, MAP4, SLCO1B3, BAD, FN1,
OPRK1, BBC3, NFKB2, NR1I2, TUBB4B
ABCB11, SLCO1B3, BAD, TUBB4A,
MAPT, BBC3, FGF2, NFKB2, ABCC1,
NR1I2
ABCB11, BMF, BCL2, MAP4, TUBB1,
GBP1, SLCO1B3, ABCB1, BAD, TWIST1,
FN1, MAPT, OPRK1, BBC3, FGF2,
NFKB2, ABCC1, NR1I2, TUBB4B
MAP4, GBP1, SLCO1B3, BAD, MAPT,
OPRK1, BBC3, NFKB2, ABCC1, NR1I2,
TUBB4B
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Tumor co-variate information was provided by METABRIC, which included Estrogen receptors (ER), Progesterone Receptor (PR), HER2, Lymph Node (LN) and PAM50
subtypes. To assess model co-variate accuracy, predictions described in Table 2.1–Table
2.5 were broken down by subtype (due to the large number of columns and rows, we refer reader to the Supplementary file 1 of [11] for more details). Subtypes with less than
20 individuals for a particular treatment combination were not analyzed. The deviation
in classification accuracy between subtypes was mostly consistent with the average. One
exception involved the RF and mRMR analyses, which was 8.3 to 23.0% below the average for (ER)-negative, (HER2)-positive and basal subtypes in patients treated with HT.
However, this deviation was not observed for CT-treated patients with the (ER)-negative
subtype, which was consistent with the fact that CT response was derived from the paclitaxel gene set. (ER)-negative patients primarily received CT [6]. Further, the accuracy
of the SVM models tested with CT and HT-treated patients was significantly higher for
(HER2)-positive patients (26 correct, 3 misclassified; 90% accurate) compared to (HER2)negative patients (40 correct, 15 misclassified; 73% accurate). MAPT expression (present
in reduced ‘CT and HT’ paclitaxel model; Table 2.1) has been shown to segregate well with
PAM50 luminal and basal subtypes1. When analyzing METABRIC patients, however, the
accuracy of these two subtypes are nearly identical to the average (78.6%, where basal and
luminal classification accuracy is 76.7% [n=30] and 76.2% [n=21], respectively).
We assessed the separate Discovery and Validation datasets, respectively, as training and test sets and repeated the previous experiments. In this scenario, the performance
of the model was poor (slightly better than random). This occurred because the gene
expression distributions of many of the paclitaxel-related genes in our signature were not
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reproducible between these two sets (based on Wilcoxon rank sum test, Kruskal-Wallis
test and t-tests; as shown in the Supplementary file 2 of [11]). Cross-study validation
allows for the comparison of classification accuracy between the generated gene signatures.
The observed heterogeneity in gene expression highlights one of the many challenges of
cross-validation of gene signatures between these data from the same study exhibit drastic
differences (for example, BCL2L1; Supplementary file 2 of [11]). Furthermore, these gene
expression differences also affect the performance of these methods when these datasets
were combined (compare Table 2.3 and Table 2.6 for RF; Table 2.4 and Table 2.7 for
mRMR). We considered the possibility that the Discovery model might be subject to overfitting. We therefore performed cross-study validation of the Discovery set-signature with
an independently-derived dataset (319 invasive breast cancer patients treated with paclitaxel and anthracycline chemotherapy [5]). The mRMR+SVM CT-models performed well
(4-year threshold model had an overall accuracy of 68.7%; 3-year threshold model exhibited lower overall accuracy [52%], but was significantly better at predicting patients in
remission [74.2%]).
To evaluate the paclitaxel models without relying on the Validation dataset, the
Discovery set was split into two distinct parts, consisting of 70% of the patient samples
randomly selected for training, and a different set of 30% of samples for testing. This
procedure was repeated 100 times using different combinations of training and test samples,
and the median performance of these runs is reported (Table 2.6 and Table 2.7). We also
compared the performance of our mRMR+SVM model with the K-TSP model [12] (Table
2.9). In most cases, our method outperformed K-TSP, based on its accuracy in classifying
new patients. Starting with the same set of Discovery genes, we also trained a separate
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model using the Validation data, and tested this data by 70/30% cross-validation (accuracy
for RF: 56–67% [CT], 67–83% [HT], 56–81% [CT-HT]; accuracy for mRMR: 33–56% [CT],
70–84% [HT], 64–82% [CT-HT]). In addition, we evaluated the performance of the model
derived from the Discovery set on a different set of patients treated with paclitaxel. These
results suggest that the aforementioned issue with Discovery training and Validation testing
was primarily due to a batch effect, rather than to over-fitting.
Table 2.6: Results of applying RF to predict outcome of the paclitaxel signature for the
METABRIC Discovery patient set.
Paclitaxel gene panel consisted of 19 genes (ABCB1, ABCB11, ABCC1, ABCC10, BAD,
BBC3, BCL2, BCL2L1, BMF, CYP2C8, CYP3A4, MAP2, MAP4, MAPT, NR1I2,
SLCO1B3, TUBB1, TUBB4A, TUBB4B). 1 For patients treated with CT with ≥ 4 year
survival and CT+ HT for ≥ 5 year, the cost for the mRMR model was set to 64. Of those
treated with CT for ≥ 4 year, genes were selected using a greedy, stepwise forward search,
while in other cases, greedy stepwise backward search was used. Also, gamma = 0 in all
cases.
Treatment
Survival years (as
threshold)

CT
3

# patients
# genes used in
random selection

HT
4

5

3

22

CT and/or HT
4

5

3

185

4

5

221

7

7

19

19

9

9

9

19

7

Accuracy (%)

61.1

66.7

66.7

77

79.1

68.9

80.2

54.8

60.5

Precision

0.62

0.64

0.72

0.78

0.73

0.533

0.68

0.554

0.57

F-Measure

0.61

0.65

0.69

0.78

0.71

0.601

0.73

0.551

0.58

MCC

0.22

0.19

0.19

0.02

0.08

-0.13

-0.07

-0.14

0.02

AUC

0.44

0.72

0.57

0.52

0.53

0.594

0.39

0.395

0.48
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Table 2.7: Results of mRMR feature selection for an SVM for predicting outcome of the
paclitaxel signature for the METABRIC Discovery patient set.
Treatment
Survival years
as threshold

CT
3

# patients

4

HT
5

3

22

CT+HT
4

5

3

185

4

5

221

Accuracy (%)

57.1

57.14

85.7

81.8

70.9

63.6

71.2

69.7

71.2

Precision

0.6

0.686

0.74

0.73

0.67

0.532

0.65

0.63

0.69

MCC

0.17

-0.26

0

-0.08

0.03

-0.08

0.04

0.07

0.25

AUC

0.58

0.333

0.5

0.48

0.51

0.477

0.51

0.52

0.59
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Table 2.8: Selected genes by mRMR and SVM for predicting outcome of the paclitaxel
signature for the METABRIC Discovery patient set, with survival years as threshold.
Treatment Survival
years

SVM
Par.
(gamma, cost)

3

(0, 64)

4

(0.5, 128)

5

(1, 8)

3

(1, 2)

4

(0.75, 64)

5

(1.5, 2)

3

(0.75, 16)

4

(0.5, 2)

5

(1, 2)

CT1

HT

CT+HT

Selected genes
TWIST1, BMF, CYP2C8, CYP3A4,
BCL2L1, BBC3, BAD, MAP2, MAPT,
NFKB2, FN1
BCL2, BMF, CYP2C8, CYP3A4, BAD,
ABCC10, NFKB2,
MAP2, BCL2, BCL2L1, BBC3, MAPT,
GBP1, NFKB2
TWIST1,
BCL2,
BMF, CYP2C8,
CYP3A4, BCL2L1, BBC3, TLR6, BAD,
ABCB11, ABCC1, ABCC10, MAP4,
MAPT, NR1I2, GBP1, NFKB2, OPRK1,
FN1
TWIST1, CYP2C8, CYP3A4, BCL2L1,
BBC3,
TLR6,
ABCB11,
ABCC1,
ABCC10, MAP2, MAPT, NR1I2, GBP1,
NFKB2, FN1
TWIST1, BMF, CYP2C8, CYP3A4,
BCL2L1, BBC3, ABCB11, ABCC1,
ABCC10, MAP2, MAP4, MAPT, NR1I2,
GBP1, NFKB2, OPRK1
BMF, CYP2C8, BCL2L1, BBC3, BAD,
ABCC1, ABCC10, MAP4, NR1I2,
OPRK1FN1
TWIST1, BMF, CYP2C8, CYP3A4,
BCL2L1, BBC3, TLR6, ABCB11, ABCC1,
ABCC10, MAP2, MAP4, MAPT, NR1I2,
GBP1, NFKB2, OPRK1, FN1
TWIST1, BMF, CYP3A4, BCL2L1,
BBC3, TLR6, BAD, ABCB11, ABCC1,
MAP2, MAP4, MAPT, NR1I2, GBP1,
NFKB2, OPRK1, FN1
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Table 2.9: Comparison on accuracy (%) between our mRMR+SVM method and K-TSP
method on Discovery patient set of the METABRIC data.
Treatment
Survival years

CT
3

# patients

HT
4

5

3

22

CT+HT
4

5

3

185

4

5

221

mRMR+SVM

57.1

57.1

85.7

81.8

70.9

63.6

71.2

69.7

71.2

K-TSP12

57.1

28.6

28.6

80.9

68.2

69.2

71.2

54.6
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While not a replication study sensu stricto, the initial paclitaxel gene set used for
feature selection was the same as in our previous study [1]. Predictions for the METABRIC
patient cohort, which was independent of the previous validation set [5] used in [1], of
the either same (SVM) or different ML methods (RF and SVM with mRMR) exhibited
comparable or better accuracies than our previous gene signature [1].
These techniques are powerful tools which can be used to identify genes that may
be involved in drug resistance, as well as predict patient survival after treatment. Future
efforts to expand these models to other drugs may assist in suggesting preferred treatments
in specific patients, with the potential impact of improving efficacy and reducing duration
of therapy

2.4

Conclusion

In this study we used METABRIC dataset to predict outcome for different survival times in
patients receiving hormone and, in some cases, chemotherapy agents. We used published
literature and various machine learning methods in order to identify optimal subsets of
genes from a biologically-relevant initial gene set that can accurately predict therapeutic
response of patients who have received chemotherapy, hormone therapy or a combination
of both treatments. The SVM methodology has been previously shown to outperform
randomized gene sets [1]. The predictions made by our method are based on the level of
an individual drug. Genomic information has been shown to correlate with tumor therapy response in previous studies [6, 13–17]. From these studies, analytical methods have
been used to develop gene signatures for chemotherapy resistance prediction5, subtypes
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(PAM50), and metastatic risk stratification (Oncotype DXTM , MammaPrint R ). We also
examined the method exhibiting the best performance in the Sage Bionetworks / DREAM
Breast Cancer Prognosis Challenge [18], which was also phenotype-based, however it produces outcome signatures based on molecular processes rather than the cancer drugs themselves. While interesting and informative, the results cannot be directly compared. Our
approach may be useful for selecting specific therapies in patients that would be expected
to produce a favorable response.

2.5

Data availability

The data referenced by this article are under copyright with the following copyright statement: Copyright: c 2017 Mucaki EJ et al.
Data associated with the article are available under the terms of the Creative
Commons Zero “No rights reserved” data waiver (CC0 1.0 Public domain dedication).
http://creativecommons.org/publicdomain/zero/1.0/
Patient data: The METABRIC datasets are accessible from the European GenomePhenome Archive (EGA [19]) using the accession number EGAS00000000083. Normalized patient expression data for the Discovery (EGAD00010000210) and Validation sets
(EGAD00010000211) were retrieved with permission from EGA. Corresponding clinical
data was obtained from the literature 6. While not individually curated, HT patients were
treated with tamoxifen and/or aromatase inhibitors, while CT patients were most commonly treated with cyclophosphamide-methotrexate-fluorouracil (CMF), epirubicin-CMF,
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or doxorubicin-cyclophosphamide.
F1000Research: Dataset 1. Predicted treatment response for each individual
METABRIC patient, 10.5256/f1000research.9417.d149864 [11]
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Chapter 3
PAFS – An Efficient Method for
Classifier-Specific Feature Selection

3.1

Introduction

In reality, many machine learning tasks involve high dimensional data that contain thousands of features and millions of samples. For example, a breast cancer dataset in [1] has
up to 13582 features, where each feature is a gene expression; some text classification problems involve thousands of m-grams. The curse of dimensionality might keep many powerful
learning techniques such as Support Vector Machine (SVM) [2–4] Bayesian Network [5],
K-Nearest Neighbors (K-NN) [2], Decision Tree [6] from being applicable in those cases.
In such data, there are usually a lot of redundant and irrelevant features that can be removed. Thus, feature selection is one of the best remedies. This pre-processing technique is
to find the most informative subset of features which can still generalize the original data.
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As a consequence, the training time on the projected data can be significantly reduced,
the result can be explained easier, and the prediction accuracy can be improved. Feature
selection is especially useful in domains where there are much more features than samples. Such domains include written text analysis, bioinformatics classification/prediction,
where there are many thousands of features but only a few tens to hundreds of samples.
It is shown in [1, 7–9] that, in many situations, only a small number among thousands
of features strongly correlate with the target feature. However, extracting useful features
from a universal set of hundreds or thousands of features is really challenging as the search
space is exponential to the number of features. Exhaustive search is almost impossible; a
level-wise search must base on reasonable some stop conditions for good quality; greedy
search like Greedy Forward Selection might find only a local optimum. Therefore, in some
cases, it requires a more suitable strategy to guide the search.
Besides, to obtain a further improvement for some learners, such as SVM, KNN, there must be an optimal parameter set. While the parameter space still can be
continuous, trying to find the global optimum is almost impossible. Grid search is a
common and straightforward way to find an optimal parameter setting by sparsely sweeping
through the parameter space. Moreover, the classification performance is different from
one combination of parameters and feature subset to another. Thus, searching for optimal
parameter after feature selection step probably miss the solution that should be chosen
(i.e., when combining a feature subset that was skipped in feature selection stage with
a suitable parameter setting, we may have better classification performance). Hence, it
seems a good idea to optimize both the subset of features and the parameters by searching
in their combination space.
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Finally, given a dataset, some classification methods might be able to learn a
good classification model but some others might not. Thus, the optimal classification
model should comprise of a classification method, the most informative feature subset and
the optimal parameters for that classifier.
Our contributions. The observations above motivate us to propose a new
method, called Parallel Apriori-like Feature Selection (PAFS), that finds the optimal classification model for a given machine learning method by exploring the features space and
the parameter space at the same time. The idea of combining the spaces may not be new,
but the way PAFS searches for the feature subset is. Its search behavior at each internal
step is oriented to the optimal results and is controllable by running options to avoid being
too exhaustive or too greedy. PAFS is mainly to cope with binary classification problems.
To handle multi-class problems, we extend the tree-based model in [1] to another algorithm called Tree-based Classification Model for Multi-class Problem (TCM) which wraps
PAFS and integrates the space of classifiers as well. It outputs a single-path tree where
each node is a binary classification model learned by PAFS. Both PAFS and TCM can be
implemented in parallel. When classifying, each binary model is applied, according to its
order, to identify whether a new instance belongs to the class of that node or not.
When applied for classifying five subtypes of breast cancer patients, our model returned accuracy of about 99%; about 5% more than that reported in [1] and required fewer
genes. On an erythemato-squamous disease dataset, we obtained the similarly high accuracy. Especially, on the METABRIC datasets, PAFS extracted better gene signatures for
predicting survival outcome of breast cancer patients treated with chemotherapy, hormone
therapy, and a combination of them than those identified in our previous study [19] (Chap65

ter 2). The results PAFS on the METABRIC datasets also might be a clue supporting
for the assumption that gene signature extraction should take the underlying mechanism
of the therapies into account for meaningful biological results. However, it is necessary to
test on many more drugs used in breast cancer treatment for a strong conclusion.

3.2

Related Works

In this section, we summarize the feature selection approaches and highlight some recent
works on feature selection and on breast cancer subtype classification that related the
most to this study. Generally, feature selection methods are categorized into the following
approaches.
Filter approaches. Filter approaches often deal with one feature at a time based
on a particular statistic criterion. Some of the popular criteria are Information Gain, Gain
Ratio [6], Chi-Square [1], mRMR [7, 8]. These approaches are usually applied to select the
most informative features to predict the classes. They are effective to shrink the feature
space, especially when the number of features in the dataset is large. Since the features are
often evaluated independently from each other, these approaches are clearly fast but might
not perfectly eliminate redundancy. The presence of one feature may reduce the impact
of some others on the class feature. And, as they are not tailored to any specific type of
classifiers, in many cases, the selected features are used as input for another processing
steps rather than as the final feature subset for classification [9, 10].
Wrapper approaches. Wrapper methods, on the other hand, consider a subset
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of features at a time and search for the optimal feature subset with regard to a specific
classifier. They somehow take the between-feature dependencies into account. For each
subset, the target classifier is trained and tested on the projected data to score the fitness.
Various strategies can be applied to traverse the space of feature subsets, including exhaustive search and greedy searching methods such as Greedy Forward Selection, Greedy
Backward Elimination, Floating with Forward Selection, Floating with Backward Selection
are likely preferred. In greedy methods, starting from a subset of features, new candidates
are gradually generated by adding/deleting a feature and then evaluated. Only one or two
best ones are maintained to generate candidates for the next step and so on. The process
stops when some conditions are met, e.g., the subset size reaches a certain threshold or
the decline of quality excesses a threshold. Basically, none of them guarantees to find the
global optimum. Wrapper methods usually produce better performance than filter ones,
but they require a lot of computations, especially when using expensive classifiers such as
SVM or Bayesian Network.
Hybrid approaches. They are combinations of filter methods and wrapper
methods. Candidate features are first selected by a filter criterion to prune the feature
search space before applying a wrapper method to find the final subset. One can see that
they can take advantage of the two previous approaches while reducing their drawbacks.
Embedded approaches. In these approaches, the search for an optimal feature
subset is integrated with the process of constructing the classifier. Decision tree learning
can be considered an instance of this method.
Based on the one-against-all strategy, the authors of [11] applied an ensemble
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learning approach to deal with a multi-label classification problem. The classification
problem of C classes is first transformed into C - 1 binary classification problems. In each
subproblem, the ith class is considered as the positive class while the others are combined
as the negative one. Then, they apply traditional feature selection for each subproblem. In
classification, all classifiers of the subproblems vote for the class label of the new instance.
To cope with the imbalanced data, the class of the minority can be oversampled. They
tested their approach with Naı̈ve Bayes, K-NN, C4.5 on 15 datasets, whose number of
features range from 4 to 64. Three of the datasets have more than 3000 samples. On
average, the accuracy of their approach was higher than some traditional approaches from
2% to 3%.
In [1], also based then one-against-all strategy, the authors introduced a treebased classification model for classifying the five PAM50 subtypes of breast cancer. Its
main idea is to transform the multi-class problem into binary problems, but the easiest
one is chosen to build the current node. Then, after removing the samples of the chosen
class, the remaining data is recursively used to build sub-trees. It results in a single-path
tree model (tree model for short) where each node is a binary classifier. When classifying,
each binary classifier verifies whether the new instance belongs to the class of that node. If
not so, the instance is passed down to the child node and the process keeps going on until
the class label of the instance is decided. They applied Chi-Square as a filter criterion and
support vector machine with radial basis kernel (SVM-RBF) as a target classifier. They
obtained a classification model with about five features for each node, and 18 features in
total for the whole tree which can yield about 95% accuracy.
The authors in [9] propose a hybrid approach. Two subsets of features are first
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filtered by F-Score and Information Gain, respectively. Then, their intersection set, denoted
as S1 , and their exclusive-OR set, denoted S2 (i.e., resulted from XOR operator) are
computed. At the wrapper stage, a Greedy Backward Elimination is conducted on S1
while a Greedy Forward Selection is executed on S2 to find the most potential candidates.
This heuristic might come from the assumption that the features in S1 are more predictive
than those in S2 , and the subsets of the large size in S1 can be more promising than the
smaller ones. In an experiment on a disorder protein dataset, they obtained a subset of
355 out of 420 features, but no improvement for accuracy. On a lung cancer dataset, they
obtained a subset of 70 out of 7129 features which returned 100% accuracy.
In [8] the authors proposed a method named Improved F-score and Sequential
Forward Floating Search (FSFFS) which applies a hybrid feature selection approach for
classifying six types of erythemato-squamous diseases. A modification of F-score was first
used to filter the features. Then, Sequential Forward Floating Search and SVM were
combined during the wrapper stage. A grid search was conducted as well to find the optimal
parameters for SVM. For an erythemato-squamous disease dataset from UCI machine
learning database with 358 samples and 34 features. The accuracy of their method ranges
from 93% to 100%, depending on the size of the test dataset
Recently, there are new algorithms for feature selection basing on particle swarm
optimization approach, such as [12], [13]. However, the comparison between these methods
to PAFS is out of the scope of this study.
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3.3

Materials and Methods

In this section, we introduce the TCM algorithm to deal with multi-class problems. It
extends the tree-based scheme introduced in [1] to allow using different binary classifiers for
different nodes in the same tree-model. Each binary model consists of a class label, a learner
(i.e., classification method), an optimal subset of features, and an optimal parameter set on
which the given classifier can produce the optimal performance. The proposed algorithm,
PAFS, will try to find a highly accurate binary classification model for a given dataset
and a classification method. The optimal models found by exploring the combination
space of features and parameters tend to be better than those found by searching only
on the feature space and then optimizing the parameters. PAFS follows this heuristics to
optimize the classifier. Especially, depending on the data dimensionality, users can adjust
the running parameters so that PAFS works more or less exhaustive, and thus also change
the intermediate data that guides the search. The idea of PAFS is adopted from the Apriori
algorithm [14] which is used for frequent itemset mining.
Let us define some notations before describing our proposed algorithms.
Definition 1. Given a feature set F and a set of class labels L, a relation or dataset D on
F x L, a class label i in L, and A, a subset of F. Let
• D *i denote the new dataset obtained from D by replacing the class label of all samples
to a new label, except those of class i ;
• D -i denote the sub-dataset obtained by removing all samples of class i from D;
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• D A denote the dataset obtained from D by projecting all samples on the subset of
features A.
Thus, D *i is the binary dataset/problem derived from D, where the samples of class i are
the positive samples and the others are the negative ones.
Definition 2. Given a dataset D *i , a set of parameters P and a real number q. Let M be
<i, C, A, P, q> denote the binary classifier obtained by using classification method C to
∗i
learn with parameters P on DA
and its the average classification performance is q. Here,

q refers to a static measure such as accuracy, recall, area under ROC curve.
Definition 3. A s-candidate is a set of s features.

3.3.1

Tree-based Classification Model for Multi-class Problem

Actually, the algorithm PAFS, described in the next section, can deal with multi-class problems directly, provided that the classification method used can handle multi-class problems,
such as K-NN, Decision Tree, Naı̈ve Bayes. However, for its application generality, PAFS
should better be applied to two-class problems, because some machine learning method
is originally designed to solve binary problems only, like SVM. Moreover, transforming a
multi-class problem into many binary problems, and then finding the tree model to solve
them seems to produce a better result than solving the original problem directly. Because
we can apply different feature subsets and parameters for different binary problems, instead of using the same setting to classifying all classes. We extend the scheme for finding
a tree-based model for multi-class problems in [1] to an algorithm, named TCM, in Figure
3.1. One can see that the main step of TCM can be solved in parallel.
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Algorithm 1 (TCM). Constructing a tree-model for multi-class classification.
Input. F, L, D: as in Definition 1; CS: a set of classifier types (i.e., SVM, K-NN,
etc).
Output. TM: the optimal tree model for classification learned from D.

Method.
1. Initialized TM as an empty tree.
2. For each class value i in L, and for each classification method C in CS, use PAFS
to find the binary model <i, C, Ai , Pi , qi > with respect to F, L, and D*i .
3. Choose the model with the maximal value of qi to construct the root node of TM.
4. Update dataset D = D-i .
5. Remove i from L.
6. While |L| > 1, go back to step 2 to build the sub-tree of the current node.

At step 2, given a classification method (e.g., SVM), for each class label i in L,
we use the PAFS algorithm to find an optimal model to discriminate instances of class
i against the rests. Then, the optimal model yielding the highest quality will be chosen
as the binary model of the current node (step 3). After that, the chosen class will be
removed from L and all samples of this class will be removed from dataset D as well (step
4, 5). Then, the process continues to build the model for the sub-tree until only one
class is left. If the original data consists of |L| classes then the tree model will have |L|
nodes. The last node contains only the remaining class label since no more classification
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is needed. This is a best-first search heuristic to avoid considering too many models;
otherwise, trying all permutations of the binary models would be very time-consuming.
Steps 2 can be implemented in parallel/distributed by assigning a binary problem to a
thread/processor/computer to solve.

3.3.2

Parallel Apriori-like Feature Selection Algorithm

In the one-versus-all scheme in TCM, the main task is to find the optimal binary model
< i, C, Ai , Pi , Qi > to predict where a new instance belongs to class i or not. Indeed, it is
to find the optimal subset of features Ai , and the optimal parameters Pi for classifying on
the binary classification problem D∗i , using classification method C. It can be done by the
algorithm PAFS described in Algorithm 2.
The idea of PAFS is to gradually generate the feature subsets in a level-wise
manner (i.e., every subset of the current step has one feature more than that of the previous
step) and select only the high-quality subsets of the current step to generate candidates for
the next step. Each candidate subset will be evaluated by the given classification method,
with a grid search for optimal parameters. The process continues until the size of the
candidates excesses a given threshold or there is no more candidate to try. Additional
stopping conditions can be integrated as well.
At the initial step, the original features are filtered by a criterion, e.g., mutual
information to reduce the search space significantly. Each selected feature forms a 1 candidate.
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Algorithm 2 (PAFS). Searching for an optimal binary classification model.

Input. D: a dataset of two classes; C: a classification method (e.g., SVM); N: the
maximum number of candidates to maintain after each step; S: the maximum size
for subsets; G: the grid of parameters to try; X: the number of features to filter.
Output. M: an optimal model for classification on D.

Method.
1. Step 1. Apply a filter criterion to select top X features from the set of all features.
They are the 1-candidates.
2. Step s. Execute the following steps until s > S or there is no more candidate:
a. For each subset A among the current s-candidates, for each parameter setting
in G.
i. Use a thread/processor/computer to learn a classification model on the
projected data DA in 10-fold cross validation using method C.
ii. Obtain the optimal parameter P and the best quality Q for A.
iii. If Q > QM , where QM is the quality of M, then M = <i, A, C, P, Q>.
b. MinQ = 0.8*QM .
c. Remove every s-candidate having quality smaller than MinQ.
d. Keep only the top N s-candidates according to their quality.
e. Generate new (s+1)-candidates from a pair of s–candidates if they share s–1
common features.
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All of the candidate subset at each iteration has the same size, and they will be
tested to remove the low-quality ones. Let call them the s-candidates. For each subset A,
and for each parameter setting, we trained and tested a classifier on the dataset projected on
A using the classification method C, under a 10 -fold cross-validation scheme. To accelerate
the process, PAFS can be implemented in parallel, where each candidate can be processed
by a thread (steps 2.a.i). The optimal parameter P and its corresponding quality q are
obtained (steps 2.a.ii). The optimal binary model for A is updated accordingly(step 2.a.iii).
After trying all s-candidates, we compute a new minimum quality threshold, MinQ, (step
2.b) which is used as a threshold to remove the low-quality candidates. Here, we want
to to keep only the the subsets of the model having quality greater than or equal to 80%
of the current best model (step 2.c). By this way, the new candidates generated for the
next iteration ten to be more promising than the current ones, hopefully. If the number
of subsets left after the removal is still too large, we keep only the top N (step 2.d). Of
course, these factors can be parameterized so that users can adjust the behavior of the
search.
A new (s+1)-candidate will be generated for the next step by joining a pair
of s-candidates if they share s–1 common features. This heuristic not only prunes the
search space but also helps to find the optimal subset quicker (as we don’t generate all
subsets of size s + 1 ). It is noteworthy that the first participant (i.e., the first subset
of s features) contains only one feature that is new to the second participant, and vice
versa. Intuitively, for a s-candidate which is evaluated and kept after step 2.d, we consider
its features “well cooperating” to each other for classification. Then, the features of the
new (s+1)-candidate will be likely to “cooperate well”. Because the s-1 common feature
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already “cooperate well” and all of them “cooperate well” with at least one of the other
features. As a consequence, the quality of the new candidate will tend to increase than
decrease. (If we adjust MinQ to just well under the value of QM , e.g., 95% of QM , then
the quality of the candidates of the next generation tends to be better or not much worse
than that of the current best model.) Thus, each currently remaining candidate acts as a
direction to the tops of its local hills. The more candidates are kept the more local hills
can be reached, so the higher chance we can find the global optimum; but, of course, there
will be more computational cost.
Note that, both N and MinQ are to adjust the greedy/exhaustive behavior of
PAFS, but with different effects. For example, when the running time is not as important
as the classification performance, users can increase N and decrease MinQ to obligate
PAFS to generate and test more candidates. If we set MinQ to a very small value (e.i.,
MinQ = 0), the top-N s-candidates will be selected. In such a case, the selected candidates
might be of too low quality. Then, they might not generate promising candidates for the
next step, and we might waste time considering them. When the dataset is large, and we
would like to use a complex classification method like SVM, we should decrease N and
increase MinQ so that PAFS will generate and test fewer candidates to save time.
Since PAFS generates and tests the candidate subsets in batch, it can return
many relatively-similar optimal subsets as outputs, providing more options for downstream
analysis.
The complexity of PAFS. Let S be the maximum allowed size of a subset, N be
the maximum number of subsets retained after each step, and |G| be the dimension of
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parameter grid G. One can see that step 1 is executed only once, and it can be very quick
as compared to the whole process of PAFS. For each other step (step s), only at most
N × (N − 1)/2 candidates are generated for the next step; each candidate is tested with
every parameter setting in the grid G. As step s is repeated S times, the number of models
to learn in (10-fold cross validation) can be S × |G| × N × (N − 1)/2 in the worst case.
Thus, N, S, and G are the primary factors to control the complexity of PAFS. Increasing
their sizes, PAFS will become close to an exhaustive search; while decreasing them, PAFS
will behave like a greedy one.

3.4
3.4.1

Experimental Results and Discussions
Experimental Settings

We used Weka’s libraries and LibSVM packages [15] to develop our own Java program, with
multi-thread programming. We used Gain Ratio and Information Gain as filter criterion
options; K-NN and SVM-RBF (SVM for short) as classifiers. For K-NN, it is recommended
to find the optimal value parameter K (the number of neighbors for voting) in the range
√
from 1 to N , where N is the number of samples. In grid search for SVM parameters,
the parameters gamma and cost are taken from predefined arrays: {0, 0.05, 0.1, 0.25, 0.5,
0.75, 1, 1.5, 2} and {1, 2, 4, 8, 16, 64, 128, 256}, respectively. Since trying all settings
for parameters can be time-consuming, we provide also an option to run PAFS without
grid-searching for parameters. This corresponds to running those classifiers with default
parameters in Weka, i.e., K = 1 for K-NN; cost = 0 and gamma = 1 for SVM.
77

Each running option setting for TCM is provided in the form of < C, F, X, S, N, G >,
where C is a classification method (e.g., SVM), F is a criterion for feature selection at filtering stage (e.g., Information Gain), X is the number of features to keep at filtering stage,
S is the maximum size of a feature subset, N is the maximum number of subsets to keep
for generating candidates for the next step, and G indicates whether grid search for parameter optimization will be applied or not. The running option settings are shown in the
captions of Table 3.1 - 3.5 for their corresponding results. We evaluate the model quality
in terms of Matthews correlation coefficient (MCC), one of the best scores to deal with
imbalanced data [16]. MCC is in the range [-1, 1]. The higher the value of MCC the better
the classification quality. We recorded also the model accuracies in order to compare with
the result in [1].
PAFS is implemented in multithreading fashion. For step 2.a, if we use T threads
to process Z subsets of features generated at each step then each thread will process about
Z/T candidates. For each feature subset A and parameter setting P, the classification
performance is evaluated in 10-fold cross-validation. We tested our approach on several
datasets and compared with the results of the previous studies. A tree model for a multiclass classification problem is presented as a table, where each row is a binary model. The
order of the rows corresponds to the order of nodes in the tree, and the last node is omitted.
For simplicity, we consider the average accuracy of its nodes except the omitted node as
the overall accuracy of the tree model. For example, for model in Table 3.1, the overall
accuracy is the average accuracy of the 4 nodes (since the dataset has five subtypes in
total) which is the average of the column Accuracy, 99.49%.
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3.4.2

Experimental Results on Predicting Five PAM50 subtypes

In this experiment, we used a microarray dataset used in [1], [17]. This dataset contains
gene expression profiles of 158 breast cancer patients with 13582 features/genes. The
class label of a patient indicates the PAM50 subtype of that patient. In total, there are
39 Basal-like samples, 22 Her2 samples, 53 LumA samples, 31 LumB samples, and 13
Normal-like samples. Figure 3.1 presents the tree-based model learned from this dataset
by the approach in [1]. According to the model, Basal is the easiest to identify with 99.36%
accuracy, followed by Normal and Her2. The classification between LumA and LumB is
said to be the hardest one, with 88.1% accuracy. As mentioned the overall accuracy of this
model is 95.11%.
For many running settings, TCM can obtain very good models with an overall
accuracy greater than 95%. Most of them share the following binary classification order
from the easiest to the hardest to classify: Basal against all → Her2 against {Normal,
LumA, LumB} → Normal against {LumA, LumB} → LumA against LumB. This is shown
in Tables 3.1, 3.2, 3.3, 3.4; in which class LumB is omitted because it is the last one to
identify.
The running setting for TCM and PAFS is shown in table captions, along with the
overall accuracies. Table 3.1 gives information about the result (tree model) when using
SVM as the classification method, Information Gain to filter the top 100 features at the
filter stage, and grid search was applied for SVM parameter tunning. The maximum size
of a feature subset to try is 5. Only at most top 40 subsets are retained after each iteration
to generate the candidates for the next iteration. Each row in the table is a binary model.
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Figure 3.1: Tree-based classification model resulted from [1] for five breast cancer subtype
prediction.
Source: [1]
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For example, the first row in Table 3.1 means that when classifying for a new patient, the
first binary model examines the genes set TFF3, AGR2 and uses SVM with gamma = 0,
cost = 1 to verify if the patient has Basal cancer or not. This test can yield 100% accuracy.
If the patient is predicted not to have Basal cancer, then the binary model of the second
row is used next, and so on. In the last model, if that patient is not predicted as LumA
cancer then he/she is predicted as LumB. The overall accuracy is 99.49%.
Table 3.1: Tree-based model for breast cancer subtype prediction learned by TCM using
running options <SVM, Information Gain, 100, 5, 40, with grid search>, 99.49% accuracy.
Class
Basal

Selected features
TFF3, AGR2

Parameters
0, 1

Accuracy
100.00%

MCC
1

Her2
Normal
LumA

HMGCS1, SLC39A6, TARS, YBX1
CX3CL1, ARAP3
MAD2L1, SRSF5, CBX8, KATNB1

0.05, 64
0, 1
0.75, 8

99.16%
100.00%
98.81%

0.973
1
0.975

Table 3.2: Tree-based model for breast cancer subtype prediction learned by TCM using
running options <SVM, Information Gain, 150, 10, 40, with grid search>, 100% accuracy.
Class

Selected features

Parameters

Accuracy

MCC

Basal

TFF3, AGR2

0, 1

100%

1

Her2

TARS, YBX1, MDP1, ATP1A1OS

1, 1

100%

1

Normal

CX3CL1, ARAP3

0, 1

100%

1

LumA

SPAG5, NDC80, LRP8,
MRPS23, NEK2, CACYBP,
RCL1, LRIG1, HMMR

0, 16

100%

1

Table 3.2 presents a perfect model with 100% accuracy overall, using SVM. Table
3.3 presents a result when using the same running setting as the case of Table 3.1 except
that K-NN, SVM is the classifier space. Here, SVM is chosen if SVM produces the same
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quality as K-NN. Thus, the model in this table is almost similar to that of Table 3.1, except
that the second row is replaced by a model of K-NN which has better quality than that of
SVM in the second row of Table 3.1.
Table 3.4 presents a result when running with almost the same options as in
Table 3.1 but without grid search, i.e., gamma is set to 0 and cost is set to 1. As it shows
here, without grid search, we can still obtain higher accuracy than the result in [1]. This
supports for the effectiveness of the way that AFS explores the feature space. However,
when comparing to the results in Table 3.1, its accuracy and MCC are lower. This implies
that when integrating the parameter search, we can improve the classification further. This
means that searching for optimal models in the combined space of features and parameters
as we are doing is a reasonable approach.
Table 3.3: Tree-based model for breast cancer subtype prediction learned by TCM using
running options <K-NN/SVM, Information Gain, 100, 5, 40, with grid search>, 99.70%
accuracy
Class

Classifier

Selected features

Parameters

Accuracy

MCC

Basal

SVM

TFF3, AGR2

0, 1

100%

1

Her2

K-NN

C2orf54, FAM134B,
DROSHA

2

100%

1

Normal

SVM

CX3CL1, ARAP3

0, 1

100%

1

LumA

SVM

MAD2L1, SRSF5,
CBX8, KATNB

0.75, 8

98.81%

0.975

As compared to the result in [1] (see Figure 3.1), all of our four tree models have
higher overall accuracy and accuracies for each corresponding binary models. Especially,
the accuracy of the binary model for classifying LumA, and LumB (the hardest case) in
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Table 3.2 reaches 100%, about 12% higher than that of [1]. The order of the second and
the third nodes in our model are the reversion of that in [1] since PAFS detected that Her2
cases are easier to be identified than Normal cases. Additionally, the model in [1] needs
18 genes in total; meanwhile, our four models need fewer genes: 12, 17, 13, and 12 genes,
respectively. Table 3.4 showed that even without a grid search, our model still obtains
higher accuracy. This supports for the effectiveness of the way that PAFS explores the
feature space. In comparison binary models for classifying LumA against LumB (the last
row) in Tables 3.1, 3.2, 3.3 to that in Table 3.4, one can see that the integration of grid
search with feature subset search can significantly improve the classification performance.
Once again, this means that searching for the optimal model in the combined space of
features and parameters is a reasonable approach.
Table 3.4: Tree-based model for breast cancer subtype prediction learned by TCM using running options <SVM, Information Gain, 100, 5, 40, without grid search>, 98.32%
accuracy
Class

Selected features

Parameters

Accuracy

MCC

Basal

TFF3, AGR2

0, 1

100.00%

1

Her2

S100A9, BZRAP1, THSD4, CEP55

0, 1

99.16%

0.972

Normal

CX3CL1, ARAP3

0, 1

100.00%

1

LumA

NUSAP1, KIF4A, CACYBP, UTP18

0, 1

94.05%

0.875
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3.4.3

Experimental Results on Predicting Erythemato-Squamous
Diseases

In the second experiment, we tried TCM on an erythemato-squamous disease dataset used
[10], and users can download from the UCI machine learning database. It has 366 samples
with 34 features, where 12 of the features are clinical and 24 of them histopathological. 32
out of them take value 0, or 1, or 2, or 3 indicating a degree; one feature is binary and
the remaining is linear. The six diseases are psoriasis (code = 1, 112 samples), seboreic
dermatitis (code = 2, 61 samples), lichen planus (code = 3, 72 samples), pityriasis rosea
(code = 4, 49 samples), cronic dermatitis (5, 52 samples), and pityriasis rubra pilaris (6,
20 samples).
For this dataset, the method FSFFS in [10] obtained 97% accuracy in average
using 12 attributes. In the best case, the accuracy is 100% using 14 attributes. In Table
3.5, we present a tree model learned from the dataset by TCM. The running option (shown
in the table caption) means that we did not filter any features at the filter stage (filter 34
out of 34 features). Class number 4 is omitted because it is the last one to identify. The
overall accuracy of the model is 99.26%, i.e., 2.26% higher than the average cases in [10]
and just slightly smaller than the best case in [10]. Moreover, we need only 10 features.
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Table 3.5: Tree-based model learned from erythemato-squamous disease dataset by TCM
using running options <SVM, Gain ratio, 34, 4, 40, with grid search>, 99.26% accuracy
Class

3.4.4

Selected features

Parameters

Accuracy

MCC

1

20, 22

1, 8

100.00%

1

3

6, 8

0.75, 1

100.00%

1

5

1, 15

0, 1

100.00%

1

6

1, 7

0.05, 1

100.00%

1

2

5, 26

0, 1

96.3

0.925

Experimental Results on Breast Cancer Treatment Outcome Prediction using METABRIC datasets

We applied PAFS using SVM as classifier on the METABRIC datasets used in [19] for
predicting survivability of breast cancer patients treated with chemotherapy (CT) and/or
hormone therapy (HT). The problems are binary classification in these cases. In [19]
(i.e., Chapter 2), mRMR and SVM were co-operated in a wrapped feature selection using Weka software to find the sets of the most informative genes among an initial set
of 26 genes for prediction. These 26 genes were carefully selected with respect to the
mechanism of chemotherapy drugs, including ABCB1, ABCB11, ABCC1, ABCC10, BAD,
BBC3, BCAP29, BCL2, BCL2L1, BIRC5, BMF, CNGA3, CYP2C8, CYP3A4, FGF2,
FN1, GBP1, MAP2, MAP4, MAPT, NFKB2, NR1I2, OPRK1, SLCO1B3, TLR6, TUBB1,
TWIST1. We tried several types of searches including Linear Floating Forward, Linear
Floating Backward, Greedy Stepwise. As shown in Table 3 of [19] (or Table 2.4 in Chapter
2), the accuracies obtained by our previous study range from 66% to 84%; however, the
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area under ROC curve (AUC) and the MCC are not high enough in some cases, suggesting
that the classifiers were rather affected by class-imbalance. Table 3.6 shows the results
when applying PAFS for predicting therapy outcome on the same problems. The selected
gene signatures for paclitaxel response suggest that PAFS may achieve better overall performance than the previous approach. For 53 CT patients with ≥ 5-year survival threshold,
a SVM based on expression of FN1, TUBB4A, BAD, MAP2, ABCB1 and ABCB11 was
90.6% accurate (AUC = 0.885 and MCC = 0.799) showing significant increases as compared to that of [19] (accuracy = 84.9%, AUC = 0.82 and MCC = 0.675, respectively).
Accuracies, AUC and MCC also increased for other survival thresholds. For 420 HT patients, the accuracies acquired by PAFS are not significantly higher than the previous
results in [19]; however, the MCCs are about doubled and AUCs are about 0.05 higher
showing significant improvements. For patients treated with CT and/or HT, and for all
three survival thresholds, either accuracy or MCC or AUC is considerably higher than that
of the previous results; while none of the three statistical measures is smaller than that of
the previous results. These new classification results appear to be less sensitive to bias in
imbalanced datasets in the composition of the different patient categories. Thus, the new
models may be more useful than prior ones.
Similarly, we also applied PAFS (with SVM) to extract the gene signatures for survivability prediction based on 420 HT-only-treated patients with 24 genes that correlated
with the GI50 of Tamoxifen. The initial genes are ABCB1, ABCC2, ALB, C10ORF11,
CCNA2, CYP3A4, E2F7, F5, FLAD1, FMO1, IGF1, IGFBP3, IRS2, NCOA2, NR1H4,
NR1I2, PIAS4, PPARA, PROC, RXRA, SMARCD3, SULT1B1, SULT1E1, SULT2A1.
Table 3.7 presents the classification results for the extracted signatures. Comparing with
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Table 3.6: Results of applying PAFS for predicting therapy outcome for patients treated
with chemotherapy and/or hormone therapy based on 26 genes that correlate to Paclitaxel.
Treatment

Year
as
threshold

Selected genes

Accuracy

AUC

MCC

3

FN1, BAD, SLCO1B3,
BCL2, TUBB1, MAPT,
MAP2, ABCC1

86.8%

0.862

0.717

4

BCL2L1, FN1, BAD,
SLCO1B3,
BBC3,
MAP2, NFKB2

88.7%

0.887

0.776

5

FN1, TUBB4A, BAD,
MAP2,
ABCB1,
ABCB11

90.6%

0.885

0.799

3

FN1, BMF, TUBB1,
MAPT,
BBC3,
CYP3A4,
ABCC10,
NR1I2

86.0%

0.618

0.315

4

FN1,
CYP3A4,
ABCB11

CYP2C8,
TUBB4B,

81.0%

0.6

0.303

5

TUBB4A,
BAD,
SLCO1B3,
MAP4,
OPRK1,
MAP2,
CYP3A4,
ABCC10,
NR1I2, ABCB11

73.1%

0.655

0.319

3

TUBB4A,
MAP4,
TUBB1, MAPT, MAP2

84.5%

0.556

0.291

4

BCL2L1, FN1, TUBB1,
MAP2,
CYP2C8,
NFKB2, ABCB11

77.6%

0.567

0.3

5

BAD,
SLCO1B3,
OPRK1,
BBC3,
FGF2, TLR6, CYP3A4,
ABCC10, ABCC1

71.0%

0.616

0.288

CT
(53 patients)

HT
(420 patients)

CT
and/or
HT
(504 patients)
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Table 3.7: Results of applying PAFS for predicting hormone therapy (HT) outcome for
420 patients based on 24 genes that correlate to Tamoxifen.
Years

Selected genes

Accuracy

AUC

MCC

3

ABCC2, F5, NR1H4, PROC, SMARCD3,
SULT1E1

0.883

0.626

0.416

4

CYP3A4, E2F7, NR1H4, PPARA, PROC,
SMARCD3, ULT1E1

0.831

0.626

0.399

5

ABCC2, CYP3A4, E2F7, FLAD1, NR1H4,
PROC, SMARCD3, SULT1E1, SULT2A1

0.776

0.625

0.374

the results for HT in Table 3.6, most of the classification measures in Table 3.7 are better
(except the AUC for 5-year threshold). This seems reasonable since the Tamoxifen is for
hormone therapy while Paclitacxel is for chemotherapy.
We applied PAFS using SVM as the classifying evaluator (PAFS+SVM) on the
METABRIC data (downloaded on December 2016) used in [20] to predict whether patients
will be disease-free or not when treated with one of the following treatments: chemotherapy
(CT), hormone therapy (HT), radiation therapy (RT), or surgery-only (SO) [21, 22]. This
METABRIC data contains 1904 patient gene expression profiles of 24369 genes. The
patients who died not due to breast cancer were excluded. The disease-free distribution
by treatment is given in Table 3.8.
The initial gene set for feature selection and classification were collected from
literature including (1) those significantly correlated to growth inhibitory effects of paclitaxel, tamoxifen, methotrexate, epirubicin, doxorubicin, and 5-fluorouracil used in [19]
(i.e., 84 genes); (2) 173 genes from [20] which include 40 breast cancer driver-genes; and
(3) those whose mutual information versus the classes are in the top 100. We compared
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Table 3.8: Disease-free distribution by treatment.
Dataset

Disease-free

Recurred/Progressed

# Samples

CT

26

19

45

HT

284

121

405

RT

174

54

228

SO

82

207

289

our approach with the wrapper feature selections using the combination of mRMR and
SVM (mRMR+SVM) or mRMR and Random Forest (mRMR+RF). Several searching algorithms including, Linear Forward Search (LFS), Linear Backward Search (LBS), Particle
Swarm Optimization (PSO) [12, 13], were applied for these combinations and the results
for the best MCC were collected. The performances of these approaches are shown in
terms of accuracy and MCC in Table 3.9, where the best values are shown in bold. The
corresponding selected genes are shown in Table 3.10.
We can see that none of the approaches is superior to the others in classification
for all cases. For chemotherapy, PAFS+SVM and mRMR+SVM (with PSO) perform
equally very well (MCC is about 0.95 or more); while, mRMR+RF (with LFS), which is
the optimal combination of techniques that we have tried, is much poorer (MMC = 0.424).
PAFS+SVM and mRMR+RF (with PSO) are the best classifiers for hormone therapy
(MCC is about 0.45), and surgery-only patients (MCC is about 0.54), but just slightly
better than mRMR+SVM (with LFS). In radiation therapy, mRMR+SVM (with LFS) is
the best (MCC = 0.669), followed by PAFS+SVM with MCC = 0.594. These results show
that for these datasets, PAFS is as effective as PSO, a powerful searching method for high
dimensional data, which has been gained a lot of interest recently.
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The accuracy and MCC returned by these feature selections are significantly high,
however, we have not conducted any further analysis/validation on the selected genes in
Table 3.10 for biological insights, except that about half of the initial genes were carefully
collected [19]. Some selected genes/transcripts that are unofficial, such as BM728771,
BC021185, which have not been assigned to any gene Entrez ID. If they are not useful,
user can choose other subsets of genes which provide relatively-similar performance for
analyze because PAFS can return multiple optimal subsets of features as output.
Table 3.9: Prediction performance by PAFS+SVM and other feature selection approaches.
Data

CT

HT

RT

NONE

Method

Accuracy

MCC

# Genes

mRMR+SVM (with PSO)

1.000

1.000

6

mRMR+RF (with LFS)

0.778

0.424

5

PAFS+SVM

0.978

0.955

7

mRMR+ SVM (with LFS)

0.775

0.417

10

mRMR+RF (with PSO)

0.785

0.445

21

PAFS+SVM

0.778

0.449

10

mRMR+ SVM (with LFS)

0.886

0.669

9

mRMR+RF (with LBS)

0.851

0.552

15

PAFS+SVM

0.864

0.594

6

mRMR+SVM (with LBS)

0.813

0.515

16

mRMR+RF (with PSO)

0.827

0.544

7

PAFS+SVM

0.820

0.535

6
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Table 3.10: Selected genes for predicting treatment outcome by PAFS+SVM and other
feature selection approaches.
Data

CT

Method

Selected Genes

mRMR+SVM

MDH1B, RPL36A, SDHAF1, C15orf33, BC038529,
KRTAP12-1

mRMR+RF

SLC25A20, TMEM120A, RPL26, FBXW7, TRAPPC3

AFS+SVM

SPATA18, RRAGD, PABPC5, AK025321, ADAMTSL5,
PRRT3, TUBGCP3

mRMR+SVM

SLC25A20, TMEM120A, AI221824, SAP30BP, OR52M1,
HIST1H4C, AI377306, C17orf106-CDK3, AI912012,
IL13RA2

mRMR+RF

SLC25A20, TMEM120A, TXNDC17, FBXW7, TRAPPC3,
NUDT18, MSRA, AI377306, KRAS, CR740230, AI912012,
TMUB1, SAP30, OVCH1, C3orf54, INSL5, CDCA3,
DB336657, LOC100132686, PDGFRB, AI694360

AFS+SVM

AA628343, AI221824, BG150403, BX105718, BX113158,
CDK15, DB338108, IL13RA2, INSL5, OR52M1, OVCH1,
PPARA, SSBP1, TBC1D21, ZBTB34

mRMR+ SVM

SPATA4, SLC13A4, TCEAL8, BM705207, TMEM31,
METTL7A, MFN2, GPSM1, OR52I2

mRMR+RF

AARS, LSS, PDHA1, APOOL, C4B, SLC13A4, ZIC2,
FOXD1, DNAJA2, CD1C, GKN1, TMEM31, AW296478,
ORC6, NR3C1

AFS+SVM

CD1C, METTL7A, SAG, ZIC4, CBWD5, PMPCB, DHFR

mRMR+SVM

HSP90AB1, KIAA0090, ADAMTS7, YWHAZ, SGOL2,
MTBP, MELK, TPX2, KIF20A, NOSTRIN, AI828382,
KIF4A, ZNF250, COL22A1, DLGAP5, C10orf32-AS3MT

mRMR+RF

HSP90AB1, ADAMTS7, MTBP, CENPE, CDCA5,
COL22A1, DLGAP5

AFS+SVM

BM728771, BC021185, ADAMTS7, ARFGEF1, HSP90AB1,
HOXA6

HT

RT

SO
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3.5

Conclusion

The following three observations inspire the idea of our proposed algorithm, PAFS, for
feature selection. (1) Feature selection is a key factor to prune the search space, reduce
data noise, and increase the prediction quality. (2) Parameter search is another technique
to improve the power of classifier and grid search is one of the suitable ways to examine the
parameter space. And (3) the classifier performance change from one dataset to another
dataset and from one parameter setting to another. Thus, by combining the feature space
and the parameter space into one, PAFS can find the classification model that is more
optimized than the approaches exploring those spaces separately. Its search behavior of
PAFS is adapted from the Apriori algorithm, but it is controllable by parameters to avoid
being too exhaustive or too greedy.
Based on PAFS and one-versus-the-rest strategy, we presented the TCM algorithm that makes use of the power of different classifiers to deal with multi-class problems.
When applying the model for classification on the experimental datasets, our acquired
models often yield better performance than that of the previous studies. Especially, on the
METABRIC datasets, among the initial gene set that were previously carefully-selected
with references to the mechanism of the therapies, for predicting survival outcome of breast
cancer patients treated with chemotherapy, hormone therapy, and a combination of them,
PAFS extracted better gene signatures than those identified in our previous study [19]. The
results in Table 3.6 and Table 3.7 might be a clue indicating that gene signature analysis
should conducted with references to the underlying mechanism of the therapies. However,
it is necessary to test on many more drugs used in breast cancer treatment for a strong
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conclusion.
On applying PAFS to predict the chance of being disease-free after treatment
for breast cancer patients using processed METABRIC datasets, the selected genes by
PAFS+SVM can produce significantly high accuracy.
The experimental results support that PAFS is effective for feature selection and
competitive to other efficient approaches.
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Chapter 4
A Novel Approach for Identifying Relevant
Genes for Breast Cancer Survivability on
Specific Therapies

4.1

Introduction

Breast cancer has a very high 5-year relative survival rate (90%) compared with other
cancers including pancreas (8%), lung (18%), and liver (18%). However, breast cancer still
accounted for 30% of all new cancer cases in women in 2015; furthermore, it is the leading
cause of cancer death for women from ages 20 to 59 years in the United States [1]. A gene
signature in cancer as a predictor for treatment and survival was investigated in earlier
works [2, 3] in which Chiaretti et al. proposed a unsupervised model in 33 adult patients
with T-cell acute lymphocytic leukemia (T-ALL). They found that a single gene interleukin
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8 (IL-8) is strongly associated with resistance to first-line treatment and that 3 genes (CD2,
TTK, and AHNAK) are highly predictive of outcome in uniformly treated adults with TALL [2,3]. De Vijver et al. used a multivariate Cox regression analysis model on a database
of 295 patients with breast cancer who have a gene expression signature associated with
poor vs good prognosis. They found that their prognosis profile were more informative in
identifying distant metastases of young breast cancer patients than standard system using
clinical and historical information [3].
Chang et al. obtained a wound response signature from 295 patients with early
breast cancer. They assume that the features of the molecular responsible for normal wound
healing might play a key role in cancer metastasis. The proposed method investigates those
signature genes’ expression in patients with cancer. They found that both overall survival
and distant metastasis-free survival are markedly diminished in patients whose tumors
expressed the wound response signature compared with tumors that did not express this
signature [4].
Pederson et al. employed a genetics specialist embedded within a multidisciplinary breast clinic and studied the hereditary cancer risk to assist the decision making in
cancer treatment. The study focuses on accelerating the surgery based on genetic information. That model was used to compare cancer care between 471 patients in 2012 and 440
patients in 2014. Before embedding a genetic counselor and the following intervention, the
results show that genetic counseling has influenced time to treatment in the 2014 cohort
of patients. Recommendation for surgery such as bilateral mastectomy is done for women
with mutations in TP53 and PTEN [5].
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In this work, we use supervised and unsupervised machine learning methods to
deal with a multiclass classification problem in which we label the samples based on the
combination of the 5-year survivability and treatment; we focus on hormone therapy, radiotherapy, and surgery. The proposed unsupervised hierarchical models are created to
find the highest separability between combinations of the classes. The supervised model
consists of a combination of feature selection techniques and efficient classifiers used to find
a potential set of biomarker genes specific to response to therapy. We used hierarchical
clustering approach based on Ward’s linkage to find better borders among the groups of
different classes and then apply standard classifiers on these clusters. The results show that
different models achieve different performance scores with accuracies ranging from 80.9%
to 100%. We have investigated the roles of many biomarkers through the literature and
found that some of the discriminative genes in the computational model such as ZC3H11A,
VAX2, MAF1, and ZFP91 are related to breast cancer and other types of cancer.

4.2

Materials and Methods

Samples from a publicly accessible data set of 2433 patients with breast cancer and survival
are used in this approach [7]. After analyzing the given data, 6 classes were identified as
the baseline of this work. These classes are the combination of each treatment (surgery,
hormone therapy, radiotherapy) with a patient status (living or deceased). The number of
samples (patients) for each class is shown in Table 4.1.
Figure 4.1 depicts the distribution of the number of samples by breast cancer
subtypes in each class. The subtypes are well-distributed in each class; at least 3 subtypes
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Table 4.1: Number of samples per class
Class

# Samples

Living and Radio therapy(LR)

132

Deceased and Radio therapy(DR)

19

Living and Hormone therapy (LH)

20

Deceased and Hormone therapy(DH)

6

Living and Surgery (LS)

130

Deceased and Surgery (DS)

40

are represented in each class, which means that the possibility of correlation between
subtypes and classes is not significant.
Based on the available data, only 3 treatment therapies are covered; they are
surgery, hormone therapy, and radiotherapy (Figure 4.2). Our proposed model is a bottomup hierarchical multiclass tree obtained using the agglomerative clustering technique. The
pipeline of the proposed model starts with filtered feature selection methods, including Chisquare [8] and Infomation-Gain, which are applied for limiting the significant number of
features (genes). Then, a wrapper method is used to obtain the best subset of genes that
represent the model using mRMR (minimum redundancy maximum relevance) feature
selection method [9]. After that class balancing techniques such as Synthetic Minority
Over-Sampling Technique (SMOTE) [10] and cost-sensitive [11] are applied to balance the
number of classes before applying a classification method. Finally, a small number of
biomarker genes are identified for prediction. To the best of our awareness, this work is
the first prediction model to combines the treatment and the survival status of a patient
as the class label.
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Figure 4.1: The distribution of number of samples by breast cancer subtypes in each class.
The distribution of the number of patients per class is shown in Figure 4.3. It is
clear that there are significant differences between the number of samples of the different
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Figure 4.2: The distribution of number of samples by breast cancer subtypes in each
treatment.
classes, which requires class balancing to achieve a fair classification.

4.2.1

The Bottom-Up Multiclass Classification Approach

In our proposed bottom-up approach, we build 5 models based on the linkage type between
classes. We start with 6 distinct data sets of samples corresponding to the 6 classes and
then build hierarchical clustering tree by a bottom-up fashion. The flow chart is illustrated
in Figure 4.4, which shows the steps (in integers) for obtaining the 5 models based on the
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Figure 4.3: The percentage of samples by class.
distance between the classes.
Generally, a hierarchical clustering method relies on a function specifying the
distance between two samples and a linkage (or criterion) to decide which pair of clusters
to be merged. Initially, each sample is a cluster, and in our case, each class is a cluster.
The method keeps choosing a pair of cluster to merge until there is only a single cluster.
The common linkages include single linkage, complete linkage, average linkage, centroid
linkage and Ward’s linkage. We used the Euclidean distance for the distance between
two samples and the Ward’ linkage [12, 13]. For details of other linkages, we refer reader
to [12, 14]. The Euclidean distance between the sample x = {x1 , x2 , ..., xn } and the sample
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Figure 4.4: Schematic representation of the proposed models based on linkage type.
y = {y1 , y2 , ..., yn }is defined as Equation (4.1).

d(x, y) = kci − cj k =

s
X

(xi − yi )2

(4.1)

i

The objective of Ward’s linkage is to minimize the within-cluster variance, rather than
reducing the distance between each pair of clusters. Ward’s linkage aims at merging the
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pairs of clusters which results in the minimum increase in the sum of squares within-cluster
variance.
The amount of increase in the sum of squares within-cluster variance when we
merge two clusters i and j can be estimated as Equation (4.2).

delta(i, j) =

Ni × Nj
kci − cj k2
Ni + Nj

(4.2)

where Ni and Nj are the numbers of samples in cluster i and j, respectively, and ci and cj
denote the centers of the clusters; k.k is the Euclidean norm (or Euclidean distance, in our
case).
The mean and cardinality of the newly merged cluster, k, is computed as follows:

ck =

1
(Ni ci + Nj cj )
Ni + Nj
Nk = Ni + Nj

4.2.2

(4.3)

(4.4)

Feature Selection

The gene expression dataset contains 24,368 genes for each of the 347 samples. The curse of
dimensionality makes it difficult to classify the dataset in its current form. Hence, feature
selection is essential to narrow down the number of genes. Chi-square and Info-Gain (i.e.,
mutual information) are applied to select the best information gain of the selected genes,
then mRMR (minimum redundancy maximum relevance) feature selection is applied to
find the best subset of significant genes.
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4.2.3

Class Balancing

The five models utilize one-versus-rest strategy to handle the multiclass problem, which can
lead to an unbalanced class dataset at each node of the hierarchical classification model.
We tried the following techniques to handle this:
• Resampling. Resampling involves removing samples of the majority class (undersampling) or generating more samples for the majority class (over-sampling). In this
work, we used one of the most popular algorithms, Synthetic Minority Over-Sampling
Technique (SMOTE).
• Cost-sensitive classifier. Cost-sensitive learning takes the costs of prediction errors into account when training a machine learning model, usually by putting more
penalty on errors in predicting the minority class. This, in turn, bias the model
to pay more attention to the minority class. In this work, we use Cost-Sensitive
Classifier in Weka that uses a classification method along with a penalty matrix to
overcome the imbalance.

4.2.4

Classification

After using a linkage for agglomerative clustering, which identifies the closest classes for
merging, we obtained a hierarchical tree, as in Figure 4.5. Then, standard classifiers can
be applied to determine which biomarker genes are the most discriminative for separating
the samples of the classes in each branch of the tree.
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We used the libSVM library [15] to train a support vector machine (SVM) classifier with radial basis function kernel was trained within a grid search algorithm to optimize
the classifiers’ parameters.

4.3

Results and Discussion

After running the algorithm on our dataset, Ward’s linkage method achieved the best
accuracy and most meaningful hierarchy among the linkages, based on the 6 classes. The
reason might be because the objective function of Ward’s linkage is to minimize the withincluster variance rather than reducing the distance between each pair of clusters; thus, it
can improve the classification performance. Ward’s linkage yielded a balanced tree of the

Figure 4.5: Ward’s linkage model: classification model with performance measures.
treatment-and-survival clusters as shown in Figure 4.5. Table 4.2 shows the discriminative
genes between each group of clusters in the tree. The separation between the clusters in
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the lower part of the tree is significantly high. The accuracies of classifying nodes are 100%
for DH vs LH, and 99.2% for DS vs LS. The accuracies remain high in the middle part
of the tree with accuracy 99.6% for the left side which is (DH, LH) vs LR, 99.5% for the
right side which is DR vs (DS, LS). The scores drop down on the root of the tree where
we classify the left side vs the right side of the tree to 81.8%. The results for the other
linkages are presented in the supplementary materials of [14].
Table 4.2: Selected genes in Ward’s linkage model.
Model

Genes

DH vs. LH

DS vs.LS

INO80,
PAX7

CA334854,
TNFRSF6B,
AX746743,
BU189136,
PLEKHB2,
IL1RAPL2,
DUSP21,
NUFIP,
LIPJ,
ARSK,
MAF1,
PRKD2

LR vs.
DH LH

AA399560,
AA884297,
CR626459,
VAX2,
ANO8,
ZBTB43,
RFT1,
TSKU

DR vs.
DS LS

LR DH LH vs.
DR DS LS

AK130741,
PDCD7,
TBX21,
ATL1,
P2RX3

FAM108B1,
AI699581,
ZC3H11A,
DSCAM,
ZNF618,
MARK2,
RPS7,
EIF2C2,
ROBO1,
IMAA

Figure 4.6 shows a multidimensional representation of the plot matrix for the 5
discriminative genes found in Ward’s linkage model for the node of DR class vs (DS, LS)
class, as an example. The figure also shows the relations among the 5 genes with each
other.
Figure 4.7 shows the boxplot for some selected genes which indicates the minimum, first quartile, median, third quartile, and maximum gene expression values for each
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Figure 4.6: The relation between the 5 genes used in node DR vs (DS, LS) of Ward’s
linkage model.
group of samples (DH vs LH) and (DR vs [DS, LS]). The gene expression of INO80 is
slightly upregulated in the DH samples comparing with the LH samples, TBX21 is also
upregulated in the DR samples comparing with the [DS,LS] samples. While, the gene
expression of PAX7 is downregulated in the DH samples comparing with the LH samples,
and that of AK130741 is also downregulated in the DR samples comparing with the [DS,
LS] samples.
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Figure 4.7: Boxplot for the biomarker genes in Ward’s linkage model shows the minimum,
first quartile, median, third quartile, and maximum gene expression values for each group
of samples (DH vs LH) and (DR vs [DS, LS]).
As shown in Figure 4.8, the gene CA334854 has a strong correlation coefficient
with the two genes AX746743 and IL1RAPL2 in the DS samples. Whereas, there is no
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Figure 4.8: Circos plot for the biomarker genes in Ward’s linkage model for the DS class
samples based on the correlation coefficient among gene expressions (p < 0.05).
significant correlation between them in the LS samples as shown in Figure 4.9.
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Figure 4.9: Circos plot for the biomarker genes in Ward’s linkage model for the LS class
samples based on the correlation coefficient among gene expressions (p < 0.05).

113

4.3.1

Biological Insight

For the node DH vs LH, INO80 and PAX7 genes are both involved in the regulation
of epigenetic histone marks and chromatin remodeling [16]. As part of the analysis of
epigenetic modifications around INO80 interaction site, Mendiratta et al. studied the
NO80-binding region of HOXC11 and PAX7 genes by ChIP with anti-H3K9ac and antiH3k27me3 followed by quantitative polymerase chain reaction. In both the cases studied,
INO80 enrichment was correlated with H3K27me3. [17] Both of them also were reported
in protein-protein interaction network for cancer. [18]
Some of the found genes in the computational model are related to breast cancer.
Cai et al. studied the identify breast cancer susceptibility loci rs4951011 at 1q32.1 in intron
2 of the ZC3H11A gene; the 3-genome study was conducted on patients from the Eastern
Asian population mainly Chinese and Koreans. They also found that expression levels of
the ZC3H11A gene were significantly higher in the tumor tissue than in adjacent normal
tissue (P = .0049) in TCGA (The Cancer Genome Atlas) data. The function of ZC3H11A
is not clear. [19]
VAX2 is a protein-coding gene that encodes a homeodomain-containing protein
from a class of homeobox transcription factors that are conserved in vertebrates [20]. Gu
et al. [21] identified the top 40 most correlated genes with similar methylation patterns calculated by Pearson correlation; VAX2 is one of them. VAX2 is found to be a transcription
factor that regulates 3 genes (PLCB4, ADCY6, and CNR1) in RNA tissue in response to
chemotherapy in patients with operable breast cancer [22]
MAF1 displays tumor suppressor activity. Surprisingly, blocking the synthesis of
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ribosomal RNA and transfer RNAs is insufficient to account for MAF1’s tumor suppressor
function. MAF1 binds to the PTEN promoter to enhance PTEN promoter acetylation and
activity. MAF1 downregulation unexpectedly leads to activation of AKT-mTOR signaling,
which is mediated by decreased PTEN expression [23]. ZFP91 serves as a positive regulator
for MAP3K14 gene, causing its stabilization and activation. Overexpression of MAP3K14
has been associated with neoplastic growth such as in melanoma, pancreatic carcinoma,
lung cancer, breast cancer, multiple myeloma, and adult T-cell leukemia. ZFP91-mediated
stabilization may tolerate one of the mechanisms of MAP3K14 oncogenic activation [24].
Labhart et al. [25] identified DSCAM as one of the target genes in breast cancer
cells which are directly regulated by the SRC-3/AIB1 coactivator. Stuhlmiller et al. [26]
defined a signature of kinases that regulate MARK2, the kinases involved in significant
changes for MIB binding after 48-hr lapatinib treatment for breast cancer cells. ROBO1
is a cell adhesion receptor that is a survival and growth factor for breast cancer [27] Using
cBioPortal [28], we investigated the pathway of genes on another breast cancer data set [29].
The genes DSCAM, MARK2m, and ROBO1 were found connected in the pathway shown
in Figure 4.10. DSCAM and MARK2 were also reported to be in two pathways combined
with RPS7 in Reactome pathway knowledgebase [30]; the two pathways are axon guidance
(R-HSA-422475) and developmental biology (R-HSA-1266738).
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Figure 4.10: Circos plot for the biomarker genes in Ward’s linkage model for the LS class
samples based on the correlation coefficient among gene expressions (p < 0.05).
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4.4

Conclusion

In conclusion, a hierarchical clustering model based on Ward’s linkage found to be discriminative in drawing borders for treatment-survival classes in breast cancer. Based on the
gene expression data, standard classifiers perform very well in the nodes of the clusters in
the constructed hierarchical tree. The results suggest subsets of genes, in which, some of
the genes in the same nodes are reported to be related in functions or pathways, and some
of them are strongly related to breast cancer. ZC3H11 is highly statistically significant
expresses in tumor tissue, MAF1 is a tumor suppressor, and ZFP91 is a positive regulator
for MAP3K14 that is related with breast cancer. MARK2 and ROBO1 have coexisted in
some pathways; also, ARSK and PRKD2 have the same case.
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Chapter 5
A Sub-network Selection Method for
Identifying Biomarkers of Breast Cancer
Survivability

5.1

Introduction

Breast cancer is characterized by uncontrolled cell growth or a decreased capacity to initiate
programmed-cell death. Breast cancer is caused by mutations that damage cellular DNA,
directly or indirectly, which subsequently confers a selective growth advantage. Because
mutations can be carried on to successive cell divisions, malignant cells may share some
common patterns in gene expression. Thus, gene expression (GE) has been used in many
machine learning approaches to develop classification models for diagnosis or prognosis of
breast cancer. One main challenge among these approaches is that the number of genes
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is usually very large and exceeds that of samples. This prevents methods from finding
good patterns for prediction purposes. Feature selection approaches are usually applied to
extract the most informative subsets of genes for prediction which can be considered as
the potential biomarker.
A common issue of traditional feature selection approaches based mainly on a
single type of data is that the classification performance tends to decrease significantly
when applying the model learned from one dataset to another dataset. Alternatively,
there is just a minor overlap between biomarkers found from different studies on the same
data [1,2] because many subsets of features can yield equally high performance and different
approaches explore the space of subsets of features differently. Additionally, without taking
other useful knowledge of the genes into account, the selected genes might not provide
evidence for revealing the disease mechanism.
Recently, a new collection of methods referred to as network-based machine learning has gained interest due to the ability to integrate existing relations among genes into
the biomarker detection processes. [1–5]. These methods often combine primary data,
e.g., GE, with one or more secondary network data expressing the functional relationships
among genes, such as protein-protein interactions (PINs), cellular pathway maps, gene
co-regulatory networks, or other “omics” data. They aim at identifying the most discriminative subsets of interacting genes for prediction, referred to as sub-network (or subnet, for
short) biomarkers. The useful knowledge from such networks might possess more evidence
of true biomarkers as the output.
As a PIN can involve thousands of nodes and millions of edges, the search space
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of the subnets is clearly vast. For example, in ConsensusPathDB data [6], there are a
lot of proteins having thousands of interactions. This consequently results in a very large
number of sub-networks to analyze in the local areas of these nodes. Many methods have
proposed scoring functions to weight the nodes, edges, or sub-networks and then applied the
searching algorithms to identify sub-network biomarkers. The search can be classified as a
greedy search, simulated annealing genetic algorithms, random walk with restart, integer
linear programming, and many more [3, 7, 8]. We will briefly summarize some networkbased machine learning approaches that utilize protein-protein interactions. Also, we will
discuss a previous study on breast cancer survivability that applied a feature selection
method.
In [1, 2], a sub-network can be considered as a meta-gene. For each patient,
the expression of the meta-gene is calculated as the average expression of its genes. The
proposed methods try to find informative meta-genes, the, transform GE data into metagene expression data, and finally applied a classification method on the new data. They
start a candidate sub-network by a seed gene and gradually extend it to neighboring genes
until a certain conditions are met. The neighboring gene chosen to extend the current subnetwork must increase the mutual information between the corresponding new meta-gene
and the class the most.
In [4], a gene-gene co-regulation network (GGCRN), induced from brain tissue
in EQTL data, and a PIN from the Human Protein Reference Database (HPRD) [9] were
combined. Then they used a random walk with restart algorithm to find Alzheimer-related
candidate genes. Two genes were considered “co-regulated” if they shared a significantly
common proportion of single-nucleotide polymorphisms. 14 out of 29 known Alzheimer125

related genes were used as source nodes and initialized with equal probabilities.
In the WMAXC algorithm [5], two networks are merged into one to solve a constrained optimization problem and find an optimal subnet. For the first network, the weight
of a node is calculated based on the differentially-expressed ratio of gene expression, and
the weight of an edge is the conditional expectation of differential gene-gene co-expression
of its pair of genes. For the second network, induced from GE and PIN, node weight and
edge weight are computed based on the node degree, the within-group distance and the
within-group variances of the pairs of genes.
ML models for breast cancer survivability/metastasis prediction can be based
on non-genomics information, such as age, hormone receptors, grade, tumor size, HER2,
treatment, lymph nodes, and locoregional recurrence [10–12], or genomics data such as gene
expression [13–15], or both. In a previous study, we applied unsupervised and supervised
methods to construct a hierarchical classification model to predict appropriate treatment
therapy for breast cancer patients based on their gene expression profile. [17]. The class
labels were combined from the treatment and survivability status of patients, thus making
this a multi-class classification problem. The hierarchical clusters were constructed by the
average linkage, whereby each leave node is the set of patients of a class. A wrapped
feature selection using Minimum Redundancy Maximum Relevance score (mRMR) [18]
and support vector machine (SVM) were conducted to select the genes for prediction at
each internal node.
In this work, we present a network-based method, named Sub-network Selection Based on Predictive Ability (SSPA), to select sub-network biomarkers for identifying
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breast cancer treatment outcomes, including disease-free survival (“Disease Free”), and
overall survival at five years (“Died Before 5-years”) and long-term (“Died After 5-years”).
Treatments investigated are hormone therapy (HT), chemotherapy (CT), radiation therapy
(RT), or surgery-only (SO). Gene expressions of the patients are used to estimate the predictive power of the sub-network candidates, and to evaluate the classification performance
of the sub-networks by SVM. Meanwhile, a PIN guides the generation of sub-network candidates. Unlike the methods in [1,2], we generally avoid generating redundant sub-networks
by selecting only a subset of seed genes to create the sub-network candidates. We also defined a scoring function to estimate the predictability of a sub-network, called PA, by which
we can rank sub-networks and further prune the search space. Therefore, only a portion
of generated subnets is evaluated at each step. After obtaining the sub-networks that can
yield high classification performance, we correlate them with cancer-relevant gene pathways
and literature to extract the most biologically meaningful biomarkers. Our method found
better sub-networks than the effective methods in [1] and [16]. The sub-networks identified in this study contain well-known breast cancer genes and genes involved in important
cancer-related pathways.

5.2

Data

We collected GE datasets and clinical information from breast cancer patients that received
one of four treatments (CT, HT, RT, SO) from the Molecular Taxonomy of Breast Cancer
International Consortium study [19]. There are about 25000 genes in total. Patients who
died from a non-cancer cause prior to 5 years of their diagnosis were excluded (because
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none of the three classes can be assigned to them). The data distribution for datasets of
the four treatments are shown in Table 5.1.
For interaction network data, we combined the HPRD version 9 with the ConsensusPathDB (downloaded on Dec 2016). After processing, we had a final network of 180614
interactions.
We collected 2382 pathways from Reactome [20], and WikiPathways [21] databases.
About 8000 cancer-related genes were gathered from several resources including [22], [23].
The intermediate extracted sub-networks will be analyzed with these data for biological
meaning.
Table 5.1: Data distribution versus treatments.
Dataset

5.3

CT

HT

RT

SO

Disease Free

7

135

119

35

Died Before 5-years

19

53

21

47

Died After 5-years

17

68

33

110

#Samples

43

256

173

192

Method

The pipeline of SSPA is shown in Figure 5.1. First, we select a set of seed genes so that
the optimal sub-network induced from each seed can be both accurate in classification
and biologically meaningful. Second, an optimal sub-network is derived from each seed
gene by repeatedly generating the candidate sub-networks, filtering out the redundant
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sub-networks, and evaluating the remaining ones by SVM. Finally, among the optimal
sub-networks, we select the ones that have Matthew Correlation Coefficient (MCC) larger
than a threshold, and then compute their relevance to pathway data and known cancerrelated genes. These top 10 sub-networks, along with their relevant information, will be
sent to biologists to investigate the biological significance. Details of each step will be
described and discussed in the subsections.
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Figure 5.1: Flow chart of SSPA.
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5.3.1

Seed Gene Selection

A set of breast cancer-related genes and predictive genes were considered as the seeds.
Predictive genes are the ones having the mutual information to the class greater than 0,
using Weka software. For random discrete variables, mutual information is computed as
Equation (5.1). Breast cancer-related genes include 40 driver-genes in [19] and 84 genes
which correlate to cellular growth inhibitory effects (i.e., GI50) of some drugs used in breast
cancer [16]. Since there is no more than 200 genes selected by the mutual information, the
number of seed genes for each treatment (dataset) is relatively small as compared to the
total number genes in the gene expression dataset.

I(X, Y ) =

X

px,y

x,y

log(px,y )
px × py

(5.1)

The seed gene selection step is a simple heuristic to eliminate redundancy in subnetworks since it reduces the incidence of generating sub-networks containing no predictive
gene at all. Some useful sub-networks might be eliminated as well, but it is an unavoidable
situation when dealing with high dimensional data. By the seed gene selection, we expect
to obtain sub-networks containing predictive genes and breast-cancer-related genes, that
could serve as biological biomarkers. The sub-networks generated will have at least a single
gene belonging to one of the two types.
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5.3.2

Optimal Sub-network Selection

Algorithm 1 illustrates the search for an optimal sub-network S for a given seed gene s,
in a bottom-up fashion because the sub-network biomarkers of small size tend to be more
robust than the large ones [24, 25]. The current subnet S is initialized by the seed gene.
New candidate sub-networks are generated by adding to S a neighboring gene of any gene
of S, with respect to the PIN structure. Only the candidates having PA ranked in the top
k will be kept to be evaluated by SVM for their quality (in 10-fold cross-validation, with
parameter tuning). The sub-network with the highest MCC is chosen for further extension
in the next iteration. This greedy search continues until there is no more neighboring gene
within the given maximum distance allowed from the seed s; or until S reaches the given
maximum allowed size.
We choose MCC as the evaluating metric because it is known to be one of the
most suitable metrics for imbalanced data.
Because there are many genes having thousands of neighboring nodes, the number
of possible sub-networks generated can grow exponentially. Evaluating all of them requires
a long period of time, especially by expensive methods such as SVM or Random Forest.
Thus, we limit k = 20, maxDepth = 4, and maxSize = 40 for our approach to complete in
an acceptable amount of time.
We define the PA score, as in Equation (5.2), to estimate the predictive ability of a
sub-network S via its genes. To improve time efficiency, only sub-networks with PA ranked
in top k (step 5) will be evaluated by SVM (step 6); the other subnets are considered as
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redundant and skipped.

P A(S) =

X
2×b
1 X
I(gi , C) −
I(gi , gj ),
|S| g ∈S
|S| × (|S| − 1) g ,g ∈S
i

i

(5.2)

j

where, C is the class and gi is a gene in S.
The PA score is actually a modified version of the mRMR [18]. The first term
(sum) of PA is the average mutual information between a gene gi in S and the class C,
which expresses average non-linear correlation of a gene and C. The second term of PA
expresses the redundancy of S via the average linear correlation of its pairs of genes (gi , gj ).
The regularization factor b is to adjust the importance of the redundancy. PA is almost
equal to mRMR when b equals 1.
Note that the mutual information between two genes might not be in the same
range as the mutual information between a gene and the class (the maximum of I(X, Y) is
the minimum of the entropies of the individual variables). If we discretize the expressions
of the genes into more (or less) number of intervals than the number of classes then the
former mutual information tends to be larger (smaller) than the latter. While the first
term is more important in estimating the predictive power of S, setting b larger than 1
might mislead the purpose of the estimation. In our experiments, we tried b with 1, 0.5,
and 0.25.
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Algorithm 1. Finding an optimal sub-network for a seed gene.

Input. s: a seed gene; PIN: a set of protein-protein interactions; k: the number of
top candidates to evaluate at each iteration; maxDepth: the maximum depth allowed
for neighboring genes; maxSize: the maximum size of the sub-network.
Output.S: the optimal sub-network for s.

Method.
1. S = {s}
2. N = {n: (n, s) in PIN}
3. repeat step 4 to step 8 if (N is not empty and |S| < maxSize); otherwise, return
S
4. Ci = S ∪ {ni } , for ni in N
5. K = {Ci : PA(Ci ) ranked in top k}
6. S = C in K, where the MCC of C is the highest, evaluated by SVM.
7. Mark g as visited, where {g} = C\ S
8. N = N ∪ {n}, for every (n, g) in PIN such that shortest path length of (n, s) ≤
maxDepth
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5.3.3

Sub-network Prioritization by Pathway-Relevant and CancerRelevant Analysis

After step 2 of SSPA, the optimal sub-networks with MCC larger than a given threshold
will be selected. We compute their relevance with pathway data and cancer-related genes
before choosing the ones that can be considered as potential biomarkers. Given BC and
OC, the lists of known breast-cancer-relevant genes and cancer-relevant genes, respectively,
we score the importance of a gene g as Equation (5.3). The equation is just based on the
intuition that breast cancer-related genes should be more important than other cancerrelated and normal genes.

Wg =





12, if (g ∈ BC) ∧ (g ∈ OC)







10, if (g ∈ BC) ∧ (g ∈
/ OC)

(5.3)




4, if (g ∈ OC) ∧ (g ∈
/ BC)







1, otherwise

Besides, if some genes in a sub-network participate in some pathways, they might
reveal certain mechanisms of the disease. Once a sub-network includes cancer-related
genes or pathway-relevant genes, it can provide us some biological insight and support the
decision whether the sub-network can be a valid bio-marker or not.
Then, the relevance between a sub-network S and a pathway P is defined based
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on their overlapping genes as Equation (5.4), where |.| denotes the set cardinality.
P

g∈S∩P Wg
R(S, P ) = p
|S| × |P |

(5.4)

Then, the importance of a network S is defined as Equation (5.5), where PL is a
list of all available pathways.
Im(S) =

X

P (S, P )

(5.5)

P ∈P L

5.4

Results and Discussion

From the top 10 sub-networks extracted at the end of step 3, by Equation (5.5), we
manually select a representative sub-network for each of the mentioned treatments (e.g.,
CT, HT, RT, and SO). They are visualized in Figures 5.2, 5.3, 5.4, and 5.5. Generally,
these sub-networks have more overlapping pathways than other sub-networks of the same
treatment and their corresponding MCC are significantly close to the highest MCC.

5.4.1

Classification Performance Comparison

Table 5.2 presents the classification performances of SSPA and four other methods, including mRMR+SVM, mRMR+RF, RFE+SVM, PinnacleZ*. The results for SSPA and SSPA*
were obtained based on the representative sub-networks and the sub-networks which have
the highest MCC, respectively. mRMR+SVM (and mRMR+RF) denotes the wrapped
feature selection approach combining mRMR and SVM with linear kernel (mRMR and
136

Random Forest, respectively) in a greedy forward selection. These wrapped feature selection approaches have shown to be effective in [16, 17], and in our experience, they have
often yielded better results than many other traditional feature selection methods. Due to
the high dimensionality problem, we applied mRMR+SVM and mRMR+RF on a reduced
initial gene set which is the union of the seed genes and their neighbors within distance 1
(according to PIN). RFE+SVM denotes the Recursive Feature Elimination (RFE) method
using SVM with linear kernel as the evaluator for feature selection. The method fits SVM
on the training datasets, ranks the features by the average coefficient and removes the
weakest feature one by one until the specified number of features is reached. The reported
measures (accuracy, MCC, etc) are averaging based on the testing datasets. PinnacleZ*
denotes an approach where we transformed the gene expression data to meta-gene expression data as the method described in [1] but after that we applied mRMR+SVM on the
transformed data (PinnacleZ does not perform a wrapper feature selection).
Generally, we observed the following trends: (1) RFE+SVM usually gives the
best classification performances, (2) SSPA* is usually ranked as the second best in MCC
and accuracy, (3) SSPA often returns higher MCC and accuracy than PinnacleZ*, except
for CT, and (4) the network-based methods (i.e., SSPA, SSPA*, and PinnacleZ*) produce
better results than mRMR+SVM and mRMR+RF. Although mRMR+RF is often ranked
the fourth in term of MCC, it often yields higher AUC than other approaches for other
treatments, except RFE+SVM and SSPA*.
All methods give high classification accuracy for CT patients. The representative
sub-network for CT yields 93% of accuracy (MCC = 0.893), almost similar to the results
returned by PinnacleZ*. mRMR+SVM and mRMR+RF give the lowest accuracy, 88.4%.
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Table 5.2: Classification performance comparison between SSPA and other methods in
terms of accuracy (ACC), MCC, and area under the ROC curve (AUC).
Dataset

CT

HT

RT

SO

Method

Accuracy

MCC

AUC

SSPA*

97.67%

0.967

1

SSPA

93.00%

0.893

0.939

mRMR+SVM

88.40%

0.816

0.911

mRMR+RF

88.40%

0.818

0.989

RFE+SVM

90.3%

0.858

0.917

PinnacleZ*

93.02%

0.9

0.974

SSPA*

79.30%

0.663

0.871

SSPA

73.44%

0.565

0.689

mRMR+SVM

65.60%

0.437

0.713

mRMR+RF

61.70%

0.338

0.789

RFE+SVM

91.7%

0.859

0.922

PinnacleZ*

70.70%

0.512

0.786

SSPA*

87.86%

0.766

0.773

SSPA

84.39%

0.702

0.728

mRMR+SVM

75.70%

0.461

0.71

mRMR+RF

78.60%

0.499

0.886

RFE+SVM

97.1%

0.948

0.963

PinnacleZ*

79.19%

0.548

0.698

SSPA*

80.21%

0.667

0.778

SSPA

82.69%

0.661

0.807

mRMR+SVM

70.80%

0.488

0.728

mRMR+RF

72.90%

0.52

0.853

RFE+SVM

96.9%

0.947

0.956

PinnacleZ*

78.13%

0.615

0.82

138

For RT, the accuracy of SSPA* and SSPA is 87.86% (MCC=0.766) and 84.39%
(MCC=0.702), respectively, which is 5% higher than the accuracy of PinnacleZ*. mRMR+RF
is the second last in terms of accuracy (78.6%), but it is the second most accurate in terms
of AUC (0.886). RFE+SVM return the highest accuracy, about 97%.
For SO, RFE+SVM returns the highest accuracy, almost 97%, followed by SSPA
with accuracy = 82.69% and the corresponding MCC is 0.661. SSPA* ranks in the second
in terms of MCC (0.667), and mRMR+RF ranks in the second in terms of AUC (0.853).
mRMR+SVM is ranked the last for all measurements.
HT patients seem to be the hardest cases to predict. RFE+SVM is still the best
in all terms with accuracy is nearly 92%. SSPA* is the second best in all terms but the
accuracy drops to 79.3%, followed by SSPA (accuracy = 73.44%) and PinnacleZ* (accuracy
= 70.7%). mRMR+RF returns the worst accuracy (61.7%) and MCC (0.338).

5.4.2

Biological Insights of the Representative Sub-networks

It is noteworthy that each sub-network generated may not have at least one breast cancerrelated gene since many seed genes are not breast-cancer-related. Surprisingly, the figures
indicate that the representative sub-networks contain many breast cancer-related genes
(red nodes). Moreover, they are also relevant to some pathways (triangular nodes). Among
the top 10 extracted sub-networks, there are more than 60 genes related to breast cancer
genes including NEDD4, FGFR2, PAPOLA, SMAD2, STAT5A, FGF8, MAPK8, CASP8,
CSTF3, EIF2S2, AKT1, GSK3B, UBA52, TERT, RARB, APC, UBE2D1, ACVR1C,
RIPK1, TP53 and PIK3CA. These genes play a critical role in pathways involving cell
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growth control, DNA repair mechanism, etc. In literature, there are a lot of publications
indicating the importance of STAT5, PIK3CA and TP53 in breast cancer. PIK3CA encodes a subunit of phosphatidylinositol 3-kinase that triggers AKT1 signaling and can
interact with ERBB4, FGFR and MAPK signaling in cancer [20].

TP53 – An Important Gene in the Representative Sub-network for CT
The representative sub-network of CT is shown in Figure 5.2, where 12 out of 14 genes
are pathway-relevant genes (triangular nodes) and 3 of them are breast cancer-related
genes (red nodes). There are several facts in the literature supporting its structure and
pathway/cancer-relevant genes. Especially, the well-known breast cancer gene, TP53 (or
p53), is a hub in this sub-network. TP53 contributes to multiple cancer-related pathways,
including “MAPK signaling pathway”, “DNA repair”, “programmed cell death”, etc. P53
is a primary tumor suppressor gene that is situated in the midst of a critical signaling hub
and is targeted in many cancer therapies. The logic for developing therapeutics targeting
p53 is that p53 is well connected as a central signaling hub. Thus, knocking it out cripples
the normal functioning of the cell and promotes malignant transformation [26].
There is evidence that links TP53 and chemotherapy. In [27], TP53 mutations
occurred in approximately 25% of breast cancers and were associated with poor prognosis
and resistance to doxorubicin treatment. In [28], chemotherapy-treated patients with TP53
wild-type tumors had poor survival, which was consistent with models demonstrating that
p53 induces cell cycle arrest and senescence as opposed to cell death. According to [29], all
cancers have been shown to have a defective p53 pathway, either by a direct TP53 mutation
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or by deregulation of another determinant of the p53 pathway. The mutant p53 molecular
profile may provide extremely precise predictors of disease outcomes and of responses to
therapy.

Figure 5.2: The representative sub-network for CT. Genes overlapped with some pathways
are shown in triangular. Breast-cancer-related genes are in red and yellow are for cancerrelated genes.

ERBB4/HER4. STAT5A, and NEDD4 –Important Genes of the Representative Sub-network for HT
Many pathways involve the human epidermal growth factor receptor ERBB4 (or HER4),
such as “Down-regulation of ERBB4 Signaling”, “Signaling by ERBB4”, “PI3K Events in
ERBB4 Signaling”, and “Nuclear Signaling by ERBB4” [20]. ERBB4 is known as a recep141

tor tyrosine kinase that interacts with NEDD4 and STAT5A [30]. Mutations in ERBB4 are
affiliated with several cancers [31]. It is shown in [32] that NEDD4, an E3 ubiquitin-protein
ligase, minimizes ERBB4 signaling through the promotion of HER4 proteolytic degradation. Additionally, NEDD4 modulates important pathways involved in cancer development.
Overexpression of NEDD4 is implicated in cancer through the negative regulation of tumor
suppressors [33]. ERBB4 signaling leads to STAT5A phosphorylation. Co-expression of
STAT5A and ERBB4 in breast cancer cells mediates tumor progression through stimulation of breast-development genes [34]. Reduced levels of STAT5A is associated with a
poorer clinical prognosis and an elevated risk of hormone therapy failure. As a prognostic
marker, STAT5A could precisely predict the response to hormone therapy [35].
Overexpression of ERBB4 in triple-negative breast cancer was linked to worse
prognosis using a 5-year survival analysis. ERBB4 may be used as a potential survival
biomarker for patients with triple-negative breast cancer [36]. Elevated expression of HER4
corresponded to a lengthier relapse-free survival period, independent of breast cancer subtype. Furthermore, HER4 was revealed to be a better predictive marker for survival in
patients with non-triple negative breast cancer. It is evident that HER4 may be used as a
survivability biomarker in patients with breast cancer [37].
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Figure 5.3: The representative sub-network for HT. Genes overlapped with some pathways
are shown in triangular. Breast-cancer-related genes are in red and yellow are for cancerrelated genes.

143

STAT3 – An Important Gene of the Representative Sub-network for RT
STAT3 exhibits considerable overlap between a sub-network for RT and the pathways.
PTK6, or protein tyrosine kinase 6, is involved in STAT3 (signal transducer and activator
of transcription 3) activation [20]. PTK6 is cytoplasmic protein kinase that is categorized
as an oncogene [38]. In tumors, PTK6 drives cell proliferation, migration, and anchorageindependent survival. PTK6 activates STAT3 via phosphorylation, which leads to the
downstream activation of SOCS3 (suppressor of cytokine signaling), which decreases PTK6
signaling via feedback inhibition. Activation of STAT3 by PTK6 is highly associated with
tumor initiation and metastasis in ERBB2-positive breast cancers [39]. Targeting PTK6STAT3 signaling by therapy may have favorable clinical outcomes in patients with breast
cancer. PTK6 protein levels may serve as a valuable prognostic indicator for predicting
the long-term survival of breast cancer patients [40]. A retrospective study revealed that
20-year disease-free survival in patients with breast cancer is correlated to the level of
PTK6 protein. Protein levels of PTK6 may serve as a significant clinical biomarker for
patient survival because protein levels are not dependent on molecular and morphological
markers, such as lymph node involvement, tumor size, and subtype classification [40].
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Figure 5.4: The representative sub-network for RT. Genes overlapped with some pathways
are shown in triangular, breast-cancer-related genes are in red and yellow are for cancerrelated genes.
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FGFR2 – An Important Gene of the Representative Sub-network for SO
FGFR2 is the most common gene of representative sub-network for SO and it relates to
many pathways, such as “Signaling by FGFR2 Fusions”, “Signaling by FGFR2 Amplification Mutants”, “Activated Point Mutations of FGFR2”, “FGFR2c Ligand Binding and
Activate”, and “FGFR2 Ligand Binding and Activation”. [20] The Fibroblast Growth Factor Receptors, or FGFRs, regulate processes involved in cellular proliferation, migration,
apoptosis, and differentiation during embryonic development and tissue repair. FGFRs are
membrane-spanning receptor tyrosine kinases that include four members: FGFR1, FGFR2,
FGFR3, and FGFR4. FGFRs dimerize upon ligand binding and then triggers the activation of PI3K-AKT, RAS-MAPK, P LCγ -PKC, and STAT pathways. Gene amplification of
FGFR2 has been reported in about 5-10% of breast cancer patients and is associated with
poor prognosis [41]. FGFR2 overexpression, because of FGFR2 gene amplification, contributes to the development of breast cancer. Specifically, overexpressed FGFR2 activates
PI3K-AKT signaling, which prevents the initiation of programmed cell-death in breast
cancer. Furthermore, FGFR2 mediated activation of ERK, a member of the RAS-MAPK
cascade, attenuates DNA repair mechanism. In addition, FGFR2 amplification is results
in the overexpression of degradation-resistant forms of the receptor [42]. FGFR2 signaling facilitates breast cancer progression by altering the downstream activation of STAT3,
which is a transcription factor known to increase breast tumor growth [43].
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Figure 5.5: The representative sub-network for SO. Genes overlapped with some pathways
are shown in triangular, breast-cancer-related genes are in red and yellow are for cancerrelated genes.
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5.4.3

Biological Insight of the Genes Selected by RFE+SVM

For each treatment, we finally obtained a subset of 189 genes by RFE+SVM. In each subset,
about 15 to 26 genes are breast-cancer-related, about 55 to 65 genes are cancer-related,
according to the list of 8016 cancer-related genes collected from various public resources.
Among them, many genes associated with cancer-relevant pathways. They include FGFR4,
EGFR, MUC16, FGFR4, GSTP1, PLA2G2A, GPC3, DUSP1, PLA2G16, RUNX2, CDH1,
CYB5A, CTGF, NCOA4, C1QB, CYB5A, CGA, ESR1, KIT, TAT, PYCARD, AIM2,
SAA1, CEACAM1, ESR1, PPP1R1B, PRKAR1A, HPGD, TP63, TGFBR3, PGR, H19.
A large number of selected genes might lead to over-fitting, especially for a small
dataset like CT. However, we hope that some small subsets of such selected genes can give
similar classification performances or at least higher classification performance than that of
SSPA shown in Table 5.2 and meaningful enough for further analysis. The selected genes
also suggest that around the local area of the genes in the interaction network we might be
able to find some combinations of subnets that can yield higher classification performance
than that of SSPA shown in Table 5.2.

5.5

Conclusion and Future Work

We proposed the network-based method SSPA used to identify potential sub-network
biomarkers for breast cancer survivability prediction after a treatment. Gene expression
data and protein-protein interactions expressing existing gene-gene relationships were integrated in a greedy search. To avoid the combinatory explosion problem, we not only
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choose a set of seed genes to generate the sub-networks but also we defined the PA score
to rank the generated sub-networks and then further reduce the number of subnets being
evaluated. After the evaluation phase, the top subnets were analyzed with cancer-related
genes and pathway data for their biological significance. Instead of returning only the
best subnet according to a specific measurement (e.g., accuracy), SSPA returns the top
sub-networks, along with the information about the cancer-related gene and/or pathways
involved. Thus, it is flexible for cancer specialists to choose the suitable ones for further
laboratory analysis.
SSPA found sub-networks with significantly high accuracy for the four mentioned
types of treatments. It outperforms the effective feature selection approaches using mRMR
combined with SVM/Random Forest [16], and the network-based method in [1]. The subnetworks extracted by SSPA contain many breast-cancer related genes and genes involved
in critical pathways. This evidence suggests that our approach is useful in detecting the
sub-network biomarkers for breast cancer survivability prediction.
The fact that RRE+SVM extracted highly accurate subsets of genes suggests
that there might better subnets to be considered as biomarkers.
In the future, we plan to applied our method to find breast cancer survivability
biomarkers for the combinations of the therapies.
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Chapter 6
Identifying Top-k Sub-networks for Breast
Cancer Survivability Prediction

6.1

Introduction

Breast cancer is a common disease in women. Approximately one in eight women commit
with breast cancer over their lifetime [1]. According to SEER data for US female patients
from 2007-2013 [2], the 5-year-survival rate was 99% for patients with tumors located only
in the breast and the rate declined to 85% if the tumors spread to regional lymph nodes,
and dropped to 26% if breast cancer becomes meta-static. In Canada, about 30% of women
patients of earlier stages are prone to develop metastatic breast cancer [3]. Chemotherapy
or hormone therapy can reduce the risk of distant metastases by one third, but still, 70-80%
of patients receiving this treatment would have survived without it [4]. According to the
authors of [5], more than 75% of breast cancers patients have ER+, but their responses
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to therapy vary significantly. This evidence suggests that diagnosis and prognosis factors
still need to be improved in order to provide better treatments [6].
Machine learning (ML) and statistical methods have been applied in order to
predict the survivability of breast cancer patients or to define groups of patients who
share some special characteristics. Both tasks aim at identifying biomarkers for the problems of interest. Some studies have used only clinical information of the patients to learn
classification models [7]. Others have relied on genomics data such as RNA or DNA sequencing, gene expression (GE), mutations, copy number variations (CNV) or copy number
alterations (CAN) to discover the useful underlying patterns in such data. Many ML or
statistical methods are suitable for such data. One of the challenges in this scenario is that
the number of features in genomics data is usually far larger than the number of samples,
though many of them are redundant. This problem, known as the curse of dimensionality,
prevents even the state-of-the-art algorithms from achieving good results. In this regard,
different feature selection approaches have been proposed to avoid over-fitting, and extract
the most informative subsets of features [8–11]. Then, the selected features are, in turn,
considered as potential biomarkers. One non-trivial phenomenon of these approaches is
that the classification performance tends to decrease considerably when a model learned on
one dataset is applied to another independent dataset. In addition, there could be significant differences among the bio-markers found in different studies on the same data [12,13].
These issues refer to the robustness and consistency of the signatures.
In the last two decades, network-based machine learning approaches have gained
a lot of interest in the research community, since they take existing relationships among
genes into account when detecting relevant biomarkers [12–16]. These methods often in158

tegrate primary data, e.g., GE, with one or more secondary network-based data expressing functional relationships among genes such as co-expression networks, cellular pathway
maps, gene regulatory networks, protein-protein interaction networks or other “omics”
data. They aim at identifying the most discriminative subset of interacting genes for prediction, called sub-network (or sub-network, for short) bio-markers. Once integrating such
useful knowledge into the machine learning process, the results from different studies on
the same problem may become more consistent/robust, or they can contain more evidence
of true bio-markers [17–20]. As the interaction network can involve thousands of nodes
and millions of edges, searching for sub-network bio-markers has been a computational
challenge. Different scoring functions have been proposed to weight the nodes, edges, and
sub-networks. Then, many searching algorithms can be used to find relevant sub-network
bio-markers, including greedy search, simulated annealing, genetic algorithms, random
walk with restart, and integer linear programming [14,19–21]. In the following paragraphs,
we briefly summarize some network-based machine learning approaches that make use of
the protein-protein interactions, as well as a previous studies on breast cancer survivability
that we compare with our approach.
In [12], Chuang et al. consider a sub-network as a meta-gene, where its expression
value for each patient is calculated as the average expression of the genes in the sub-network
for that patient. Their idea is to transform GE data into a meta-gene data and conduct the
classification on the meta-gene data. The key is to identify the informative sub-networks. A
sub-network can be initialized by a seed gene, and then gradually extend it to its neighbors
until some conditions based on the mutual information are met. As genes of a sub-network
might correlate to the response variable in opposite directions, the authors of [13] proposed
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the Direction Aware Average operator to compute meta-gene expressions. Furthermore,
they used Sparse Group Lasso as the classifier, which embeds the meta-gene selection in
the model learning step to improve classification performance.
In [22], Galbrun Esther et al. proposed a method to discover the top-k overlapping
dense subgraphs in an unweighted graph. First, they generate the sub-graphs in a top-down
manner and identify the densest subgraph among the sub-graphs of the same size. Then,
they select a set of k subgraphs with respect to an objective function that can maximize
the sum of the density of the individual subgraphs in the set while minimizing the overlap
between the subgraphs. This method motivates us to find the top-k sub-networks of genes
(meta-genes) for prediction. However, our sub-networks will be generated in a bottom-up
manner since in classification we prefer the model based on a small number of features/genes
and small sub-network biomarkers tend to be more robust than large ones.
In a previous study [24] (Chapter 2), we developed classification models to predict the 5-year survivability of breast cancer patients treated with paclitaxel and other
drugs under different circumstances, including combinations of hormone therapy (HT) and
chemotherapy (CT). The initial genes were selected by from the literature. Then, the
Minimum Redundancy Maximum Relevance score (mRMR) [8]) was used to reduce the
available genes. Finally, random forest (RF) or support vector machine (SVM) with radial
basis function kernel were used in a greedy search procedure to select a subset of indicative
genes. These approaches yielded fairly good accuracy in prediction for many cases. However, due to the imbalance of the classes in the datasets, the limited number of available
genes, and other reasons, for some cases, the corresponding Matthews correlation coefficient (MCC) showed that the classifiers were just slightly better than random, especially
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when using RF. We believe that when using more available genes for feature selection we
will get higher classification performances. As long as the available genes are chosen with
respect to the existing knowledge/mechanism about the disease and/or the treatments we
can obtain accurate and meaningful biomarkers [25, 26].
In this work, we introduce a network-based machine learning approach, named
Top-k Dense Sub-networks Based on Joint Mutual Information (KDS), to identify subnet
biomarkers for predicting survivability at five years of breast cancer patients after a treatment. GE and protein-protein interaction network data are integrated into a weighted
gene-gene interaction network (WGGN). One of the contributions is that the weight of an
edge is computed via joint mutual information which expresses the power of the combination of the two genes involved in predicting the class. Thus, this WGGN differs from
the common gene-gene co-expression networks in the sense that edge weight in gene-gene
co-expression networks usually expresses the correlation between the two genes, not the
predictive power of their combination. The second contribution is in the way we generate the candidate subnets. We define a density score for a sub-graph in a weighted graph,
which can also be interpreted as an estimation of the predictive ability of the subnet. Then,
we search for the locally densest subnets and evaluate their classification performance by
SVM or RF. We also apply two techniques to reduce the effects of imbalanced data. The
prediction results show that our approach outperforms the methods of [24]. The third
contribution is that we propose a greedy search to find the top-k subnets that can together
produce better prediction results than using the single best subnet. The MMCs for the
best settings are about 0.618 or higher, and the accuracies are about 81% or higher, accordingly. This implies that our model is effective in predicting breast cancer survivability
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while reducing the effect of imbalanced data.

6.2

Data

We used the breast cancer datasets of the Molecular Taxonomy of Breast Cancer International Consortium study (METABRIC) used in [24]. That data contains GE of about
18,000 genes of almost 2,000 primary breast tumors with long-term clinical follow-up. Each
patient underwent a combination of therapies. In our work, we consider only three subdatasets for the patients treated with chemotherapy (CT), hormone therapy (HT), or at
least one of them (i.e., chemotherapy or hormone therapy (CT HT)). The distribution of
samples of the 5-year survival for the sub-datasets are given in Table 6.1.
Table 6.1: Data distribution versus treatments.
Dataset

Died Before 5-years

Died After 5-years

# Samples

# Genes

CT

33

20

53

15293

HT

118

302

420

15293

CT HT

169

335

504

15293

We collected the protein-protein interactions from the STRING database (version
10 [27]), and from the Pathways Common database (version 9 [28]). The protein-protein
interaction network was converted to gene-gene network (GGN) by mapping the proteins
to their corresponding gene based on Entrez ID. The genes or proteins that could not
be mapped were removed from the GE data and the network data, respectively. We also
removed duplicate edges to yield an undirected graph of 15,293 vertices (genes) and 290,328
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edges (interactions).

6.3

Method

Figure 6.1 summarizes the pipeline of KDS used to find a set of k sub-nets that can result
in an optimal classification result, for each of the three treatments mentioned in Table
6.1. The pipeline comprises of four main steps. First, we compute a weighted gene-gene
network (WGGN) from the GGN and the corresponding GE data. Second, for each gene,
we search for a locally densest sub-network based on the WGGN. Third, we evaluate those
sub-networks by SVM and Random Forest and keep only the sub-networks whose MCC is
greater than a given threshold. Finally, we search for a set of k best sub-networks that can
together produce an improved classification result when voting for the survivability of the
patients.
The MCC can be calculated from the confusion matrix by Equation (6.1). It is
one of the best measurement in evaluating the classifier learned from imbalanced data.
TP × TN − FP × FN
,
M CC = p
(T P + F P ) × (T P + F N ) × (T N + F P ) × (T N + F N )

(6.1)

where, TP, TN, FP, and FN stand for number of true positives, number of true negatives,
number of false positives, and number of false negatives, respectively.
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Figure 6.1: The workflow of KDS.

6.3.1

Generating Gene-Gene Interaction Network Based on Joint
Mutual Information

Given gene expressions of a dataset in Table 6.1 and a GGN, we can obtain a WGGN by
assigning to each edge (X, Y ) of GGN a weight which is the join mutual information of X,
Y ) and the class C. The join mutual information between a pair of genes (X, Y ) and the
class C, denoted as I((X, Y ); C ) or I(X, Y ; C ), is calculated as in Equation (6.2), based
on gene expression data. Details of join mutual information can be found in [29]. The
join mutual information expresses the ability of the combination of gene X and gene Y in
predicting the class. We used the ChiMerge method [30] to discretize gene expressions of
each gene into maximum 5 intervals. All edge weights are scaled to the range [0..1].

I(X, Y ; C) = I(Y ; C) + I(X; C|Y ),
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(6.2)

where, I (Y ; C ) is the mutual information between Y and C, and I(X ; C|Y ) is the
conditional mutual information between X and C given Y. They are calculated as in
Equations (6.3)-(6.6)
I(Y ; C) = H(Y ) − H(Y |C)

(6.3)

I(X; C|Y ) = H(X|Y ) + H(C|Y ) − H(X, C|Y ),

(6.4)

H(Y ) = −

X

p(y)log(p(y)),

(6.5)

y∈Y

X

H(Y |C) = −

p(y, c)log(

y∈Y, c∈C

6.3.2

p(y, c)
)
p(c)

(6.6)

Finding an Optimally-Dense Sub-network for a Seed Gene

Given a sub-network S having n nodes/genes (n > 2), which is a sub-graph of WGGN,
and E is the set of edges in S, the density of S is calculated as in Equation (6.7). This
density function is an estimation of the predictive power of the sub-network S based on
the weight of its edges. The denser the sub-network, the more predictive it tends to be.
We search for an optimally-dense sub-network in WGGN for each seed gene as described
in Algorithm 1.
P
density(S) =

I(X, Y ; C)
√
0.5 × n × n − 1
(X, Y )∈E
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(6.7)

Algorithm 1. Finding an optimally-dense sub-network for a seed gene.

Input. s: a seed gene; W: a set of weighted edges presenting a weighted graph;
Output.S: an optimally-dense sub-network for s.

Method.
1. S = {s}
2. Repeat step 3 and step 4 to gradually extend S until its density cannot be improved; otherwise, return S.
3. N = the set of neighboring genes of any gene in S, according to the WGGN
structure.
4. Add to S the gene in N which improves the density of S the most.

In our approach, we assume that each gene in a sub-network of n genes has,
√
on average, n − 1 edges connecting to other genes in the sub-network. The numerator
of Equation (6.7) is the sum of the weights of the edges; while the denominator is the
average number of edges in a sub-network of n vertices. Practically, it is difficult to find a
polynomial-time function f (n) (where f (n) ∈ O(nm )) that can fairly expresses the average
sum of weights of the edges in a sub-network of n vertices in a weighted graph for different
values of n, even if the edge weights are in range [0..1]. When m = 1, the numerator of
Equation (6.7) and f (n) increase linearly by the size of the sub-network. However, the
numerator tends to increase faster than the denominator when n gets large enough. Thus,
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in this case, the densest sub-network for a seed gene tends to be a large component of
WGGN containing the seed gene. Meanwhile, when m ≥ 2, f (n) tends to increase much
faster than the numerator when n gets larger. Thus, sub-networks of small size tend to be
denser than sub-networks of large size. The function that we selected for the denominator
√
of Equation (6.7) is 0.5 × n × n − 1, (i.e., m = 1.5) which a balance between the cases
m = 1 and m = 2.

6.3.3

Evaluating the Classification Performance of a Sub-network

For each sub-network S, the GE data projected on the genes in S will be used to train
and test a classification model (classifier) using SVM or RF with 5-fold cross-validation.
The average MCC of the classifier based on the testing dataset(s) will be reported as the
measure of the predictive power of S since MCC is one of the best measurement for the
classification performance on class-imbalanced data. For each of the three treatments listed
in Table 6.1, we keep only the top sub-networks whose MCC is greater than or equal to
the MCC obtained by the method of [24].
To deal with imbalanced data, we also implemented two other techniques. First,
we used the technique called Distribution Optimally Balanced Stratified Cross-Validation
(DOB-SCV) proposed in [31] to stratify the “close-by” samples in the projected GE data
into different folds. The notation “close-by” is based on the Euclidean distance between
the projected GE profiles. The idea is to make the five folds as similar as possible, so that
each fold can have the representative samples for different regions of the current problem,
hopefully. For this purpose, we take a sample and move it to the first fold. Then, we find its
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four nearest neighbors of the same class and move them to the four other folds. Second, we
applied the heuristic called Synthetic Minority Oversampling (SMOTE) introduced in [32]
to duplicate the minority class in the training set. For each sample in the minority class,
denoted as x, SMOTE randomly picks one neighbor, denoted as y, among its k−nearest
neighbors of the same class (e.g., k = 5). A synthetic sample will be created by adjusting
each coordinator of x by a random amount of the difference between the corresponding
coordinators of x and y.
In the current context, given a classification method (e.g., SVM) the notation
“classifier” and “subnet” can be used interchangeably; the quality of a classifier implies
the usefulness of the corresponding subnet.

6.3.4

Finding the Top-k Subnets for Weighted Voting

The next step is to search for the top-k subnets from the ones obtained after step 3 of
KDS that can together produce better performance than using any single subnet. The
classification for a new patient by the top-k subnets/classifiers can be done via a weighted
voting scheme where the MCC of a subnet is used as the weights. That is, each classifier
will predict the patient’s survivability based on her GE profile and the final decision is
assigned to the class having the highest sum of weight.
Let W be the set of available models/subnets, V be a dataset of GE profiles, and
MCC(W , k, V ) be the MCC obtained on the data set V by the weighted voting scheme
using the first-k subnets in W . We search for the top-k sub-networks as Algorithm 2.
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Algorithm 2. Searching for top-k subnets for classification by weighted
voting.

Input.W: an initial set of models/subnets sorted by their MCCs; T: GE profiles for
training; and V: GE profiles for testing.
Output. k first subsets in W, along with the classification performances using the
voting scheme on V.

Method.
1. k = 1.
2. While (MCC(W, k, T) ≤ MCC(W, k+1, T) increase k by 1.
3. Return the first k subnets of the sorted W. The reported classification performances for the top-k subnets will be MCC(W, k, V)

6.3.5

Finding an Optimal Set of Subnets for Weighted Voting

Instead of ranking the subnets and then search for the top-k subnets as Algorithm 2, we
can search for an optimal subset of subnets for weighted voting in a greedy fashion, as
Algorithm 3.
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Algorithm 3. Searching for an optimal set of subnets for classification by
weighted voting.

Input.W: an initial set of models/subnets; T: a set of training datasets; V: a set of
testing datasets.
Output.OS: a subset of W which can yield an optimal MCC by weighted voting.

Method.
1. Initialize OS by the empty set.
2. Among the non-selected subnets in W, keep adding to OS the subnet which can
improve the average training MCC the most, using the datasets in T and the
subnets in OS, until OS cannot be improved.
3. Return OS along with the average performance measures (e.g., testing MCC),
using the optimal models trained at step 2 and test on datasets in V

In Algorithm 3, we randomly split the learning dataset into a training set (more
than 50%) and a testing set (the remaining samples) 500 times. Then, the training MCC,
in step 2, is the average MCC computed from the training sets; while, the average MCC
(and other measures) computed based on the testing sets will be used as the reported
measures for the optimal set of subnets. This cross-validation procedure will result in an
optimal set of subnets with the classification performance is more robust than that of the
simple cross-validation used in Algorithm 2.
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6.4

Results and Discussion

We have applied KDS on the three datasets CT, HT, CT HT described in Table 6.1,
using either SVM or Random Forest (RF) for sub-network evaluating. We also tried KDS
with every combination of the two techniques DOB-SCV or SMOTE to examine their
efficiency on reducing the effect of imbalanced data. Table 6.2 shows the abbreviations of
the experimental settings that presents the combinations of KDS with SMOTE and DOBSCV. A setting is given in the form of three letter SDK, where S, D, and K can be either
“Y” (yes) or “N” (no) indicating whether SMOTE, DOB-SCV is applied and whether
KDS will extract the top-k sub-networks or only one best sub-network, respectively. For
example, the setting NYN means that KDS will find only one best sub-network using
DOB-SCV to stratify data into five folds of cross-validation, but without using SMOTE
for over-sampling the minority class. In contrast, the setting YNY means that we try to
find the top-k sub-networks (i.e., using Algorithm 2) where the five folds will be stratified
randomly, but the training sets will be over-sampled by SMOTE.
Tables 6.3-6.8 show the classification performance of our approaches on the three
datasets CT, HT, CT HT, respectively, for every setting, using SVM and RF. The measures
for classification performance are accuracy, MCC, and area under the curve (AUC) of the
receiver operating characteristics (ROC) curve. For comparison purposes, the three tables
also contain classification performances obtained by the method of [24] which applied a
wrapper feature selection approach using mRMR and SVM or RF (see Table 2 and Table 3
in [24] or Table 2.4 and Table 2.6 in Chapter 2). For convenience, we denote the approach
in [24] as “F1000”. There is also the results obtained by the AFS algorithm (which is the
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Table 6.2: The abbreviations for running settings.
Abbreviation

With SMOTE

With DOB-SCV

Voting scheme

NNN

NO

NO

NO

NNY

NO

NO

YES

NYN

NO

YES

NO

NYY

NO

YES

YES

YNN

YES

NO

NO

YNY

YES

NO

YES

YYN

YES

YES

NO

YYY

YES

YES

YES

combination of PAFS [9] and SVM) [33], copied from Table 3.6 (for CT and CT HT) and
from Table 3.7 (for HT) in Chapter 3.
The comparison on the MCCs obtained by SVM and RF for different settings are
shown in Figures 6.2, 6.3 and 6.4. In these figures, the results based on the single best
sub-network are shown in the first four groups (NNN, YNN, NYN, YYN); the results based
on the weighted voting scheme by top-k sub-networks are shown in the last four groups
(NNY, YNY, NYY, YYY). The best result by sub-networks voting is shown in bold; while
the best result by one single best sub-network is shown in bold and italic.
The classification performances for the optimal sets of subnets obtained by Algorithm 6.3.5 are presented in Tables 6.4, 6.6, 6.8.
All in all, the voting scheme has significantly improved the classification performances of that based on the single best subnet. SVM often works better than RF.
DOB-SCV is more efficient than SMOTE in dealing with class-imbalanced data. The re172

sults based on the voting scheme using SVM and DOB-SCV, with or without SMOTE, are
among the best.

6.4.1

Classification Performances on CT

On CT, our approach produces much better classification results than F1000, and SVM
yields better results than RF. Using the best subnet, for the best setting YYN, the MCCs
obtained by RF and SVM is 0.722 and 0.883, respectively. They are about three to four
times larger than the MCC in F1000. As a result, the accuracies increased by about 20%
and 26%, respectively. DOB-SCV contributes smaller improvement for SVM than for RF
when applied alone; in contrast, SMOTE does not improve the results.
When using the voting scheme based on the top-k subnets, SVM can only improve
the classification performance for the setting NYY (i.e., only DOB-SCV is applied). In
this case, MCC = 1, about 10% increased as compared to that for the setting NYN. The
highest MCC can be obtained by Random Forest is 0.81, for the settings NNY and NYY.
For other cases, the voting scheme could not improve the performance.
The performance of PAFS is similar to that of KDS using the single best subnet
and is about 10% lower than the best results of SVM using the top-k subnets.
As shown in Table 6.4, the optimal subnets obtained by the greedy search described in Algorithm 3 produce slightly better accuracy than the top-k subnets for most
of the settings.
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Table 6.3: Classification results on patients treated with chemotherapy.
Algorithm

RF

SVM

Setting

Accuracy

MCC

AUC

#Subnets or #Genes

F1000

66.00%

0.23

0.653

19

NNN

81.10%

0.59

0.78

14

NYN

86.80%

0.717

0.855

3

YNN

79.30%

0.563

0.784

14

YYN

86.80%

0.722

0.864

21

NNY

90.90%

0.81

0.938

4

NYY

90.90%

0.81

0.938

6

YNY

81.80%

0.542

0.771

15

YYY

81.80%

0.543

0.771

1

F1000

84.90%

0.675

0.82

10

PAFS

90.60%

0.799

0.885

6

NNN

90.60%

0.811

0.905

15

NYN

92.50%

0.839

0.92

15

YNN

90.60%

0.811

0.914

25

YYN

94.30%

0.883

0.925

14

NNY

90.90%

0.81

0.938

3

NYY

100%

1

1

9

YNY

90.90%

0.81

0.938

5

YYY

90.90%

0.81

0.938

3
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Figure 6.2: Classification performance on chemotherapy-treated patients. The results
based on the single best sub-network are shown in the first four groups (NNN, YNN,
NYN, YYN). The results based on the weighted voting scheme by the top-k sub-networks
are shown in the last four groups (NNY, YNY, NYY, YYY).
Table 6.4: Classification performance on chemotherapy-treated patients obtained by the
Greedy Search (Algorithm 3).
Algorithm

RF

SVM

Setting

ACC

MCC

AUC

#Subnets

NNY

82.90%

0.660 (0.21)

0.814

4

NYY

91.30%

0.835 (0.11)

0.898

4

YNY

88.40%

0.765 (0.19)

0.867

6

YYY

93.50%

0.872 (0.13)

92.6

3

NNY

93.30%

0.861 (0.12)

0.917

9

NYY

100.00%

1.000 (0.00)

0.991

9

YNY

93.30%

0.861 (0.12)

0.917

9

YYY

100.00%

1.000 (0.00)

0.991

3
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6.4.2

Classification Performances on HT

Although the classification results on HT are not as high as the results on CT, Figure 6.3
still shows that our approach is much better than F1000. In comparing the settings NYN
and YNN against NNN (or NYY and YNY against NNY), DOB-SCV seems to deal with
imbalanced data better than SMOTE and has contributed more to the improvement in
MCC. SVM often yields better results than RF; RF only defeats SVM when DOB-SCV
is applied alone (i.e., the setting NYN and NYY). However, it is the voting scheme that
brings about the most positive impact.

Figure 6.3: Classification performance on hormone-therapy-treated patients. The results
based on the single best sub-network are shown in the first four groups (NNN, YNN, NYN,
YYN). The results based on the weighted voting scheme by the top-k sub-networks are
shown in the last four groups (NNY, YNY, NYY, YYY).
With the best settings for the single best subnet (i.e., NYN and YYN) the MCCs
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Table 6.5: Classification results on patients treated with hormone therapy.
Algorithm

RF

SVM

Setting

Accuracy

MCC

AUC

#Subnets or #Genes

F1000

71.00%

0.059

0.632

9

NNN

71.90%

0.21

0.585

4

NYN

76.90%

0.366

0.651

2

YNN

69.50%

0.261

0.633

8

YYN

69.30%

0.265

0.637

2

NNY

66.70%

0.285

0.563

3

NYY

76.20%

0.52

0.688

6

YNY

69.50%

0.31

0.636

4

YYY

70.20%

0.337

0.639

5

F1000

72.90%

0.173

0.548

10

PAFS

77.60%

0.374

0.625

9

NNN

73.10%

0.275

0.622

4

NYN

74.50%

0.309

0.634

4

YNN

74.80%

0.258

0.572

15

YYN

70.20%

0.323

0.672

4

NNY

69.10%

0.354

0.594

17

NYY

73.80%

0.439

0.668

4

YNY

69.10%

0.354

0.594

27

YYY

81.00%

0.618

0.75

37
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Table 6.6: Classification performance on hormone-therapy-treated patients obtained by
the Greedy Search (Algorithm 3).
Algorithm

RF

SVM

Setting

ACC

MCC

AUC

#Subnets

NNY

75.60%

0.257 (0.16)

0.568

4

NYY

81.70%

0.497 (0.14)

0.68

4

YNY

79.20%

0.433 (0.15)

0.686

6

YYY

78.30%

0.409 (0.15)

0.679

4

NNY

82.10%

0.516 (0.14)

0.678

6

NYY

80.80%

0.505 (0.14)

0.68

4

YNY

80.20%

0.530 (0.14)

0.688

6

YYY

87.80%

0.678 (0.11)

0.794

7

obtained by RF and SVM are 0.366 and 0.323, respectively. They are six times and two
times higher than the MCCs in F1000, accordingly. The MCCs become the highest, 0.520
and 0.618, respectively when we use the voting scheme based on the top-k (for the settings
NYY and YYY). They are about eight and four times better than the MCCs in F1000.
The performance of PAFS is better than that of KDS using the single best subnet
but it is still considerably lower than the best results of RF and SVM using the top-k
subnets.
In comparing Table 6.5 and Table 6.6, we can see that the optimal subnets obtained by Algorithm 3 produce higher accuracy than the top-k subnets for most of the
settings, from about 5% to 10%, except the settings NNY and NYY for RF. The corresponding increases in MCC are about 0.06 to 0.12.
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6.4.3

Classification Performances on CT HT

Generally, on CTHT, SVM usually yields better MCC than RF; the voting scheme significantly boosts up the classification performance; and DOB-SCV is still more efficient than
SMOTE. Using the single best subnet, the best MCC for RF is 0.328 for the setting NYN
and the best MCC for SVM is 0.330 for the setting YYN. These MCCs are about 4 times
and 1.38 higher than the corresponding ones of F1000. Using the top-k subnets, SMOTE
almost produces better MCC than DOB-SCV for both RF and SVM. The combination of
DOB-SCV and SMOTE yields the highest MCC, 0.731 for RF and 0.858 for SVM, which
are respectively about 2 times and 2.5 times more than the best MCC based on the single
best subnet.
The performance of PAFS is slightly worse than that of the best results of RF
and SVM using the single best subnet and is much lower than the best results of RF and
SVM using the top-k subnets.
In comparing Table 6.7 and Table 6.8, we can see that the optimal subnets obtained by Algorithm 3 usually produce slightly lower accuracy than the top-k subnets for
most of the settings. However, the decline becomes as much as about 10% for the setting NYY for RF and SVM. The corresponding decreases in MCC are about 0.2 and 0.17
respectively, to 0.12.

179

Table 6.7: Classification results on patients treated with chemotherapy and/or hormone
therapy.
Algorithm

RF

SVM

Setting

Accuracy

MCC

AUC

#Subnets or #Genes

F1000

65.30%

0.086

0.588

7

NNN

68.50%

0.214

0.585

8

NYN

71.60%

0.328

0.65

2

YNN

64.70%

0.231

0.619

5

YYN

67.10%

0.288

0.648

2

NNY

74.30%

0.292

0.596

3

NYY

76.20%

0.377

0.658

4

YNY

85.20%

0.628

0.779

10

YYY

89.10%

0.731

0.846

77

F1000

67.90%

0.238

0.61

11

PAFS

71.10%

0.288

0.616

9

NNN

69.10%

0.267

0.624

4

NYN

71.60%

0.314

0.636

10

YNN

64.90%

0.251

0.63

23

YYN

69.30%

0.33

0.669

3

NNY

76.30%

0.364

0.629

6

NYY

82.20%

0.554

0.71

4

YNY

83.20%

0.61

0.813

51

YYY

94.10%

0.858

0.929

89
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Table 6.8: Classification performance on chemotherapy and/or hormone-therapy-treated
patients obtained by the Greedy Search (Algorithm 3).
Algorithm

RF

SVM

Setting

ACC

MCC

AUC

#Subnets

NNY

73.70%

0.387 (0.13)

0.601

7

NYY

77.00%

0.454 (0.14)

0.663

6

YNY

74.14%

0.382 (0.13)

0.673

6

YYY

79.00%

0.515 (0.16)

0.753

6

NNY

77.40%

0.457 (0.13)

0.672

6

NYY

78.60%

0.492 (0.13)

0.708

4

YNY

82.00%

0.580 (0.12)

0.743

8

YYY

85.90%

0.682 (0.10)

0.834

8
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Figure 6.4: Classification performance on patients treated with chemotherapy and/or hormone therapy. The results based on the single best sub-network are shown in the first four
groups (NNN, YNN, NYN, YYN). The results based on the weighted voting scheme by
the top-k sub-networks are shown in the last four groups (NNY, YNY, NYY, YYY).
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The accuracy of a classifier can be misled due to the imbalance in training data.
Showing accuracy, AUC, and MCC at the same time can help us interpret the performance
better than using only one of them. Ideally, accuracy (and AUC) should be about (MCC
+1)/2. The results obtained by F1000 for RF and SVM in Table 6.5 and Table 6.7 show
that there is a large disagreement between accuracies, AUCs, and MCCs. According to
the MCCs in these cases, the accuracies for RF on HT and CT HT should be about 53%
and 54%, and the accuracies for SVM on HT and CT HT should be about 59% and 62%,
respectively; they should not be as high as shown in the tables. This means the models
in F1000 are just slightly better than random and they are influenced by the imbalance in
training data. Meanwhile, the measures for our approach are more consistent with each
other; the MCCs match with at least accuracy or AUC. The increases in MCC, as compared
to that of F1000, imply that our approach did take the class imbalance into account and
produced better results. For every treatment, we found good classification models (with
MCC ≥ 0.52) for both SVM and RF.

6.4.4

Biological Insights

There are 1246 unique genes in 393 selected subnets for both SVM and RF, for all settings,
for the three datasets. There are 377 unique genes in 46 subnets for CT, 498 unique genes in
103 subnets for HT, and 781 unique genes in 244 subnets for CT HT. Among them, SP1 and
NOG are the most frequent genes for the three types of treatments, (32/46, 50/103, 90/244)
and (32/46, 43/103, 58/244), respectively. For many years, the transcription factor SP1 has
been viewed as a basal transcription factor and also an implication of inflammation. SP1 is
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over-expressed in many cancers, including breast cancer (according to the Human Protein
Atlas) and is associated with a negative prognosis. Targeting SP1 in cancer treatment
has been suggested; however, its functions are extremely complex. SP1 both activates and
suppresses the expression of a number of essential oncogenes and tumor suppressors, as
well as genes responsible for cancer cell growth, survival, migration/invasion, and drug
resistance [34, 35]. In addition, NOG, a BMP inhibitor, provides metastatic breast cancer
cells with the ability to colonize the bone [36].
Table 6.9 lists the breast-cancer-related genes, according to [37, 38], that are frequent in at least 25 subnets among all subnets in all sets of top-k subnets for the three
treatments. Most of them are oncogene or fusion or tumor suppressor genes. These genes
play a critical role in pathways involving cell growth control, DNA repair mechanism,
etc [39]. We encounter three other highly frequent genes MYC, PIK3CA, and TP53 that
have been well-known to be important in breast cancer. For example, PIK3CA encodes
a subunit of phosphatidylinositol 3-kinase that triggers AKT1 signaling and can interact
with ERBB4, FGFR and MAPK signaling in cancer [38, 41–43]. According to [43], “all
cancers have been shown to have a defective p53 pathway, either by a direct TP53 mutation
or by deregulation of another determinant of the p53 pathway. The mutant p53 molecular
profile may provide extremely precise predictors of disease outcomes and of responses to
therapy”. As summarized in [44], MYC is a transcription factor that situated as an essential signaling hub in multiple cellular processes that sustain growth of many types of
cancers. MYC regulates expression of RNA that controls central metabolic pathways, cell
death, proliferation, differentiation, stress pathways, and mechanisms of drug resistance.
MYC-dependent pathways are often elevated in acquired resistance to anti-cancer thera184

pies. Activation of MYC has been widely reported in breast cancer progression. MYC
amplification has been reported biomarker of complete pathological response (i.e., all of
the cancer or tumor disappears) to neoadjuvant chemotherapy.
In addition, the following 26 highly frequent genes are cancer-related: CDC42,
RHOQ, JUN, IL6, UBA52, GCLC, HIST1H4I, HIST1H4C, ATP7B, DVL2, SERPINE1,
NECAP1, CD4, CLTCL1, HIST1H4B, ACTR3, AGFG1, CREB1, VDR, HIST1H2BJ,
LDLR, PACSIN2, INPP5D, CCL5, TRIM24, BAZ1A. They are listed in descending order
of frequency, from 176/393 to 25/393. Some of them might be breast-cancer-related as well.
We also encounter several frequent tuples of genes such as SP1, NOG, CDC42, RHOQ,
JUN, IL6, GCLC, TP53. The frequent genes and tuples may imply that there are frequent
interactions or chains of interactions. Identifying them may help us filter the pathways
involved the treatments/disease.
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Table 6.9: Breast-cancer-related genes that are highly-frequent in 393 subnets of the sets
of top-k subnets for the three treatments, for all settings, and for both SVM and RF.
Frequency
Gene

GeneType

In CT

In HT

In CT HT

Sum

SP1

32

50

94

176

NOG

32

43

58

133

TP53

19

19

34

72

oncogene, tumor suppressor, fusion

MYC

24

12

16

52

oncogene, fusion

PIK3R1

0

27

13

40

tumor suppressor

BRDT

0

0

40

40

MUC16

0

6

32

38

oncogene

DAB2

0

26

11

37

tumor suppressor

PML

16

8

13

37

tumor suppressor, fusion

BIN1

1

25

5

31

tumor suppressor

PIK3CA

2

13

12

27

oncogene

PBRM1

0

4

22

26

tumor suppressor

CLU

18

3

4

25

tumor suppressor

SIRT1

3

9

13

25

tumor suppressor
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tumor suppressor

6.5

Conclusion and Future Works

Network-based approaches have gained a lot of interest in the last two decades since they
have made use of knowledge from various data sources to detect relevant biomarkers. In
this work, we have developed a network-based method, KDS, used to identify the subnets
of functionally related genes capable of predicting survivability of breast cancer patients.
KDS integrates GE data with protein-protein interaction data into a weighted gene-gene
interaction network based on joint mutual information. The edge weight implies the potential of the combination of the two involved genes in predicting the class. We propose
a scoring criterion used to estimate the predictive power of candidate subnets, by which,
we can reduce the number of subnets for evaluating and thus, save computation cost. Either SVM or Random Forest is used to evaluate the subnets. DOB-SCV and SMOTE are
applied to deal with class-imbalanced data.
Furthermore, based on a weighted voting scheme using multi subnets for classification, we present a simple method to select top-k subnets and another greedy method to
select an optimal set of subnets. Both of them can significantly improve the classification
performance for patients treated with hormone therapy and patients treated with either
chemotherapy or hormone therapy, as compared to that obtained by using the single best
subnet.
In general, KDS using SVM can yield better performance than using Random
Forest, and DOB-SCV often bring higher performance than SMOTE. Using the single best
subnet, for the best settings, KDS significantly outperformed the approach in [24]. The
prediction performance can be improved further by using the voting scheme based on the
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optimal/top-k subnets. The MCCs show that our model can deal with imbalanced data
while being effective to predict survivability of breast cancer patients. There are 14 breastcancer-related genes frequently-encountered in the top-k selected subnets, including the
well-known genes SP1, TP53, MYC, and PIK3CA.
In the future, we plan to analyze in more details the genes in the selected subnets
with pathway data or cancer-related genes to reveal meaningful biomarkers and perform
their corresponding biological validation using relevant literature. The frequency of the
interactions in the selected subnets should be also investigated as they might provide some
biological insights.
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Chapter 7
NUCLEAR: An Efficient Method for Mining
Frequent Itemsets and Generators from
Closed Frequent Itemsets

7.1

Introduction

Association rule mining is one of the most interesting and popular problems in data mining.
It is widely used for decision making in retail, e-commerce, medicine, bioinformatics, and
many other domains. Mining frequent itemsets (FIs) is the first and the main step in the
discovery of association rules (ARs). Since its first introduction in 1993 [1], the research
has attracted a lot of attention and has been extended and applied in various ways. For
instance, some popular variations of the FI mining problem are to discover high utility
patterns [2,3], uncertain frequent patterns [2] and high utility association rules [2,4]. Most
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algorithms for mining FIs partition the search space into subclasses in order to apply the
parallel approaches to improve their performance. However, the performance of many
parallel FI mining algorithms is limited by the speed of disk accesses, as they repeatedly
scan the input database, which can still lead to long execution [5,6]. To address this issue,
some researchers proposed more efficient parallel algorithms, which compress the database
in a frequent pattern tree and perform tree projections [7, 8]. Another approach which
can speed up the FI mining process is to first mine all the closed frequent itemsets (CFIs)
and then derive the FIs from them without the need of re-scanning the data file. This
approach is more efficient than mining FIs directly because the number of CFIs is usually
much less than that of FIs (see Table 7.4). Charm [9], FPClose [7], DCI PLUS [10] and
NAFCP [6] are among the best algorithms for mining CFIs. In 2010, a parallel algorithm
(PLCMQS) for mining CFIs has been proposed [11]. The authors of Charm proposed the
CharmL algorithm [8], which builds the lattice of CFIs. Formal concept (i.e., lattice of
CFIs) analysis is also another way of mining FIs as well as ARs [6, 12, 13].
Mining FIs from the lattice of CFIs has several advantages over mining FIs directly from data. First, the number of CFIs is often much smaller than the number of
FIs; therefore, this requires less memory. Second, each CFI can stand for an equivalence
class of FIs having the same closure (i.e., these FIs shares the same set of transactions
containing them); thus, we can develop parallel algorithms or “divide-and-conquer” approaches to facilitate the process of deriving FIs from CFIs. Third, when users want to
try different minimum support (minsup) thresholds to find an optimal set of FIs for a
certain downstream procedure, the cost of updating the set of CFIs can be much lower
than mining them from scratch in a database many times. However, to extract FIs from
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CFIs, the current algorithms requires the generators for each CFI, and mining them might
take a significant amount of time.
Contribution. In this work, we present a method to mine the FIs from a lattice
of CFIs without the need of the generators. We introduce the concepts of “kernels” and
“extendable sets” which can be used to further partition the equivalence classes represented
by the CFIs into smaller subclasses. Then, each pair of kernel and extendable set stands for
a subclass of FIs which are supersets of the kernel and subsets of the union of the kernel
and the extendable set. Thus, once a pair of kernel and extendable set are identified,
enumerating the FIs, and even the generators in that subclass is straightforward. Our
proposed an algorithm, called NUCLEAR, to generate kernels and extendable sets for each
CFI is simple and efficient and then enumerate the FIs. Its inputs are just a CFI and the
largest CFIs those are subsets of that CFI. Then, the time to induce all FIs from the lattice
of CFIs is significantly shorter than the time to construct the lattice from data. As the
generators play an important role in extracting the “minimal association rules”, we also
provide the options for NUCLEAR to mine them by similar fashion. We also present a
simple method, called NUC, that wraps CharmL and NUCLEAR to mine a lattice of CFIs
from data and then infers the FIs from the lattice. The fact that NUCLEAR does not
require the generators makes it more efficient than the approaches infer FIs from CFIs and
generators. In the comparison of NUC against dEclat [8], a well-known algorithm which
mines FIs directly from data, NUC is faster when the number of FIs is much larger than
the number of CFIs. When NUC is slower, the reason is that CharmL, the algorithm used
to construct the lattice of CFIs from data before applying NUCLEAR, is already slower
than dEclat.
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The rest of this work is organized as follows. Section 7.2 introduces some related
concepts. Section 7.3 reviews the related works. Section 7.4 presents novel theoretical
results that are the basis of the proposed algorithm, including a recurrent formula for
generating kernels and extendable sets. Section 7.5 presents the proposed NUCLEAR
algorithm. Section 7.6 reports experimental results that show the efficiency of the proposed
algorithm. Finally, a conclusion is drawn and future work is discussed in section 7.7.

7.2

Preliminaries

Let consider a context (T, I, R) where I is a set of items (or attributes), T is a set of
transactions (or objects) and R is a binary relation on T × I.
Definition 1 (Galois connection). For each a non-empty subset A (itemset) of I and
a non-empty subset O of T , the two functions λ and ρ below define a Galois connection
between 2T and 2I (reader can refer to [9] for more details):

λ : 2T → 2I : λ(O) = {a ∈ I|(o, a) ∈ R, ∀o ∈ O}, λ(∅) = I

(7.1)

ρ : 2I → 2T : ρ(O) = {a ∈ T |(o, a) ∈ R, ∀a ∈ A}, ρ(∅) = T

(7.2)

Definition 2 (Frequent itemset). Given a user-specified minimum support threshold
minsup, such that 0 < minsup ≤ 1, the support of an itemset A is denoted and defined as
supp(A) = |ρ(A)|/|T |. A is said to be “frequent” if supp(A) ≥ minsup.
Definition 3 (Association rule mining). Given T , minsup, and minconf , which are a
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transactional dataset, a minimum support threshold, and a minimum confidence threshold,
respectively. The task of association rule mining is to find all rules of the form X → Y
such that supp(X ∪ Y ) ≥ minsup and supp(X ∪ Y )/supp(X) ≥ minconf . supp(X ∪ Y )
is called the support of the rule, and supp(X ∪ Y )/sup(X) is called the confidence of the
rule.
As (X ∪ Y ) must be frequent in order to X → Y be frequent, identifying the
frequent itemsets has been considered as the main task.
Definition 4 (Closed frequent itemset, or frequent closed itemset). h = λ ◦ ρ in
2I is called the closure operator, and h(A) = λ ◦ ρ(A) is said to be the closure of A. Itemset
C is “closed” if and only if h(C) = C. C is a closed frequent itemset if it is “closed” and
it is “frequent”. [C] = h(C) = {A ∈ I|(h(C) = h(A))} is an equivalence class of C, i.e.,
the set of all itemsets having the same closure, which is h(C).
The itemsets in [C] share the same set of transactions, which is ρ(C). This means
they have the same support.
Let CS and CF S denote the set of all closed itemsets and the set of all CFIs,
respectively. Then, L ≡ (CF S, I ) is a lattice of CFIs, where I is an order relation based
on the operator “⊆” between subsets of I. A lattice of CFIs can be represented by a Hasse
diagram where every arc links from a CFI to one of its direct subsets (see Figure 7.1).
Definition 5 (Generator). An itemset G is called a “generator” of a closed itemset C
if and only if h(G) = h(C) and (∀G0 )(∅ ⊂ G0 ⊂ G =⇒ h(G0 ) ⊂ h(G)).
For any itemset A ⊆ I, the equivalence class [A] has only one closed itemset, and
one or more generators.
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Example 1. Given I = {1, 2, 3, 4, 5, 6}, T = {t1 , t2 , t3 , t4 , t5 , t6 }, and R as in the Table
7.1. Let itemset X = {1, 4, 5}, then ρ(X) = {t1 , t2 }, supp(X) = 2/4, and λ(t1 , t2 ) =
{1, 4, 5, 6}. Then, X is not a CFI since h(X) = λ ◦ ρ(X) = 1, 4, 5, 6 6= X. Now, let
C = {1, 4, 5, 6}, we have h(C) = C. Thus, C is a CFI. And, we have, [X] = [C] =
{{1, 4}, {1, 5}, {1, 6}, {1, 4, 5}, {1, 4, 6}, {1, 4, 5, 6}}, in which, the sets {1, 4}, {1,
5}, {1, 6} are the generators of C. The lattice of CFIs mined from R for minsup = 0.25
(i.e., absolute minimum support = 1) is shown in Figure 7.1. In this lattice, each node
(rectangle) represents a CFI and its absolute support, separated by a colon (“:”) and each
directed edge links a CFI to the CFIs which are its largest subsets.
Table 7.1: The relation R = T × I, where I = {1, 2, 3, 4, 5, 6}, T = {t1 , t2 , t3 , t4 , t5 , t6 }.
Transactions

Items

t1

1

t2

1

t3

1

t4

2

3

4

5

6

4

5

6

4

5

6

3
2

3

Definition 6 (Minimal association rule). A rule X → Y is called “minimal” if there
is no other rule A → B such that (A ⊆ X) and (Y ⊆ B) and h(X ∪ Y ) = h(A ∪ B) and

Figure 7.1: The lattice of CFIs mined from R with minsup = 0.25.
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h(X) = h(A).
For any minimal association rule X → Y , X ∪ Y is a closed (frequent) itemset
and X is a generator (X is either in [X ∪ Y ] or in [C], where C ⊂ X ∪ Y ) [14, 15].

7.3
7.3.1

Related Work
Mining Closed (Frequent) Itemsets

In recent years, several algorithms have been proposed for FI mining such as dEclat, and
Node-list-based algorithms [5, 16–18]. The dEclat was one of the most effective algorithms
according to [19]. It scans a database once to generate the transaction sets (tidsets) for
all itemsets of 1 item (1-itemset). Then, it applies the “diffset” strategy to enumerate all
FIs without repeatedly scanning the database. Deng et al. [16] proposed a novel structure
named N -list for mining FIs. The proposed algorithm first compresses the dataset into
a PPC-tree structure, and then, using that tree, the algorithm generates N -lists for each
1-itemset. Finally, the algorithm applies a divide-and-conquer approach to mine FIs using
these lists. Experimental evaluation has shown that the N -list-based algorithm outperforms state-of-the-art FI mining algorithms on a variety of real and synthetic datasets.
Recently, Deng and Lv [17] proposed an improved N -list based frequent itemset mining
algorithm named PrePost+, which applies a novel pruning strategy called children-parent
equivalence pruning to reduce the search space. Subsequently, Vo et al. [18] combined the
N -list structure with the subsume concept to further increase the performance of FI mining. Recently, Deng [16] proposed an efficient algorithm relying on an improved Nodeset
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structure, named DiffNodesets.
As defined in section 7.2, the closure of an itemset is the set of all items that appear
in all transactions containing the itemset. CFIs have attracted a lot of studies as they can
be used to partition FIs into equivalence classes. This inspires the development of parallel
or “divide-and-conquer” approaches to mine FIs from CFIs without scanning the database
for the support. However, there have not been many approaches showing how to FIs from
the CFIs efficiently. Several researchers have studied retrieving FIs using the generator
itemsets and eliminable itemsets in the equivalence classes of their closures [10, 14, 19–21].
For this purpose, algorithms were proposed that efficiently discover FIs using the lattice of
CFIs, without performing duplicate checks, and by processing only one CFI at a time, that
is, without considering its relationship to other CFIs. Generator itemsets can be mined
independently or at the same time as CFIs. Zaki et al. [9] proposed the Minimal Generators
algorithm to mine generators from the lattice of CFIs using a level-wise approach inspired
by the Apriori algorithm. However, to identify the generators of a CFI, the algorithm
had to scan all its subsets. Thus, the algorithm can be very slow. Szathmary et al. [22]
proposed the Talky-G algorithm to mine generators from data, using an IT-tree structure.
The algorithm uses the Charm algorithm [8] to separately mine the CFIs and then, matches
the generators with each CFI. Talky-G guarantees that when an itemset X is visited during
the search, all its subsets have been already visited, and thus all generators that are subsets
of X have already been found. Consequently, an itemset X is a generator if no already
found generator is subset X and has the same support as X ’s support. To quickly select
the generators for that check Talky-G stores the support of visited generators in a hash
table using the number of transactions containing each itemset as the hash function. This
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hash function is also used to match each CFI to its generators. The algorithm is effective
when minsup is high. However, the time required for finding generators is similar to the
time for mining CFIs. GENCLOSE [23] is an algorithm that concurrently mines CFIs
and generators. The authors introduced necessary and sufficient conditions to generate
generators (k + 1)-itemsets, i.e., itemset containing k+1 items, using the generators of kitemsets. Using these conditions, the closure of each generator can be extended gradually to
find generators. In 2005, the CHARM [9] and dCHARM [8] algorithms have been proposed
for mining CFIs using the “diffset” structure introduced in the dEclat algorithm. In 2012,
the DBV-Miner [24] algorithm improved this approach by compressing the tidsets of 1itemsets using dynamic bit vectors. It was shown that this can greatly reduce the memory
required for storing tidsets and compute the support of itemsets efficiently. Then, Sahoo
et al. [10] proposed the DCI PLUS algorithm for mining CFIs and their generators. The
algorithm compresses the database using a BitTable structure, which is built using a single
database scan. In [20], Tran et al. proposed the GEN ITEMSETS algorithm to generate
all itemsets from a lattice of CFIs and generators without repetitions. More recently, Le
and Vo [12] proposed an N -list-based algorithm for mining CFIs, named NAFCP. The
experimental evaluation of this work has shown that NAFCP outperforms state-of-art CFI
mining algorithms in terms of run-time and memory usage in most cases.

7.3.2

Lattice-based Approaches for Mining Association Rules

In general, two types of lattices are considered for association rule mining, which are the
frequent itemset lattice (FIL) and the closed frequent itemset lattice (CFIL) [12]. Vo and
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Le [13] have presented a lattice-based approach for building the FIL, here called FIL-2009.
Each node of the structure used in FIL-2009 represents an itemset X and stores a tuple
(X, Tidset, Children) where Tidset is the list of transactions containing X and Children
are pointers to nodes representing supersets of X. To mine the minimal non-redundant
association rules, Vo and Le [25] extended the structure used by FIL-2009 (here called
FIL-2011) by adding two fields in each node indicating if a node is a minimal generator
or a closed frequent itemset, respectively. These values are determined during lattice
construction. The structure is then used by FIL-2011 to effectively mine minimal nonredundant association rules. Thereafter, an efficient approach named PFIL was proposed,
which supports incremental mining using the pre-large concept. It was shown that this
approach is especially efficient for huge databases containing a large number of FIs [21].
The PFIL algorithm uses the diffset structure to quickly build a FIL. Then it uses the prelarge concept and diffset structure for maintaining the pre-large FIL. For a given dataset
and a minsup threshold, building the CFIL is generally much faster than building the
FIL because the number of CFIs is usually much less than that of FIs. CharmL [8] is an
effective algorithm to build the lattice of CFIs. To update the lattice, researchers have
proposed an algorithm [6] that runs efficiently in the case of large databases with a small
number of inserted transactions.
For parallel algorithms or for the survey on algorithms for mining FIs and ARs,
we refer readers to [26–31] .
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7.4

Theoretical Results

From now on, for convenience, whenever we use the variables C or G without condition, it
implicitly means that C ∈ CS or ∅ ⊂ G ⊆ C, respectively. Let “:” stand for “such that”
or “|”, and “,” stand for the logical operator “∧” in the logical propositions. We derive
some theoretical results that are the basis of our proposed algorithms.
Definition 7 (The immediately closed subsets of a closed itemset). Let SC = {Y ∈
CS : (Y ⊂ C) ∧ (@Z ∈ CS)(Y ⊂ Z ⊂ C)} be the set of all largest closed itemsets that are
subsets of a given closed itemset C. The itemsets in SC are called the “immediately closed
subsets of C”.
Proposition 1. Given C and G (G ⊆ C), we have: G ∈ [C] ⇐⇒ (∀Y ∈ SC )(∃x ∈ G :
x∈
/ Y ).
Proof. For all G ⊆ C,
“=⇒”:
Since G ∈ [C], we have h(G) = C.
Now, assume that (∃Y ∈ SC )(∀x ∈ G)(x ∈ Y ). Thus, G ⊆ Y ⊂ C. Then,
h(G) ⊆ h(Y ) = Y ⊂ C. This leads to a contradiction: h(G) ⊂ C ∧ h(G) = C.
Thus, (∃x ∈ G)(x ∈
/ Y ).
“⇐=”:
Assume that ((∀Y ∈ SC )(∃x ∈ G)(x ∈
/ Y )) ∧ G ∈
/ [C]
By Definition 7 we have: (∀X ⊂ C)(X ∈ CS =⇒ ∃Y ∈ SC : X ⊆ Y ) (a) .
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By Definition 4, we have h(G) ∈ CS

(b)

.

By the assumption (G ⊆ C and G ∈
/ [C]), we have h(G) ⊂ C) (c) .
Then, by

(a)

,

(b)

, and

(c)

, we can replace X with h(G) in

(a)

to have: (∀h(G) ⊂

C)(h(G) ∈ CS =⇒ (∃Y ∈ SC )(h(G) ⊆ Y )). Or, simply, (∃Y ∈ SC )(h(G) ⊆ Y ))(b) .
Since G ⊆ h(G), we have (∃Y ∈ SC )(G ⊆ Y ). Or, (∃Y ∈ SC )(∀x ∈ G)(x ∈ Y )).
This is a contradiction to the assumption.

Proposition 1 points out a way to find [C] by searching for FIs that are subset of
C and satisfy the condition in the right-hand side of Proposition 1. However, it might be
not efficient if we scan every subset of C. We will derive the theoretical results that allow
generating only the FIs in [C].
Corollary 1. ∀Yk ∈ SC , let Mk = C\Yk , n = |SC |, 1 ≤ k ≤ n, and M = {M1 , . . . , Mn }.
We have, G ∈ [C] ⇐⇒ (∀Mk )(∃x ∈ G)(x ∈ Mk ).
Proof. G ∈ [C] ⇐⇒ (∀Y ∈ SC )(∃x ∈ G)(x ∈
/ Y ) ⇐⇒ (∀Mk )(∃x ∈ G)(x ∈
Mk ).

Definition 8 (Kernel and extendable set). Given two disjoint itemsets G and E. Let
the notation [G, E] denote the class of all itemsets those are supersets of G and subsets of
G + E, i.e., [G, E] = {X : G ⊆ X ⊆ G + E}. G is called the kernel and E is called the
extendable set of the class.
The following results provide an easy way to find the pairs of kernel and extendable
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set that can help partition [C] into equivalence classes.
Definition 9. Let Mk = C\Yk , ∀Yk ∈ SC , M = {M1 , . . . , Mn }, n = |SC |, Sk = {M1 , . . . , Mk }
(for 1 ≤ k ≤ n) denotes the set of k first elements of M , and S0 = ∅.
An itemset G is said to “satisfy Sk ” if (∀Mi ∈ Sk )(∃x ∈ G)(x ∈ Mi ).
Let [Sk ] denote the set of all FIs that satisfy Sk , and [S0 ] = 2C .
The following lemmas are obtained by Definition 9 and Corollary 1.
Lemma 1. Given G ⊆ C, E ⊆ C, G ∩ E = ∅, 1 ≤ k ≤ n, where n = |SC|, we have:
a) [Sk ] ⊆ [Sk−1 ],
b) ∀G ∈ [Sk ] =⇒ (∀X ∈ [G, E])(X ∈ [Sk ]),
c) [C] = [Sn ].
Proof. By Definition 9, for all G ∈ [Sk ] we have G satisfies Sk . Thus, (∀Mi ∈
Sk )(∃x ∈ G)(x ∈ Mi ). Thus, (∀Mi ∈ Sk−1 )(∃x ∈ G)(x ∈ Mi ). This means, G satisfies
Sk−1 , or, G ∈ [Sk−1 ]. Thus, (∀G ∈ [Sk ])G ∈ [Sk−1 ]. Thus, a) is proved.
By Definition 9, for all G ∈ [Sk ] we have, (∀Mi ∈ Sk )(∃x ∈ G)(x ∈ Mi ). In
addition, for all X ∈ [G, E], we have, G ⊆ X. Thus, we have, (∀Mi ∈ Sk )(∃x ∈ X)(x ∈
Mi ). Or, X satisfies Sk . Or, X ∈ [Sk ]. Thus, b) is proved.
By Corollary 1, we have, G ∈ [C] ⇐⇒ (∀Mk )(∃x ∈ G)(x ∈ Mk ) ⇐⇒ G ∈ [Sk ].
Thus, c) is proved.
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Lemma 2. Given G∗ ∈ [Sk−1 ], G = G∗ + {x} (where, 1 ≤ k ≤ |SC |, x ∈ C and x ∈
/ G), we
have: (Mk ∩ G∗ 6= ∅) ∨ (x ∈ Mk ) =⇒ G ∈ [Sk ].
Proof. Since G∗ ∈ [Sk−1 ], we have (∀Mi ∈ Sk−1 )(∃y ∈ G∗ )(y ∈ Mi ).
Let consider the case (Mk ∩ G∗ 6= ∅). We have, (∃a ∈ G∗ )(a ∈ Mk ). Thus, we
have, (∀Mi ∈ Sk−1 )(∃y ∈ G∗ )(y ∈ Mi )∧(∃a ∈ G∗ )(a ∈ Mk ). Or, we have, (∀Mi ∈ Sk )(∃y ∈
G∗ )(y ∈ Mi ). Or, G∗ ∈ [Sk ]. This implies, G ∈ [Sk ]. (i) .
Let consider the case (x ∈ Mk ). Since G = G∗ + {x}, we have, (∀Mi ∈ Sk−1 )(∃y ∈
G∗ )(y ∈ Mi )∧(∃x ∈ G)(x ∈ Mk ). Or, (∀Mi ∈ Sk−1 )(∃y ∈ G)(y ∈ Mi )∧(∃x ∈ G)(x ∈ Mk ).
This implies G ∈ [Sk ]. (ii)
By

(i)

and

(ii)

Lemma 2 is proved.


In the condition of the first case (i.e., (Mk ∩ G∗ 6= ∅), x is not necessary for G to
satisfy Sk since G∗ already satisfies Sk . In the second case, it is.
P
From now on, for convenience, we use the operator “+” (and “ ”) in place of
the union operator for two (and many, respectively) disjoint sets, and the sign “,” in place
of the logical operator “∧”. The Definition 10 below leads to the idea of generating the
kernel sets.
Definition 10 (k-minimal set). Given Mk defined as in Definition 9, X ⊆ Mk , and
G = G∗ ∪ X. G is “k-minimal” if one of the following conditions is satisfied:
a) G∗ is “(k − 1)-minimal”, Mk ∩ G∗ 6= ∅, X = ∅ (i.e., G = G∗ , and no more item are
needed for G∗ to satisfy Sk ).
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b) G∗ is “(k − 1)-minimal” Mk ∩ G∗ = ∅, and X = {x}, (where, x ∈ Mk (i.e., x is the
new item needed for G∗ to satisfy Sk ).
c) G = ∅ (G is “0-minimal”).
We can see that if G is “k-minimal” then G satisfies Sk . The cases (a) and (b)
are based on Lemma 2.
It is worthy to note that G is “k-minimal” does not imply that there is no subset
of G satisfying Sk . It just means that no prefix of G satisfies Sk if G is treated as a sequence
of items.
Hereafter, we assume that there exists an order over the items in C (e.g., alphabetic order), and every Mk is sorted in the increasing order.
Definition 11 (A partition of [Sk ] based on the kernels and extendable sets).
Given C, SC , and Mk defined as in Definition 9, and let the set Qk contains the pairs of
kernel set and extendable set defined recurrently as follows:
a) Q0 = {(∅, C)}
b) Q1 = {(Gi , Ei ) : Gi = {xi }, xi ∈ M1 , Ei = C\{y ∈ M1 : y ≤ xi }}
c) ∀k > 1, Qk = Bk + Ck , where
• Bk = {(G, E) : (G, E) ∈ Qk−1 , G ∩ Mk 6= ∅},
• Ck = {(G + {xi }, E\Ei ) : (G, E) ∈ Qk−1 , G ∩ Mk = ∅, Nk = Mk ∩ E, xi ∈ Nk , Ei =
{y ∈ Nk : y ≤ xi }.
In details, Bk contains the pairs of the form (G, E) in Qk−1 , where G is “(k-1)minimal” and is also “k-minimal”, according to Definition 10.a. Thus, (G, E) belongs to
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Qk also. Meanwhile, Ck contains the pairs (G, E) such that G = G0 + xi , where G0 is
“(k-1)-minimal” but not “k-minimal”, and xi is the new necessary item for G to become
“k-minimal” (as Definition 10.b).
Theorem 1. For 0 ≤ k ≤ |SC|, {[G, E] : (G, E) ∈ Qk } is a partition of [Sk ], where each
[G, E] is an equivalence class, and G is “k-minimal”.
Proof.
A. We’ll first prove that Theorem 1 holds with k = 0.
For k = 0, Q0 = {(∅, C)} by Definition 11.a. And, [Sk ] = 2C by Definition 9.
We have: [∅, C] = {X : X ⊆ C} = 2C . Since {[∅, C]} is a partition of 2C and ∅ is
“0-minimal”, let G = ∅ and E = C then Theorem 1 holds for k = 0.
B. Assume that Theorem 1 holds for any k − 1, 0 < k ≤ |SC| (i.e., the set
{[G, E] : (G, E) ∈ Qk−1 } is a partition of [Sk−1 ], where each [G, E] is an equivalence class,
and G is “(k − 1)-minimal”), we will prove that Theorem 1 holds for k.
By assumption, we have [Sk−1 ] =

P

[Gi , Ei ], where (Gi , Ei ) ∈ Qk−1 .

By Lemma 1.a, the necessary condition for an itemset X to be in [Sk ] is that it
must be in [Sk−1 ].

(a)

By assumption, (∀(Gi , Ei ), (Gj , Ej ) ∈ Qk−1 )([Gi , Ei ] ∩ [Gj , Ej ] = ∅), where i 6= j.
In other words, [Gi , Ei ] and [Gj , Ej ] are two disjoint sets of FIs that satisfy Sk−1 .
From

(a)

and

(b)

(b)

, we only need to prove that given a pair (G, E) ∈ Qk−1 , we can

partition [G, E] into disjoint subclasses, where each subclass either is in the form of [G0 , E 0 ]
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and G0 is a “k-minimal” (i.e., all FIs in [G0 , E 0 ] satisfy Sk , or (G0 , E 0 ) ∈ Qk ), or contains
only the itemsets which do not satisfy Sk .

(∗)

If Mk ∩ G 6= ∅ then G satisfies Sk . This implies (G, E) ∈ Qk . Or,

(∗)

is proved.

In this case, (G, E) belongs to Bk as in Definition 11.c, thus, it belongs to Qk .

(i)

Now, let assume that Mk ∩ G = ∅. If Mk ∩ E = ∅, then (∀Y ∈ [G, E])(Y ∈
/ Sk ).
Then

(∗)

is proved.

(ii)

Now, let assume that Mk ∩ G = ∅ and Mk ∩ E 6= ∅. Denote Nk = Mk ∩ E =
{x1 , .., xn }, and for 0 < i ≤ n, denote Gi = G + xi (where, xi ∈ Nk ), Ei = E{xj : xj ∈
Nk , j ≤ i}. Let U1 = {G1 + T : T ⊆ E1 } = [G1 , E1 ], and V1 = {G + Y : Y ⊆ E\{x1 }} =
[G, E1 ].
Then, (∀X ∈ U1 )(x1 ∈ X) and (∀Y ∈ V1 )(x1 ∈
/ Y ). This means, U1 and V1 are
disjoint.
We can further divide V1 into two disjoint sets U2 and V2 , where, every itemset
in U2 contains x2 , and every itemset in V2 does not contain x2 .
One can see that Ei = Ei−1 \{xi }. This implies, U2 = {G2 + T : T ⊆ E2 } =
[G2 , E1 \{x2 }] = [G2 , E2 ], and similarly, V2 = [G, E2 ].
By the same way, the division process can continue until Vn−1 is divided into two
disjoint sets: Un = [Gn , En ] and Vn = [G, En ].
One can see that, [G, E] = Vn +

P

[Gi , Ei ], where, 0 < i ≤ n, n = |Nk |.

Since Mk ∩ G = ∅ and En = ∅, we have: (∀Y ∈ Vn )(Y ∈
/ [Sk ]). Meanwhile,
(∀i ≤ n)(Nk ∩ Gi = {xi } =
6 ∅). This implies, (∀i ≤ n)(Mk ∩ Gi 6= ∅). Or, (∀i ≤ n)(Gi is
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“k-minimal”) by Definition 10.b, and (∀X ∈ [Gi , Ei ])(X ∈ [Sk ]). This means, (Gi , Ei ) is
generated as Definition 11.c. Then, (Gi , Ei ) ∈ Qk .
Then
By

(∗)

is proved.

(i) (ii)

,

, and

(iii)

(iii) (∗)

,

is proved, and Theorem 1 is proved.


Corollary 2. Let n = |SC | then {[G, E] : (G, E) ∈ QN S} is a partition of [C], where, each
[G, E] is an equivalence class and G is “n-minimal”.
Proof. This is result of Theorem 1, where k = |SC | and [C] = [Sk ].


Figure 7.2: Search tree for generating the kernels and extendable sets of Q3 , where Q3 =
{(G2 , E2 ), (G5 , E5 ), (G6 , E6 ), (G6 , E7 )}.
Example 2. Let consider the relation R shown in Table 7.1 and the lattice of CFIs mined
from R with minsup = 0.25 (i.e., absolute minimum support = 1) shown in Figure 7.1.
The following paragraphs explain how to find all FIs in [C] for C = {1, 2, 3, 4, 5, 6}.
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According to the lattice, the immediately closed subsets of C are Y1 = {2, 3, 4, 5, 6},
Y2 = {1, 4, 5, 6} and Y3 = {1, 3}. In other words, SC = {Y1 , Y2 , Y3 }. Figure 7.2 presents
the search tree that can be built, implicitly, during the process of generating the kernels and extendable sets using a breadth-first search.

Here, Q1 = {(G1 , E1 )}, Q2 =

{(G2 , E2 ), (G3 , E3 )}, and Q3 = {(G2 , E2 ), (G5 , E5 ), (G6 , E6 ), {(G6 , E7 )}, where Gi is a kernel and Ei is its corresponding extendable set. (We do not have to compute the pair
(G4 , E4 ), the rectangle with dash-lined border.) They are found by the following steps:
With M1 = C\Y1 = {1}, let G1 = {1}, E1 = C\{1} = {2, 3, 4, 5, 6}) we have:
Q1 = {(G1 , E1 )}, by Definition 11.b. (Then, implicitly, [S1 ] = [G1 , E1 ], but we do not need
to compute it!)
Now, we will find Q2 based on (G1 , E1 ) and M2 , where M2 = C\Y2 = {2, 3}).
Let N2 = M2 ∩ E = {2, 3}. Using item 2 in N2 , we have G2 = G1 + {2} = {1, 2}, and
E2 = E1 \{2} = {3, 4, 5, 6}. Using item 3 in N2 , we have G3 = G1 + {3} = {1, 3}, and
E3 = E2 \{3} = {4, 5, 6}. Then, Q2 = {(G2 , E2 ), (G3 , E3 )} as nodes of level 2 in Figure
7.2.
Now, we will find Q3 based on {(G2 , E2 ), (G3 , E3 )} and M3 , where M3 = C\Y3 =
{2, 4, 5, 6}. With (G2 , E2 ), one can see that G2 satisfies S3 since M3 ∩ E2 = {2} =
6 ∅.
Thus, (G2 , E2 ) belongs to Q3 . With (G3 , E3 ), we have N3 = M3 ∩ E3 = {4, 5, 6}.
With item 4 in N3 , we have G5 = G3 + {4} = {1, 3, 4}, and E5 = E3 \{4} = {5, 6}. With
item 5 in N3 , we have G6 = G3 + {5} = {1, 3, 5}, and E6 = E5 \{5} = {6}.
With item 6 in N3 , we have G7 = G3 + {6} = {1, 3, 6}, and E7 = E6 \{6} = ∅.
Then, Q3 = {(G2 , E2 ), (G5 , E5 ), (G6 , E6 ), (G6 , E7 )} as nodes of level 3 in Figure 7.2.
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Table 7.2: The partition of 23 FIs in [{1, 2, 3, 4, 5, 6}] based on Q3 as in Figure 7.2.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16

[G2, E2]

[G5, E5]

[G6, E6]

[G7, E7]

{{1, 2},
{1, 2, 3},
{1, 2, 3, 4},
{1, 2, 3, 4, 5},
{1, 2, 3, 4, 5, 6},
{1, 2, 3, 4, 6},
{1, 2, 3, 5},
{1, 2, 3, 5, 6},
{1, 2, 3, 6},
{1, 2, 4},
{1, 2, 4, 5},
{1, 2, 4, 5, 6},
{1, 2, 4, 6},
{1, 2, 5},
{1, 2, 5, 6},
{1, 2, 6}}

{{1, 3, 4},
{1, 3, 4, 5}
{1, 3, 4, 5, 6},
{1, 3, 4, 6},

{{1, 3, 5},
{1, 3, 5, 6}}

{{1, 3, 6}}
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Theorem 2 (A necessary and sufficient condition for an itemset to be a generator). Let GS be the set of all generators of C, and KS = {G: (G, E) ∈ QN S } be the set
of all kernels. We have:
a) GS ⊆ KS
b) G ∈ GS ⇐⇒ (G ∈ KS) ∧ (@K ∈ KS)(K ⊂ G))
In other words, the generators are the minimal kernels of the subclasses in QN S
Proof. By Corollary 2, Qn (where, n = |SC |) induces a partition of [C], where
each [K, E] (with (K, E) ∈ Qn ) is an equivalence class. Then, (∀G ∈ GS)(∃(K, E) ∈
Qn )(G ∈ [K, E]). This mean h(G) = h(K) = C. Then, by Definition 5 and Definition
8, G = K since (∀X ∈ [K, E])(K ⊆ X). Thus, (∀G ∈ GS)(∃K ∈ KS)(G = K). Or,
GS ⊆ KS. This means Theorem 2.a is proved. As a consequence, a kernel is a generator
if an only if it is not a superset of any other kernel, i.e., Theorem 2.a is proved.


7.5

Our Proposed Algorithms

In this section, based on Definition 11, Theorem 1, and Theorem 2, we present the algorithm NUCLEAR for enumerating the FIs/generators from a lattice of CFIs, for all closed
frequent itemset. There are options for it to find only the generators, or both FIs and
generators. We also introduced the NUC algorithm, which wraps NUCLEAR to mine
FIs/generators from scratch (i.e., from transactional data). NUC uses a certain algorithm
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(e.g., CharmL) to construct the lattice of CFIs from data, which will be used as the input for NUCLEAR. NUCLEAR will call the algorithm FindKandE BFS to enumerate the
pairs of kernels and extendable sets for each closed frequent itemset, in breadth-first-search
manner. Depending on the output type(s) required, the FIs and/or the generators will be
enumerated accordingly. In NUCLEAR algorithm, for each frequent closed subset C in
lattice L, the kernel G and the extendable set E are initialized as G = ∅ and E = C.
If SC = ∅, the class [C] contains all non-empty subsets of C. Otherwise, the recursive
FindKandE BFS algorithm is called.
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Algorithm 1 (NUC). Mining FIs/generators from data.

Input.
• D: the transactional dataset,
• minsup: the minimum support threshold,
• returnFIs: “true” to return all FIs for each closed frequent itemset,
• returnGenerators: “true” to return all generators for each closed frequent
itemset.
Output. all FIs/generators satisfying minsup.

Method.
1. L = The lattice of CFIs mined from D for the given minsup (using a certain
algorithm, e.g., CharmL).
2. return NUCLEAR (L, returnFIs, returnGenerators)
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Algorithm 2 (NUCLEAR). Mining FIs/generators from a lattice of closed
frequent itemsets.

Input.
• L = the lattice of CFIs,
• minsup: the minimum support threshold,
• returnFIs: “true” to return all FIs for each closed frequent itemset,
• returnGenerators: “true” to return all generators for each closed frequent itemset.
Output. all FIs/generators satisfying minsup.

Method. (∀C ∈ L : supp(C) ≥ minsup),
1 n = |SC |
2 M = {Mi : Mi = C\Yi , Yi ∈ SC }
3 Q0 = {(∅, C)}
4 Qn = F indKandE BF S(1, Q0 , M )
5 (∀(G, E) ∈ Qn
a. if (returnFIs) then generate and save [G, E] for C
b. if (returnGenerators) and (@(K, E 0 ) ∈ Qn )(K ⊂ G)) then save G for C
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Algorithm 3 (FindKandE BFS). Mining all pairs of kernel and extendable
for a closed frequent itemset C.

Input.
• k: a positive interger,
• Qk−1 : The set of pairs of kernel and extendable set generated as Definition 11.
Output. Qn : all pairs of kernel and extendable set of the closed frequent itemset C.

Method.
1. if (k > n) return Qk−1 , where n = |SC |
2. Qk = ∅
3. ∀(G, E) ∈ Qk−1 ,
a. if(Mk ∩ G 6= ∅) then Qk = Qk ∪ {(G, E)}
b. else
i. Ei = E
ii. ∀x ∈ Mk ∩ E,
• Ei = Ei {x}
• Qk = Qk ∪ {(G + {x}, Ei )}
4. FindKandE BFS (k + 1, Qk )
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7.6

Experimental Results and Discussion

In this section, we compare the running time (in seconds) for mining all FIs from data of
three frameworks dEclat, GenIT, and NUC. Details of these frameworks are described as
follows.
• dEclat mines FIs directly from data.
• NUC use CharmL algorithm to mine the lattice of CFIs from data before applying
NUCLEAR to generate the kernels and extendable sets. The FIs are inferred during
this process.
• GenIT is not an algorithm but a combination of algorithms of previous studies, which
is slightly different from NUC. In GenIT, we first use CharmL algorithm to mine the
lattice of CFIs from data. Then, MinimalGenerator [9] algorithm is applied to mine
the generators from the CFIs. Then we apply GEN ITEMSETS to extract FIs from
the CFIs and the generators by FIs.
Thus, to be fair, the total times reported for NUC includes the time of CharmL
and the time of NUCLEAR; whereas, that for GenIT includes the time of CharmL, the
time of Minimal Generator, and the time of GEN ITEMSETS. These algorithms have been
executed on a Pentium (R) Dual-Core CPU E6500 @ 2.93GHz, equipped with 1.94GB of
RAM, running the Microsoft Windows XP Version 2002 operating system.
Seven datasets (available at http://fimi.ua.ac.be/data) have been used to compare
the frameworks under different values of minsup. Information about the datasets is given
in Table 7.3.
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Table 7.3: Characteristics of the datasets.
Database

Abbreviation

#Items

#Transactions

#Average

Chess

CH

75

3,196

37

Connect

CO

129

67,557

43

Mushroom

MU

119

8,124

23

Retail

RE

16,469

88,162

10.3

T40I10100K

T4

1,000

100,000

40

C20d10k

C2

192

10,000

20

C73d10k

C7

1,592

10,000

73

Table 7.4: Number of patterns extracted from the datasets. #FS: the number of frequent
itemsets; #CS: the number of frequent closed itemsets; #G: the number of generators;
#K: the number of kernels which is also number of extendable sets; #FS/CS: the number
of frequent itemsets over the number of frequent closed itemsets; #CS/K: the number of
frequent closed itemsets over the number of kernels; #K/G: the number of kernels over the
number of generators.
Data

minsup

#FS

#CS

#G

#K

#FS/CS

#CS/K

#K/G

C2

0.8

8165081

99785

122031

122359

81.83

0.82

1.00

C2

0.85

7525408

95533

116126

116416

78.77

0.82

1.00

C2

0.9

7017040

92087

111297

111564

76.20

0.83

1.00

C2

0.95

6525355

88695

106575

106813

73.57

0.83

1.00

C2

1

6092449

85608

102316

102519

71.17

0.84

1.00

Continued on next page

222

Table 7.4 – continued from previous page
Data

minsup

#FS

#CS

#G

#K

#FS/CS

#CS/K

#K/G

C7

50

25696439

482902

765450

765449

53.21

0.63

1.00

C7

55

9698268

222253

346029

346028

43.64

0.64

1.00

C7

60

4188627

108428

166918

166917

38.63

0.65

1.00

C7

65

1472818

47491

71875

71874

31.01

0.66

1.00

C7

70

543081

19501

29008

29007

27.85

0.67

1.00

CH

50

900355

369450

372603

372603

2.44

0.99

1.00

CH

60

156551

98392

98418

98418

1.59

1.00

1.00

CH

70

24997

23991

23991

23991

1.04

1.00

1.00

CO

60

21184454

68349

68349

68349

309.95

1.00

1.00

CO

70

4093971

35875

35875

35875

114.12

1.00

1.00

CO

75

1561212

24346

24346

24346

64.13

1.00

1.00

CO

80

518875

15107

15107

15107

34.35

1.00

1.00

MU

2

23596649

31767

57728

82483

742.80

0.55

1.43

MU

3

9934877

22229

37972

52165

446.93

0.59

1.37

MU

4

4324745

16565

26984

35597

261.08

0.61

1.32

Continued on next page
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Table 7.4 – continued from previous page
Data

minsup

#FS

#CS

#G

#K

#FS/CS

#CS/K

#K/G

MU

5

3727905

12854

21160

27801

290.02

0.61

1.31

RE

0.006

975063

504142

532342

542565

1.93

0.95

1.02

RE

0.008

480620

286435

293235

294709

1.68

0.98

1.01

RE

0.01

240852

189077

191265

191650

1.27

0.99

1.00

RE

0.02

67186

65301

65329

65330

1.03

1.00

1.00

RE

0.03

40153

39552

39552

39552

1.02

1.00

1.00

RE

0.04

26925

26666

26666

26666

1.01

1.00

1.00

RE

0.05

19836

19698

19698

19698

1.01

1.00

1.00

T4

0.8

480531

480531

480531

480531

1.00

1.00

1.00

T4

0.85

432211

432211

432211

432211

1.00

1.00

1.00

T4

0.9

350323

350323

350323

350323

1.00

1.00

1.00

T4

0.95

210610

210610

210610

210610

1.00

1.00

1.00

T4

1

66278

66278

66278

66278

1.00

1.00

1.00
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Table 7.5: Runtimes of the frameworks and of the breakdown processes. tCS: time to
find CFIs using CharmL; tG: time to find the generators using MinimalGenerator; tN:
time to generate kernels and extendable sets by NUCLEAR; tNI: time to enumerate FIs
from kernels and extendable sets by NUCLEAR; tNNI: time to find FIs from lattice of
CFIs, (tNNI = tN + tNI); tGI: time to generate FIs based on CFIs and generators using GEN ITEMSETS; NUC: time to find FIs from data using CharmL and NUCLEAR
(NUC = tCS + tNNI); GenIT: time to find FIs using CharmL, Minimal Generator, and
GEN ITEMSETS (GenIT = tCS + tG + tGI); dEclat: time to find FIs from data using
dElat; OM: “out of memory”.
Data

minsup

tCS

tG

tN

tNI

tNNI

tGI

GenIT

dEclat

NUC

C2

0.8

14.8

3.6

2.4

6.1

8.5

14.1

32.5

24.6

23.3

C2

0.9

13.9

3.4

2.3

5.3

7.7

12.8

30.1

22.6

21.6

C2

0.9

13.1

3.3

2.2

5.0

7.2

11.9

28.3

21.2

20.3

C2

1.0

12.5

3.2

2.3

4.6

6.9

11.2

26.9

19.6

19.5

C2

1.0

12.0

3.1

1.9

3.9

5.8

10.3

25.4

18.4

17.8

C7

50.0

192.5

33.3

23.6

16.3

40.0

OM

OM

88.1

232.4

C7

55.0

58.9

14.0

9.2

5.4

14.6

19.4

92.2

33.2

73.5

C7

60.0

20.0

6.3

3.9

2.0

5.9

7.8

34.1

14.6

25.9

C7

65.0

6.5

2.4

1.5

0.7

2.2

2.7

11.6

5.3

8.7

C7

70.0

2.3

0.9

0.4

0.4

0.8

0.9

4.1

2.1

3.1

Continued on next page
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Table 7.5 – continued from previous page
Data

minsup

tCS

tG

tN

tNI

tNNI

tGI

GenIT

dEclat

NUC

Ch

50.0

109.3

17.4

5.5

0.6

6.1

3.0

129.6

5.0

115.4

Ch

60.0

14.3

3.9

1.3

0.1

1.5

0.6

18.7

1.1

15.8

Ch

70.0

1.8

0.8

0.3

0.0

0.3

0.1

2.7

0.3

2.1

Co

60.0

35.2

2.4

1.8

16.5

18.3

OM

OM

95.0

53.4

Co

70.0

13.3

1.2

0.9

2.9

3.8

7.3

21.8

20.5

17.1

Co

75.0

7.9

0.8

0.5

0.9

1.4

2.6

11.3

8.7

9.4

Co

80.0

4.7

0.6

0.3

0.3

0.6

0.8

6.1

3.5

5.3

M

2.0

3.8

2.3

1.1

18.3

19.3

OM

OM

71.2

23.1

M

3.0

2.7

1.3

0.4

8.0

8.4

28.2

32.1

30.1

11.1

M

4.0

1.9

0.8

0.5

3.2

3.7

13.8

16.5

13.3

5.6

M

5.0

1.6

0.9

0.3

2.9

3.2

11.1

13.7

11.3

4.8

RT

0.0

101.2

9.8

4.9

0.8

5.7

7.8

118.8

60.6

106.9

RT

0.0

57.2

5.2

2.4

0.3

2.7

1.2

63.6

27.2

59.8

RT

0.0

39.0

3.1

1.5

0.1

1.6

0.5

42.7

16.5

40.6

RT

0.0

17.1

1.1

0.4

0.0

0.5

0.1

18.3

5.7

17.6

Continued on next page
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Table 7.5 – continued from previous page
Data

minsup

tCS

tG

tN

tNI

tNNI

tGI

GenIT

dEclat

NUC

RT

0.0

12.0

0.6

0.2

0.0

0.3

0.1

12.8

3.8

12.3

RT

0.0

9.0

0.4

0.2

0.0

0.2

0.1

9.4

2.8

9.2

RT

0.1

7.2

0.4

0.1

0.0

0.2

0.0

7.6

2.2

7.4

T4

0.8

427.7

28.9

7.4

0.3

7.7

1.4

458.0

41.2

435.4

T4

0.9

372.0

24.6

5.9

0.2

6.1

1.3

397.9

35.2

378.2

T4

0.9

289.2

19.3

5.3

0.2

5.5

1.3

309.8

29.9

294.7

T4

1.0

120.8

9.7

2.8

0.1

2.8

0.6

131.1

25.2

123.6

T4

1.0

75.4

1.9

0.6

0.0

0.6

0.1

77.4

21.1

76.0

The number of patterns that can be mined from each dataset are shown in Table 7.4.
Table 7.5 shows the overall runtime for NUC, GenIT, and dEclat in the columns of the
corresponding names, and other details. The visual comparisons of the three approaches
are also given in the Figures 7.3-7.8. In our experiment, NUC is faster than dEclat when
testing on the Mushroom and Connect datasets (Figure 7.3, Figure 7.4). The reasons
include: (1) as shown in column tCS and column dEclat, the time for CharmL is smaller
than that of dEclat because the number of CFIs in a dataset is much less than that of
FIs, and (2) as shown in column tNNI and column dEclat, the time for NUCLEAR is also
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smaller than that of dEclat. On the other datasets, NUC is slower than dEclat. The main
reason is that CharmL, which is used to acquire the input for NUCLEAR, is already slower
dEclat. Whereas, the time for NUCLEAR is significantly small as compared to those of
CharmL and dEclat.
Table 7.5 shows that NUC is about 1.25 time faster than GenIT. To emphasize
the advantages of NUCLEAR, we break down the run-time of GenIT and NUC by different
stages of their process including:
1. Constructing the lattice of CFIs by CharmL (column tCS),
2. Mining generators by MinimalGenerator (column tG),
3. Extracting FIs from the CFIs and the generators by GEN ITEMSETS (column tGI),
4. Generating kernels and extendable sets from the lattice of CFIs by NUCLEAR (column tN),
5. Enumerating FIs from the kernels and extendable sets by NUCLEAR (column tNI).
In comparing tG against tN, one can see that the run-time of MinimalGenerator to
mine the generators from the lattice of CFIs is about as twice as the time for NUCLEAR to
generate the kernels and extendable sets (tN). Similarly, comparing tGI against tNI shows
that the time for GEN ITEMSETS (tGI) is about twice as that for NUCLEAR to extract
the FIs. In other words, generating FIs from the kernels and extendable sets is faster than
from the generators and CFIs. These make NUC more efficient than GenIT in extracting
the intermediate results and the final results.
Besides, the time for mining FIs from the lattice of CFIs using NUCLEAR (tNNI)
is mostly much smaller than that for constructing the lattice (tCS) using the CharmL
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algorithm. Thus, in applications where users have to try different minsup thresholds to
find an optimal set of FIs for a certain downstream process, our approach might be more
efficient than repeatedly mining FIs from scratch like dEclat. Because, the lattice can be
constructed only once for a small-enough minsup, the cost for updating/filtering the lattice
is expected to be small, and after that NUCLEAR can be used to query FIs many times.
For example, in bioinformatics, we can use NUC to conduct a feature selection to reduce
the number of features before applying another machine learning algorithm. The feature
selection might have to be conducted many times to obtain an optimal set of features.
From Table 7.4, we can see that the number of pairs of kernel and extendable set
(#K) is almost similar to the number of generators (#G) and just slightly bigger than the
number of CFIs (#CS). The lowest value of #CS/K is 0.55 means that, in average, there
are no more than two kernels per CFI. Thus, identifying the kernels and extendable sets,
as demonstrated in Example 2, will be fast. As there are only a few kernels in each CFI
and the number of generators is almost similar to the number of kernels (#K/G is almost
equal to 1). Then, extracting the generators among the kernels would be very quick.
Finally, we do not need to store the kernels and extendable sets but just the
lattice of CFIs. Because, for each CFI C, we easily identify SC , (the largest CFIs that are
subsets of C) to generate the kernels, extendable sets, generators, and FIs, and this can be
done quickly. Thus, using NUCLEAR can save a lot of memory as well.
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Figure 7.3: Run-time comparison on Mushroom (MR).

Figure 7.4: Run-time comparison on Connect (CO).
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Figure 7.5: Run-time comparison on C20d10k (C2).

Figure 7.6: Run-time comparison on Retail (RT).
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Figure 7.7: Run-time comparison on C73d10k (C7).
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Figure 7.8: Run-time comparison on T40I10100K (T4).

7.7

Conclusions and Future Work

Mining FIs from the lattice of CFIs is a reasonable approach since the number of CFIs is
often much smaller than the number of FIs. The lattice of CFIs can be mined once for
a low minimum support threshold and used many times later to derive FIs for different
higher minimum support thresholds. In general, it is easier to directly acquire the CFIs
than the FIs, especially, when there are parallel and distributed algorithms to mine CFIs.
More important, the CFIs can be useful for other tasks such as quickly extracting the
non-redundant association rules. Or, CFIs can be used to partition FIs into equivalence
classes, thus, allowing us to efficiently process a subclass of FIs based on some of the
representatives and inspiring the parallel methods to process many subclasses at the same
time.
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Current approaches might need both generators and closed frequent itemsets to
generate the FIs, and association rules. In this work, we derive a recurrent formula for
generating the kernels and extendable sets from a given closed frequent itemset, by which,
the FIs can be easily and quickly enumerated. We also induce a “necessary and sufficient”
condition for an itemset to be a generator, based on that the generators can be quickly extracted as well. The proposed algorithm, NUCLEAR, implements such theoretical results.
We propose a framework, called NUC, that applies an existing method (e.g.,
CharmL) to mine a lattice of CFIs from data and then uses NUCLEAR to enumerate the
FIs and/or generators from that lattice. NUC is more efficient than GEN IT, a similar
approach that requires the generators to enumerate the FIs from the lattice. NUC is slower
than dEclat, which mines FIs directly from data, in the major cases. But it’s just because
CharmL is already slower than dEclat; whereas, the time for obtaining the FIs from the
lattice by NUCLEAR is still considerably small.
In the future, we will apply our algorithms on bioinformatics problems, such as
survivability prediction, or risk of recurrence prediction in breast cancer. Numerical data
must be discretized before applying the algorithms. In such cases, data has a lot more
items/features than samples and FIs cannot be mined directly within a reasonable amount
of time. The lattice or FCIs can be mined concerning a subset of selective features (e.g., the
seed gene in Chapter 5), and then, the association rules will be extracted for classification.
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Chapter 8
Conclusions and Future Work

8.1

Conclusions

Genomic information has been shown to correlate with tumor therapy response in previous
studies. In Chapter 2, we applied feature selection approaches (including, multiple factor
analysis with SVM as evaluator, mRMR with SVM or Random Forest as evaluator) to
extract the gene expression signatures for classifying survival outcome at different time of
breast cancer patients receiving hormone (HT) and, in some cases, chemotherapy (CT)
agents. The initial genes for feature selection are those collected from the literature, with
respect to their involvement in the mechanism of HT agent (tamoxifen) and CT agents
(methotrexate, epirubicin, doxorubicin, and 5-fluorouracil). Paclitaxel gene signatures
exhibited the best performance, especially for patients treated with chemotherapy alone
or both chemotherapy and hormone therapy. Other agents also predicted survival with
acceptable accuracies when using SVM.
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In Chapter 3, we develop the feature selection algorithm PAFS that can be implemented in parallel. In PAFS, candidate subsets are generated and evaluated in a breathfirst-search manner. A candidate of size k is generated from two subsets of size (k − 1) that
share (k − 2) common features at the previous step. It also requires that the classification
performance of the two parent sets (of size k − 1) must not be considerably lower than
that of the current best performance to increase the chance that the candidates of the
next generation tend to yield better performance than the current ones. As a result, PAFS
can return more than one optimal subsets of features for output, thus, providing multiple
alternatives for downstream analysis. Besides, there are running options to keep the PAFS
from being too greedy or too exhaustive. When applying on the METABRIC datasets of
patients receiving HT, CT, and a combination of them to predict their survivability, using
the same initial genes set as described in Chapter 2, PAFS extracts better gene signatures,
the classification performances is significantly improved. When applying PAFS to predict
the chance to become disease-free for patients receiving a single therapy among CT, HT,
radiation therapy, and surgery, using an extended initial genes set, the classification performances are significantly high; the accuracies are about 78% or more (MCCs ≤ 0.449,
respectively). We also introduce an algorithm, named TCM, that wraps PAFS to deal
with multiple-class problems. It yields almost perfect accuracy when applied to classify on
a PAM50 subtype data and an erythemato-squamous disease data.
In Chapter 4, we integrate an unsupervised method and a supervised method to
develop a classification model to predict the 5-year survivability of breast cancer patients
treated with either hormone therapy, or radiotherapy, or surgery. The approach is to build
a multiple-label classification model that can suggest an optimal treatment for new pa240

tients based on their gene expression profiles. We divide patients into initial clusters, by
the combination of their treatment and survival status, then apply a bottom-up agglomerative clustering with Ward’s linkage to obtain hierarchical clusters. Finally, a feature
selection using mRMR and SVM is applied, at each node, to select a set of discriminative
genes for separating the corresponding two groups. The accuracy of the model at each
node ranges from 81.8% to 100%, showing a significantly high overall-accuracy. There are
pieces of evidence in the literature showing that some of the discriminative genes in the
computational model such as ZC3H11A, VAX2, MAF1, and ZFP91 are related to breast
cancer and other types of cancer.
The network-based method SSPA presented in Chapter 5 is to identify several
optimal sub-networks for predicting breast cancer survivability of a treatment. Gene expression data and protein-protein interaction network are integrated. The candidate subnetworks are gradually generated based on a protein-protein interaction network structure,
starting from a seed gene. During this step, they are filtered based on their predictability,
estimated by a proposed score named PA (predictive ability), and then evaluated by SVM
for their actual classification performance based on gene expression data. The heuristics
applied can save time for evaluating the redundant sub-networks. The informative seed
genes are collected with regards to either their breast cancer relevance or their predictive
ability using mutual information, including the drug-correlated genes described in Chapter
2. This is also a strategy to avoid generating the redundant sub-networks, while increasing the chance to obtain the accurate sub-network biomarkers with informative genes for
biological analysis. SSPA provides more than one final sub-networks for consideration as
biomarkers or for further analysis. Since, in the end, the optimal sub-networks are fil241

tered by their classification performance and prioritized based on known cancer-relevant
genes and pathway data. When applied on METABRIC datasets for predicting survival
outcome of patients treated with chemotherapy, hormone therapy, radiation therapy, or
surgery only, SSPA significantly outperformed some gene-expression-based approaches and
another network-based approach. The extracted sub-networks resulted in high accuracy,
73% to 93%, and include genes related to breast-cancer, to other cancers and many cancer
pathways. Especially, in an extracted sub-network for chemotherapy, the gene TP53 is
situated as the central hub which is consistent with the key roles of TP53 that have been
reported.
We also applied the Recursive Feature Elimination (RFE) method on gene expression data, with SVM linear kernel as the evaluator, and obtained highly accurate subsets
of genes that can predict with more than 90% accuracy. Although the extracted subsets
of genes are quite large to be considered as good biomarkers. A further gene/sub-networks
selection on these subsets or their extension might result in better biomarkers than the
current ones identified by SSPA.
In Chapter 6, we propose another network-based machine learning approach,
named KDS, to identify an optimal set of sub-networks of functionally-related genes that
can be used as a biomarker to predict if breast cancer patient will survive after 5-year
treated with chemotherapy, or hormone therapy, or a combination of these. A weighted
graph is constructed from gene expressions and protein-protein interactions, where the
edge weight is computed by joint mutual information expressing the predictability of the
combination of the two genes involving. (Whereas, in common gene-gene co-expression
networks, edge weight usually expresses the correlation between the pair of genes which is
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sometimes considered as the redundancy between the two genes in predicting the class.)
We define a density function for a weighted sub-graph which is also an estimation for
its predictability. By which, for one seed gene we extract only one optimally-dense subnetwork, with acceptable cost. Then, they are evaluated by a machine learning method
(e.g., support vector machine and random forest) for the real performance, two techniques
to deal with class-imbalance data are implemented before training classification models.
Furthermore, based on a weighted voting scheme using multiple subnets for classification,
we presented two simple methods to select an optimal set of subnets that can improve the
classification performance of the single best subnet. KDS has significantly improves the
results presented in Chapter 2. Our best subnet can yield 94.3% accuracy (MCC = 0.883)
in predicting chemotherapy-treated patients using one single best subnet, while for other
treatments, the optimal set of subnets can yield more than 80% accuracy. Interestingly, we
found the well-known genes SP1, TP35, MYC, PIK3CA among 14 breast-cancer-related
genes that frequently appear in the sets of top-k selected subnets.
The frequent itemsets (FIs) and closed frequent itemsets (CFIs) might be useful
for bioinformatics problems, including association rule extraction for classification [1]. Owing to the high interpretability, the rules and patterns mined from biological data might
help understand the mechanism of the diseases better than other machine learning tools
such as SVM, Random Forest, Neural Network. Mining the CFIs from data first and then
inferring the FIs has been considered as a preferred approach due to many reasons. However, the generators may be required for inferring and it takes an extra cost to mine them.
In Chapter 7, we have introduced the NUCLEAR algorithm which can enumerate the FIs
and generators quickly, given a lattice of FCIs. It is based on some theoretical results
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around the notations “kernel” and “extendable set” to infer the FIs as easily and quickly
as enumerating all subsets of a given set. More important, we have shown a “necessary and
sufficient condition” for an itemset to be a generator, by which the generators can be also
quickly identified via the kernels. The generators can be later used, along with the CFIs,
to generate the non-redundant association rules, which can be used to induce all other
rules [2]. Experimental results showed that NUCLEAR is more effective than an approach
utilizing a combination of some state-of-the-art algorithms. More specifically, (1) the time
to generate the kernels and extendable sets by NUCLEAR is smaller than the time to
mine the generators from CFIs by the MinimalGenrator algorithm [3], (2) extracting the
generators for each CFI from the kernels almost takes no time, (3) extracting FIs from
the kernels and extendable sets is much quicker than from the generators and CFIs as the
way the algorithm GEN ITEMSETS does [4], and (4) the total time for NUCLEAR to
enumerate all FIs from the CFIs is considerably small as compared to the time to mine
the CFIs from data.
In general, our proposed methods in this thesis can be applied to other classification problems in cancers without significant modifications. The modifications mainly
involve selecting the initial gene set for feature selection, the seed genes for subnet initialization, or cancer-related genes for biological, those should be tailored to the problem of
interest.
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8.2

Limitations and Future Work

We outline below some limitations in our approaches, as well as the future work that can
improve the current results:
• As described in Chapter 2, the result obtained by Random Forest and some other
cases showed that the models were strongly affected by the imbalance in data while
being trained. Some ML techniques can deal with that such as DOB-SCV or SMOTE
described in Chapter 5. Some other reasons have prevented the approaches to find
accurate signatures. The limited number of available genes in the initial gene set
is a reason which makes the more optimized signatures that are not in the current
search space ignored. Syed Haider argued that current clinical biomarkers typically
derived from a small number of genes cannot recapitulate the full complexity of the
disease [5]. There must be more genes that respect the mechanism of the therapies
since other drugs and combinations of drugs used in the therapies have not been
taken into account to obtain more initial genes. Or, an online tool like the HuGE
Navigator [6] can suggest thousands of breast-cancer-relevant genes for consideration.
As mentioned in [7], the differentially-expressed genes (DEGs) play an important role
in deriving robust gene signatures. Thus, DEGs, or at least the DEGs interacting with
the therapy-relevant genes, or the known breast-cancer-related genes that interact
with the DEGs should be considered as well, since they can help to explain the current
known disease/therapy mechanisms or derived new consistent finding. Widening the
available genes for feature selection in such ways can increase the chance to obtain
better signatures.
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• Another reason leads to low-quality signatures is that patients who died before the
survival threshold but not due to breast cancer were not removed from the training
and testing set as they are noise. Removing those noise and applying PAFS or other
approaches again with an extended initial gene set can result in biologically meaningful signatures with higher accuracy than the one we have improved in Chapter
3.
• In PAFS, we have not considered the robustness (please see section 1.3) of the candidate feature subsets into account, except that we train and test the classifier under
10-fold cross-validation. This can be done by measuring the classification performance on more random training and testing datasets (in a reasonable way) or by
returning only the robust subsets that have the highest performance.
• In addition, PAFS does not favor the large subsets of features as the number of
parent sets available for generating new candidates drops quickly when the size of
the candidates gets big enough. Although we have not had a good solution for this
phenomenon yet, the allowance to mutate the features in the current candidates
might somewhat deal with it. By this reason, PAFS might not work well on high
dimensional data without a feature filtering step.
• The proposed methods are used to identify biomarkers for predicting the outcome
of patients received a specific therapy. Stratifying the datasets further by certain
information, such as subtypes, hormone receptor status, or stages, will result in a
new classification problem with a heterogeneity reduction in genomics profiles of
the related patients since data samples are more condition-specific. Thus, the new
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biomarkers identified can be more accurate provided that the sub-datasets are still
large/generalized enough to draw a conclusion.
• The multi-label classification model proposed in Chapter 4 might be more valuable
for methodology than for practical application. Since it is built from datasets of
patients who received only one therapy among hormone therapy, radiation therapy,
or surgery, it can only suggest to patients one of the three therapies or none of them.
(For example, if a patient is predicted to be “DH”, i.e., died after 5 years treated
with hormone, this means that the model does not suggest any of the three therapy
to the patient). Additionally, the classifier trained based on a small dataset of only
26 hormone-therapy patients will be at a high risk of over-fitting. Instead of the three
mentioned therapies, the eight combinations of chemotherapy, hormone therapy, and
radiation therapy should be studied, regardless of surgery. Even radiation therapy can
be ignored but the problem of interest is still meaningful. Although the heterogeneity
in the datasets increases, the datasets contain more samples for training, or for further
stratification.
• We have not considered the robustness of the subnets (please see section 1.3) into account while searching for sub-network biomarkers, except that we have applied 5-fold
cross-validation. Cross-validation models with re-sampling techniques can alleviate
this limitation, provided that we have enough data samples.
• Integrating other “–omics” data such as mutations, CNA/CNVs, can help detect robust biomarkers. The problem becomes more complex now, however, the WMAXC
algorithm in [8] is an example of integrating multiple types of data into a single net247

work for applying an existing algorithm to find a sub-network biomarker. Applying
the ideas in this algorithm to our problems with other available data types can help
to find new biomarkers that are biologically consistent.
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Appendix A
Identifying the Gene Biomarkers of Breast
Cancer Survivability from Time-Series Data

A.1

Introduction

Studying gene expression through various time intervals of breast cancer survival may
provide new insights into the recovery from the disease. In this work, we propose an
approach that applies a hierarchical clustering method to separate dissimilar groups of
gene time-series profiles, which have the furthest distances from the rest of the profiles
throughout different time intervals. The isolated outliers might be useful for identifying
potential biomarkers of Breast Cancer survivability.
To the best of our knowledge, this preliminary work is the first time-series model
that is built on the survival time of the patient after the treatment. (As this is a preliminary
result, we present it in an appendix instead of a chapter)
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A.2

Resources and Methods

We used the gene expressions of breast cancer patients in the METABRIC dataset used
in [1] to modelize time-series data. The framwork of our approach is presented in Figure
A.1.

Figure A.1: The framework of our approach.

The time-series data was created by partitioning the time axis (survival time in
months) into bins of length six months, starting from 0-6 up to 49-55 month intervals,
and then, for each gene, we average its expression level over all patients who appear in a
survival bin. The average gene expressions throughout those time points are cubic spline
interpolated to create a trending profile for each gene. After universally aligning the
profiles to minimize the vertical area between each pair of profiles, we cluster the genes
using hierarchical clustering based on minimized vertical distances [2]. An appropriate
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number of clusters was chosen based on the profile alignment and agglomerative clustering
(PAAC) index as well as visual observations of the clusters [2].

A.3

Results

Figure 1A.2 shows the background cluster, where the majority of the profiles are clustered,
i.e., the trends of the profiles over the time-points. We identified 24 genes that are isolated
as singleton clusters. Of these, prosaposin (PSAP), CD81, and EEF1A1 have been previously reported in the literature to play some role in breast cancer. For example, in [4],
Kang et al. found that “the introduction of PSAP in highly metastatic cells significantly
reduced the occurrence of metastases, whereas inhibition of PSAp production by tumor
cells was associated with increased metastatic frequency. They suggested that prosaposin,
or other agents that stimulate TP53 activity in the tumor stroma, may be an effective therapy by inhibition of the metastatic process”. Figures A.3, A.4, and A.5 show the trends
of the cubic-spline-interpolated expression of three genes PSAP, CD81, and EEF1A1 over
time points. These genes are subjective to be considered as potential biomarkers of breast
cancer survivability. However, more computational work should be done to verify that
such as how effective they are in predicting survival time or how differentially the genes
expressed between groups of samples.
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Figure A.2: Background cluster.

Figure A.3: Cubic-spline-interpolated expression profile of the gene CD81.
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Figure A.4: Cubic-spline-interpolated expression profile of the gene EEF1A1.

Figure A.5: Cubic-spline-interpolated expression profile of the gene PSAP.
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